STERIS Plc (Ireland) 10-K 30 May 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2018	May 25, 2018	Sep. 29, 2017
DEI [Abstract]
Entity Registrant Name	STERIS plc
Entity Central Index Key	1,624,899
Document Type	10-K
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		84,618,075
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 7,420,705,027
Entity Voluntary Filers	No

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Statement of Financial Position [Abstract]
Asset Retirement Obligation, Current	$ 1,798	$ 0
Allowance for Doubtful Accounts Receivable, Current	12,472	10,357	[1]
Current assets:
Cash and cash equivalents	201,534	282,918
Accounts receivable (net of allowances of $12,472 and $10,357 respectively)	528,066	483,451
Inventories, net	205,731	197,837
Prepaid expenses and other current assets	54,326	53,596
Total current assets	989,657	1,017,802
Property, plant, and equipment, net	1,010,524	915,908
Intangible Assets, Net (Including Goodwill)	3,160,764	2,956,190
Other assets	39,389	34,555
Total assets	5,200,334	4,924,455
Current liabilities:
Accounts payable	135,866	133,479
Accrued Income Taxes, Current	379	14,640
Accrued payroll and other related liabilities	94,000	78,575
Accrued expenses and other	168,217	154,889
Total current liabilities	398,462	381,583
Long-term indebtedness	1,316,001	1,478,361
Deferred income taxes, net	159,971	171,805
Other Liabilities, Noncurrent	108,600	82,673
Total liabilities	1,983,034	2,114,422
Commitments and contingencies (see note 11)
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding	15	15
Ordinary shares, with £0.10 par value; £17,006 aggregate par amount authorized; 84,747 and 84,948 ordinary shares issued and outstanding, respectively	2,048,037	2,085,134
Retained earnings	1,146,223	954,155
Accumulated other comprehensive income	11,685	(240,702)
Total shareholders' equity	3,205,960	2,798,602
Noncontrolling interest	11,340	11,431
Total equity	3,217,300	2,810,033
Total liabilities and equity	$ 5,200,334	$ 4,924,455
[1]	Net allowance for doubtful accounts and allowance for sales and returns.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) £ in Thousands, $ in Thousands	Mar. 31, 2018GBP (£)£ / sharesshares	Mar. 31, 2018USD ($)shares	Mar. 31, 2017GBP (£)£ / sharesshares	Mar. 31, 2017USD ($)shares
Statement of Financial Position [Abstract]
Allowance for Doubtful Accounts Receivable, Current | $		$ 12,472		$ 10,357	[1]
Serial preferred shares authorized	100,000	100,000	100,000	100,000
Serial preferred shares issued	100,000	100,000	100,000	100,000
Preferred Stock, Shares Outstanding	100,000	100,000	100,000	100,000
Preferred Stock, Par or Stated Value Per Share | £ / shares	£ 0.10		£ 0.10
Aggregate Amount of Shares Authorized | £	£ 17,006		£ 17,006
Common shares issued	84,747,000	84,747,000	84,948,000	84,948,000
Common shares outstanding	84,747,000	84,747,000	84,948,000	84,948,000
Common Stock, Par or Stated Value Per Share | £ / shares	£ 0.10		£ 0.10
[1]	Net allowance for doubtful accounts and allowance for sales and returns.

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016
Revenues:
Product	$ 1,220,633	$ 1,198,319		$ 1,128,985
Service	1,399,363	1,414,437		1,109,779
Total revenues	2,619,996	2,612,756		2,238,764
Cost of revenues:
Product	646,177	624,020		617,368
Service	879,596	963,104		725,915
Total cost of revenues	1,525,773	1,587,124		1,343,283
Gross Profit	1,094,223	1,025,632		895,481
Operating expenses:
Selling, general, and administrative	629,884	680,069		626,710
Goodwill, Impairment Loss	0	58,356	[1]	0
Research and development	60,782	59,397		56,664
Restructuring Costs	103	215		(820)
Total operating expenses	690,769	798,037		682,554
Income (loss) from operations	403,454	227,595		212,927
Non-operating expenses, net:
Interest expense	50,629	44,520		42,708
Interest income and miscellaneous expense	(2,157)	(1,571)		(1,665)
Total non-operating expenses, net	48,472	42,949		41,043
Income (loss) before income tax expense (benefit)	354,982	184,646		171,884
Income tax expense (benefit)	63,360	74,015		60,299
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	291,622	110,631		111,585
Net Income (Loss) Attributable to Noncontrolling Interest	707	666		822
Net (loss) income	$ 290,915	$ 109,965		$ 110,763
Net income (loss) per common share
Basic	$ 3.42	$ 1.29		$ 1.57
Diluted	3.39	1.28		1.56
Cash dividends declared per common share outstanding	$ 1.21	$ 1.09		$ 0.98
[1]	For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 291,622	$ 110,631	$ 111,585
Net Income (Loss) Attributable to Noncontrolling Interest	707	666	822
Net Income (Loss) Attributable to Parent	290,915	109,965	110,763
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Tax	1,860	963	(700)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	1,792	851	(1,741)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax	(4,387)	(7,463)	(3,032)
Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax	0	0	17,029
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	254,982	(165,931)	(13,746)
Total other comprehensive loss attributable to shareholders	252,387	(172,543)	(1,490)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	543,302	(62,578)	109,273
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	516	402	(266)
Other Comprehensive Income (Loss), Defined Benefit Plan, Adjustment for Settlement or Curtailment Gain (Loss), Tax	0	0	10,563
Accumulated Other Comprehensive Income (Loss)
Net Income (Loss) Attributable to Parent			0
Total other comprehensive loss attributable to shareholders	$ 252,387	$ (172,543)	$ (1,490)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		$ 291,622	$ 110,631		$ 111,585
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, depletion, and amortization		178,332	188,142		143,740
Deferred income taxes		(24,722)	31,274		704
Share-based compensation		22,187	18,794		16,147
Pension Cost (Reversal of Cost)		0	0		26,470
Payment for Pension Benefits		0	0		(4,641)
Loss on the disposal of property, plant, equipment, and intangibles, net		2,582	760		1,813
Loss (Gain) on Disposition of Business	[1]	14,547	86,574		0
Excess Tax Benefit from Share-based Compensation, Operating Activities		0	0		(6,281)
Goodwill, Impairment Loss		0	58,356	[1]	0
Other items		32,229	(13,242)		(14,328)
Changes in operating assets and liabilities:
Accounts receivable, net		(37,731)	(48,140)		(31,560)
Inventories, net		(5,178)	(12,829)		1,810
Other current assets		(1,244)	2,324		(9,599)
Accounts payable		563	6,884		5,249
Accruals and other, net		(15,555)	(5,442)		13,566
Net cash provided by operating activities		457,632	424,086		254,675
Investing activities:
Purchases of property, plant, equipment, and intangibles, net		(165,457)	(172,901)		(126,407)
Proceeds from the sale of property, plant, equipment, and intangibles		2,094	4,846		844
Proceeds from Divestiture of Businesses		8,888	135,713		0
Payments to Acquire Investments		0	(6,356)		0
Investments in businesses, net of cash acquired		(46,271)	(65,557)		(604,021)
Payments for (Proceeds from) Other Investing Activities		(3,083)	0		0
Net cash used in investing activities		(203,829)	(104,255)		(729,584)
Financing activities:
Proceeds from Issuance of Private Placement		0	293,730		350,000
Repayments of Long-term Debt		(222,500)	(172,500)		(92,567)
Proceeds Under Credit Facility, net		29,065	(196,613)		369,451
Amortization of Financing Costs		(2,029)	(1,073)		(5,169)
Payments of Merger Related Costs, Financing Activities		(2,064)	(9,918)		0
Repurchases of ordinary shares		(65,485)	(97,509)		(14,369)
Cash dividends paid to common shareholders		(102,929)	(93,193)		(65,203)
Proceeds from Issuance or Sale of Equity		0	5,022		625
Stock option and other equity transactions, net		9,758	4,955		11,240
Excess Tax Benefit from Share-based Compensation, Financing Activities		0	0		6,281
Net cash (used in) provided by financing activities		(356,184)	(267,099)		560,289
Effect of exchange rate changes on cash and cash equivalents		20,997	(18,655)		(4,228)
Increase (Decrease) in cash and cash equivalents		(81,384)	34,077		81,152
Cash and cash equivalents at beginning of period		282,918	248,841		167,689
Cash and cash equivalents at end of period		$ 201,534	$ 282,918		$ 248,841
[1]	For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Ordinary Shares	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 1,073,646	$ 264,853	$ (320,343)	$ 1,193,791	$ (66,669)	$ 2,014
Shares, Issued		59,675,000	10,364,000
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 0.98
Net Income (Loss) Attributable to Parent	$ 110,763	$ 0	$ 0	110,763	0
Net Income (Loss) Attributable to Noncontrolling Interest	822					822
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	111,585
Total other comprehensive loss attributable to shareholders	(1,490)				(1,490)
Ordinary Shares, Acquired		(267,000)	(248,000)
Payments for Repurchase of Ordinary Shares	14,369	$ (1,020)	$ (12,974)	(375)	0
Noncontrolling Interest, Increase from Business Combination						13,574
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		(664,000)	(538,000)
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	27,291	$ 13,624	$ 13,667	0	0	0
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	1,443					1,443
Stock Repurchased and Retired During Period, Value		$ (20,133)		(299,517)
Noncontrolling Interest, Increase from Business Combination		25,839,000
Treasury Stock, Shares, Retired			(10,074,000)
Retirement of Stock Resulting from Synergy Combination			$ 319,650
Stock Issued During Period, Value, Acquisitions	1,901,068	$ 1,887,479
Purchase of subsidiary shares from non controlling interests		9,000
Purchase of subsidiary shares from non controlling interest		$ 635
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	(818)					(1,453)
Stock Issued During Period, Value, Stock Options Exercised		0	0
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	6,281	6,281
Excess tax benefit from share-based compensation			0	0	0	0
Dividends, Ordinary Shares, Cash	(65,203)	0	0	(65,203)	0	0
Noncontrolling Interest, Change in Redemption Value	(542)	0	0	0	0	(542)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,038,892
Stockholders' Equity Attributable to Parent		$ 2,151,719	$ 0	939,459	(68,159)
Noncontrolling interest						15,858
Shares, Issued		85,920,000	0
Preferred Stock, Shares Outstanding	100,000
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding	$ 15
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 1.09
Net Income (Loss) Attributable to Parent	$ 109,965			109,965
Net Income (Loss) Attributable to Noncontrolling Interest	666					666
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	110,631
Total other comprehensive loss attributable to shareholders	(172,543)				(172,543)
Ordinary Shares, Acquired		(1,455,000)	0
Payments for Repurchase of Ordinary Shares	97,509	$ (95,433)	$ 0	(2,076)	0
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		(416,000)	0
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	23,826	$ 23,826	$ 0	0	0	0
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	530					530
Purchase of subsidiary shares from non controlling interests		67,000
Purchase of subsidiary shares from non controlling interest		$ 5,022
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	(352)					(5,374)
Dividends, Ordinary Shares, Cash	(93,193)	0	0	(93,193)	0	0
Noncontrolling Interest, Change in Redemption Value	(249)					(249)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,810,033
Stockholders' Equity Attributable to Parent	2,798,602	$ 2,085,134	$ 0	954,155	(240,702)
Noncontrolling interest	$ 11,431					11,431
Shares, Issued		84,948,000	0
Preferred Stock, Shares Outstanding	100,000
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding	$ 15
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 1.21
Net Income (Loss) Attributable to Parent	$ 290,915			290,915
Net Income (Loss) Attributable to Noncontrolling Interest	707					707
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	291,622
Total other comprehensive loss attributable to shareholders	252,387				252,387
Ordinary Shares, Acquired		(793,000)	0
Payments for Repurchase of Ordinary Shares	65,485	$ (69,567)	$ 0	4,082	0
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		(592,000)	0
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	32,470	$ 32,470	$ 0	0	0	0
Dividends, Ordinary Shares, Cash	(102,929)	0	0	(102,929)	0	0
Noncontrolling Interest, Change in Redemption Value	(798)					(798)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,217,300
Stockholders' Equity Attributable to Parent	3,205,960	$ 2,048,037	$ 0	$ 1,146,223	$ 11,685
Noncontrolling interest	$ 11,340					$ 11,340
Shares, Issued		84,747,000	0
Preferred Stock, Shares Outstanding	100,000
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding	$ 15

CONSOLIDATED STATEMENTS OF SHA8

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Statement of Stockholders' Equity [Abstract]
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 1.21	$ 1.09	$ 0.98

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	Nature of Operations. STERIS plc (“Parent”) was organized in 2014 under the laws of England and Wales under the name Solar New HoldCo Limited as a private limited company for the purpose of effecting the combination (“Combination”) of STERIS Corporation, an Ohio corporation (“Old STERIS”), and Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). Effective November 2, 2015, the Parent was re-registered as a public company under the name of STERIS plc and the Combination closed. As a result of the Combination closing, STERIS plc became the ultimate parent company of Old STERIS and Synergy. Synergy has been re-registered under the name of Synergy Health Limited. The acquisition of Old STERIS was accounted for in the consolidated financial statements as a merger between entities under common control; accordingly the historical consolidated financial statements of Old STERIS for periods prior to November 2, 2015, are considered to be the historical financial statements of STERIS plc. STERIS plc is a leading provider of infection prevention and other procedural products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration. We operate and report in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. We describe our business segments in Note 11 to our consolidated financial statements titled, "Business Segment Information." Our fiscal year ends on March 31. References in this Annual Report to a particular "year," "fiscal year," or "year-end" mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below. Principles of Consolidation. We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. In prior periods, we presented income attributable to noncontrolling interests in the "Interest income and miscellaneous expense" line of our Consolidated Statements of Income and the amounts were not material. Use of Estimates. We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. Cash Equivalents and Supplemental Cash Flow Information. Cash equivalents are all highly liquid investments with a maturity of three months or less when purchased. We invest our excess cash in short-term instruments including money market funds and time deposits with major banks and financial institutions. We select investments in accordance with the criteria established in our investment policy. Our investment policy specifies, among other things, maturity, credit quality and concentration restrictions with the objective of preserving capital and maintaining adequate liquidity. Information supplementing our Consolidated Statements of Cash Flows is as follows: Years Ended March 31, 2018 2017 2016 Cash paid during the year for: Interest $ 48,663 $ 42,797 $ 37,165 Income taxes 85,629 78,009 60,885 Cash received during the year for income tax refunds 7,747 2,002 1,697 Revenue Recognition. We recognize revenue for products when ownership passes to the Customer, which is based on contract or shipping terms and for services when the service is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor. We have no further obligations related to bringing about resale and our standard return and restocking fee policies are applied. Revenues are reported net of sales and value-added taxes collected from Customers. We also have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. Returns, rebates, and similar allowances are estimated based on historical experience and trend analysis. In transactions that contain multiple elements, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each element based on its relative selling price, based on the price for the product or service when it is sold separately. We offer preventive maintenance agreements to our Customers with contract terms of one to five years which require us to maintain and repair our products during this time. Amounts received under these Customer contracts are initially recorded as deferred service revenues and then recognized as service revenues ratably over the contract term. Accounts Receivable. Accounts receivable are presented at their face amount, less allowances for sales returns and uncollectible accounts. Accounts receivable consist of amounts billed and currently due from Customers and amounts earned but unbilled. We generally obtain and perfect security interest in products sold in the United States when we have a concern with the Customer's risk profile. We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed by Customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, Customer payment practices, and general economic conditions. We also analyze significant Customer accounts on a regular basis and record a specific allowance when we become aware of a specific Customer’s inability to pay. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible. We maintain an allowance for sales returns based upon known returns and estimated returns for both capital equipment and consumables. We estimate returns of capital equipment and consumables based upon recent historical experience. Inventories, net. Inventories are stated at the lower of their cost or market value. We determine cost based upon a combination of the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods. For inventories valued using the LIFO method, we believe that the use of the LIFO method results in a matching of current costs and revenues. Inventories valued using the LIFO method represented approximately 26.0% and 29.0% of total inventories at March 31, 2018 and 2017 , respectively. Inventory costs include material, labor, and overhead. If we had used only the FIFO method of inventory costing, inventories would have been $17,280 and $16,706 higher than those reported at March 31, 2018 and 2017 , respectively. We review inventory on an ongoing basis, considering factors such as deterioration, obsolescence, and other items. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to cost of revenues. Property, Plant, and Equipment. Our property, plant, and equipment consists of land and land improvements, buildings and leasehold improvements, machinery and equipment, information systems, radioisotope (cobalt-60), and construction in progress. Property, plant, and equipment are presented at cost less accumulated depreciation and depletion. We capitalize additions and improvements. Repairs and maintenance are charged to expense as they are incurred. Land is not depreciated and construction in progress is not depreciated until placed in service. Depreciation of most assets is computed on the cost less the estimated salvage value by using the straight-line method over the estimated remaining useful lives. Depletion of radioisotope is computed using the annual decay factor of the material, which is similar to the sum-of-the-years-digits method. We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table: Asset Type Useful Life (years) Land improvements 3-40 Buildings and leasehold improvements 2-50 Machinery and equipment 2-20 Information Systems 2-20 Radioisotope (cobalt-60) 20 When we sell, retire, or dispose of property, plant, and equipment, we remove the asset’s cost and accumulated depreciation from our Consolidated Balance Sheet. We recognize the net gain or loss on the sale or disposition in the Consolidated Statements of Income in the period when the transaction occurs. Interest. We capitalize interest costs incurred during the construction of long-lived assets. We capitalized interest costs of $528 and $1,141 for the years ended March 31, 2018 and 2017 , respectively. Total interest expense for the years ended March 31, 2018 , 2017 , and 2016 was $50,629 , $44,520 , and $42,708 , respectively. Identifiable Intangible Assets. Our identifiable intangible assets include product technology rights, trademarks, licenses, and Customer and vendor relationships. We record these assets at cost, or when acquired as part of a business acquisition, at estimated fair value. We generally amortize identifiable intangible assets over periods ranging from 5 to 20 years using the straight-line method. Our intangible assets also include indefinite lived assets including certain trademarks and tradenames that were acquired in connection with business combinations. These assets are tested at least annually for impairment. Investments. Investments in marketable securities are stated at fair value and are included in "Other assets" on the Consolidated Balance Sheets. Unrealized gains and losses on marketable securities classified as available-for-sale are recorded in Accumulated Other Comprehensive Income (Loss). Asset Impairment Losses. Property, plant, equipment, and identifiable intangible assets are reviewed for impairment when indicators of impairment exist and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We monitor for such indicators on an ongoing basis and if an impairment exists, we record the loss in the Consolidated Statements of Income during that period. Asset Retirement Obligations. We incur retirement obligations for certain assets. We record initial liabilities for the asset retirement obligations ("ARO") at fair value. Recognition of ARO includes: estimating the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and a periodic review of the ARO liability estimates and discount rates used in the analysis. We provide additional information about our asset retirement obligations in Note 5 to our consolidated financial statements titled, “Property, Plant and Equipment.” Acquisitions of Business. Assets acquired and liabilities assumed in a business combination are accounted for at fair value on the date of acquisition. Costs related to the acquisition are expensed as incurred. Goodwill. We perform our annual impairment test for goodwill in the third quarter of each year. We may consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. We may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. We review the book value compared to the fair value at the reporting unit level. We calculate the fair value of our reporting units based on the present value of estimated future cash flows. Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows to measure fair value. Assumptions used in our impairment evaluations, such as forecasted growth rates and cost of capital, are consistent with internal projections, strategic plans, and operating plans. We believe such assumptions and estimates are also comparable to those that would be used by other market place participants. Self-Insurance Liabilities. We record a liability for self-insured risks that we retain for general and product liabilities, workers’ compensation, and automobile liabilities based on actuarial calculations. We use our historical loss experience and actuarial methods to calculate the liability. This liability includes estimates for both losses and incurred but not reported claims. We review the assumptions used to calculate the estimated liability at least annually to evaluate the adequacy of the amount recorded. We maintain insurance policies to cover losses greater than our estimated liability, which are subject to the terms and conditions of those policies. We are also self-insured for certain employee medical claims. We estimate a liability for incurred but not reported claims based upon recent claims experience. Benefit Plans. We sponsor defined benefit pension plans. We also sponsor a post-retirement benefits plan for certain former employees. We determine our costs and obligations related to these plans by evaluating input from third-party professional advisers. These costs and obligations are affected by assumptions including the discount rate, expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other factors. We review the assumptions used on an annual basis. We recognize an asset for the overfunded status or a liability for the underfunded status of defined benefit pension and post-retirement benefits plans in our consolidated balance sheets. This amount is measured as the difference between the fair value of plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for other post-retirement benefit plans). Changes in the funded status of the plans are recorded in other comprehensive income in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 9 to our consolidated financial statements titled, “Benefit Plans.” Fair Value of Financial Instruments. Except for long-term debt, our financial instruments are highly liquid or have short-term maturities. We provide additional information about the fair value of our financial instruments in Note 17 titled, “Fair Value Measurements.” Foreign Currency Translation. Most of our operations use their local currency as their functional currency. Financial statements of subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate for each period for revenues, expenses, gains and losses. Translation adjustments for subsidiaries whose local currency is their functional currency are recorded as a component of accumulated other comprehensive income (loss) within equity. Transaction gains and losses resulting from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized as incurred in the accompanying Consolidated Statement of Income, except for certain inter-company balances designated as long-term in nature. Forward and Swap Contracts. We enter into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies, including inter-company transactions.We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are marked to market, with gains and losses recognized within “Selling, general, and administrative expenses” or "Cost of revenues" in the accompanying Consolidated Statements of Income. Warranty. Warranties are provided on the sale of certain of our products and services and an accrual for estimated future claims is recorded at the time revenue is recognized. We estimate warranty expense based primarily on historical warranty claim experience. Shipping and Handling. We record shipping and handling costs in costs of revenues. Shipping and handling costs charged to Customers are recorded as revenues in the period the product revenues are recognized. Advertising Expenses. Costs incurred for communicating, advertising and promoting our products are generally expensed when incurred as a component of Selling, General and Administrative Expense. We incurred $10,886 , $12,622 , and $10,785 of advertising costs during the years ended March 31, 2018 , 2017 , and 2016 , respectively. Research and Development. We incur research and development costs associated with commercial products and expense these costs as incurred. If a Customer reimburses us for research and development costs, the costs are charged to the related contracts as costs of revenues. Income Taxes. We defer income taxes for all temporary differences between pre-tax financial and taxable income and between the book and tax basis of assets and liabilities. We record valuation allowances to reduce net deferred tax assets to an amount that we expect will more-likely-than-not be realized. In making such a determination, we consider all available information, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and if applicable, any carryback claims that can be filed. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes and the effective tax rate. We evaluate uncertain tax positions in accordance with a two-step process. The first step is recognition: The determination of whether or not it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate tax authority and that the tax authority will have full knowledge of all relevant information. The second step is measurement: A tax position that meets the more-likely-than-not threshold is measured to determine the amount of benefit to recognize in the financial statements. The measurement process requires the determination of the range of possible settlement amounts and the probability of achieving each of the possible settlements. The tax position is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. No tax benefits are recognized for positions that do not meet the more-likely-than-not threshold. Tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not recognition threshold are derecognized in the first subsequent financial reporting period in which the threshold is no longer met. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes.” Medical Device Excise Tax. The Medical Device Excise Tax became effective January 1, 2013. The excise tax was mandated by the 2010 health care reform legislation and assesses a 2.3% tax on the sale or use of certain medical devices that are sold or manufactured in the United States. Many of our products are subject to the excise tax. Late in 2015, Congress enacted legislation that suspended the excise tax for 2016 and 2017. Early in 2018, U.S. Congress enacted legislation that extended the suspension of the excise tax for 2018 and 2019. Therefore, we did not incur Medical Device Excise taxes during fiscal 2018 or 2017. Should the U.S. Congress take no further action with regard to this tax we will begin to incur excise tax in the fourth quarter of fiscal 2020. We incurred Medical Device Excise taxes of $5,802 during fiscal year 2016, which was included in cost of revenues in the period of sale. Share-Based Compensation. We describe share-based compensation in Note 14 to our consolidated financial statements titled, “Share-Based Compensation.” We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. We record liability awards at fair value each reporting period and the change in fair value is reflected as share-based compensation expense in our Consolidated Statements of Income. The expense is classified as cost of goods sold, selling, general and administrative expenses or research and development expenses in a manner consistent with the employee’s compensation and benefits. These costs are recognized in the Consolidated Statement of Income over the period during which an employee is required to provide service in exchange for the award. Restructuring. We recognize restructuring expenses as incurred. Asset impairment and accelerated depreciation expenses primarily relate to inventory write-downs for rationalized products and adjustments in the carrying value of the related facilities and machinery and equipment to their estimated fair value. In addition, the remaining useful lives of other property, plant, and equipment associated with the related operations are reevaluated based on the respective restructuring plan, which may result in the acceleration of depreciation and amortization of certain assets. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323) March 2016 The standard replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2018 The prospective adoption of this standard did not have a material impact on our consolidated financial statements. ASU 2015-11, "Inventory - Simplifying the Measurement of Inventory" (Topic 330) July 2015 The standard requires an entity to measure inventory within the scope of this update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years and should be applied prospectively. Early adoption is permitted. First Quarter Fiscal 2018 The prospective adoption of this standard did not have a material impact on our consolidated financial statements. ASU 2017-04, "Intangibles - Goodwill and Other, Simplifying the Test for Goodwill Impairment" (Topic 350) January 2017 This standard eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedures that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, under the amendments of this standard, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The loss should not exceed the total amount of goodwill allocated to that reporting unit. Tax effects should be considered. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. Third Quarter Fiscal 2018 The prospective adoption of this standard did not have a material impact on our consolidated financial statements. ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718) March 2016 The standard simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 As a result of the adoption of this standard, we recorded $6.6 million and $5.1 million of excess tax benefits associated with share based compensation in the Consolidated Statements of Income for the years ended March 31, 2018 and 2017, respectively, and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated. Standards that have not yet been adopted ASU 2014-09, "Revenue from Contracts with Customers" and subsequently issued amendments May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We have completed our evaluation of our revenue streams and contracts and have adopted this standard on April 1, 2018 using the modified retrospective method. We have identified certain historical revenue transactions for which the timing of recognition would have been different under this standard. The amount of the cumulative adjustment required to defer revenue based on these transactions at the end of fiscal 2018 represents less than 0.5% of fiscal 2018 revenues, which will reduce retained earnings as of April 1, 2018. We are in the process of finalizing our revenue accounting policy and implementing changes to our business processes, disclosures and controls. Additionally, we expect to provide the required additional disclosures in periods subsequent to the adoption. ASU 2016-01, "Financial Instruments - Overall - Recognition and Measurement of Financial Assets and Liabilities" (Subtopic 825-10) January 2016 The standard changes how equity investments are measured and presents changes in the fair value of financial liabilities measured under the fair value option. Presentation and disclosure requirements for financial instruments are also affected. Entities will be required to measure equity investments that do not result in consolidation and are not recorded under the equity method at fair value with changes in fair value recognized in net income. The standard clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. N/A The impact that the standard will have on our consolidated financial statements will depend on the future variability in the fair values of our equity investments. However, based on current investment holdings, the impact is not expected to be material. ASU 2016-02, "Leases" (Topic 842) February 2016 The standard will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are currently evaluating the impact that the standard will have on our consolidated financial statements. We are also evaluating our lease portfolio, software packages, process and policy change requirements. We anticipate that most of our operating leases will result in the recognition of additional assets and corresponding liabilities in our Consolidated Balance Sheet, however we do not expect the standard to have a material impact on our financial position. The actual impact will depend on our lease portfolio at the time of adoption. More information regarding our total operating lease commitments at March 31, 2018, is disclosed in Note 5, "Property, Plant and Equipment". ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" June 2016 The standard requires a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2016-15, "Statement of Cash Flows" (Topic 230) August 2016 This standard provides guidance on the following specific cash flow issues: Debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interes

Business Acquisitions and Dives

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)	12 Months Ended
	Mar. 31, 2018
Business Combinations and Divestitures [Abstract]
Business Combination Disclosure [Text Block]	Fiscal 2017 Acquisitions Compass Medical, Inc. On September 16, 2016, we purchased the assets of Compass Medical, Inc. ("Compass'') for approximately $16.0 million . The purchase price was financed with bank credit facility borrowings. Compass specializes in the sale and repair of flexible endoscopes. On an annual basis, Compass has generated revenues of approximately $6.0 million and is being integrated into our Healthcare Specialty Services segment. Phoenix Surgical Holdings, Ltd. and Endo-Tek LLP On August 31, 2016, we purchased 100% of the shares of Phoenix Surgical Holdings, Ltd. and the assets of Endo-Tek LLP ("Phoenix Surgical and Endo-Tek") for approximately $14.3 million combined, net of cash acquired. The purchase price was financed with cash on hand. On an annual basis, these operations, which specialize in the repair of endoscopes, generated approximately $8.0 million in combined revenue and are being integrated into our Healthcare Specialty Services segment. Medisafe On July 22, 2016, we purchased 100% of the shares of Medisafe Holdings, Ltd. ("Medisafe"), a U.K. manufacturer of washer/disinfector equipment and related consumables and services for approximately $34.5 million , net of cash acquired. The purchase price was financed with cash on hand. On an annual basis, the Medisafe product line has generated $18.0 million in revenue. The acquisition of Medisafe provides washer manufacturing and research and development capabilities in the U.K. Medisafe's products and services are being integrated into our Healthcare Products segment. Fiscal 2016 Acquisitions Synergy Health plc On November 2, 2015, STERIS acquired all outstanding shares of Synergy in a cash and stock transaction valued at £24.80 ( $38.17 ) per Synergy share, or a total of approximately $2.3 billion based on the lowest trading price of Old STERIS’s stock of $73.02 per share on November 2, 2015. The Combination brought together businesses that generate revenues from over 100 countries and that are geographically complementary. Total costs of approximately $63.8 million before tax were incurred during fiscal year 2016 related to the Combination and are reported in Selling, general and administrative expense. During the fiscal 2017 third quarter, adjustments were made to finalize the opening balance sheet fair value estimates. Adjustments related primarily to property, plant and equipment, intangible assets and goodwill. The cumulative impact of the final purchase price allocation resulted in a cumulative decrease in depreciation, amortization and depletion expense of approximately $20.0 million , of which approximately $17.0 million was recorded within Selling, general and administrative expense and approximately $3.0 million was recorded within Cost of revenues in the Consolidated Statements of Income. The cumulative foreign currency translation adjustment recorded as a result of the finalization of purchase accounting was approximately $170.0 million . Actual and Pro Forma Impact Our fiscal 2016 consolidated financial statements include Synergy's results of operations from the date of acquisition on November 2, 2015 through March 31, 2016. Net sales and operating income attributable to Synergy during this period and included in our consolidated financial statements for the fiscal year ended March 31, 2016 total $254.9 million and $3.7 million , respectively. The following unaudited pro forma information gives effect to our acquisition of Synergy as if the acquisition had occurred at the beginning of fiscal 2016 and Synergy had been included in our consolidated results of operations for fiscal year ended March 31, 2016. Fiscal Year Ending Amounts are unaudited March 31, 2016 Net revenues $ 2,619,056 Net income from continuing operations 188,269 The historical consolidated financial information of STERIS and Synergy has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transaction, (2) factually supportable and (3) expected to have a continuing impact on the combined results. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up, the incremental depreciation from the fair value adjustments to property, plant and equipment, and the incremental intangible asset amortization to be incurred based on the valuations of the assets acquired. Adjustments to financing costs and income tax expense also were made to reflect the capital structure and anticipated effective tax rate of the combined entity. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred prior to the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings. Gepco On July 31, 2015, we acquired all of the outstanding shares of General Econopak, Inc. (“Gepco”), since renamed STERIS Barrier Products Solutions, Inc., for a purchase price of $176.5 million in cash, including a customary working capital adjustment. Gepco is a Pennsylvania-based manufacturer of product solutions in the areas of sterility maintenance, barrier protection, and sterile cleanroom products for pharmaceutical, biotechnology and veterinary Customers. Gepco has been integrated into our Life Sciences business segment. The purchase price was financed through a combination of credit facility borrowings and cash on hand. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date. The acquisition qualified for joint election tax benefit under Section 338 (h)(10) of the Internal Revenue Code, which allows goodwill and intangibles to be fully deductible for tax purposes. Black Diamond On June 12, 2015, we acquired the capital stock of Black Diamond Video, Inc. ("Black Diamond"), a California-based developer and provider of operating room integration systems. The purchase price was approximately $46.2 million , which included a working capital adjustment, deferred consideration of $5.9 million and contingent consideration of $0.8 million . The transaction consideration paid at closing was funded with cash on hand. Black Diamond has been integrated into our Healthcare Products business segment. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date. Other 2016 Acquisitions We also completed several other minor purchases that continued to expand our service offerings in the Healthcare Products, Healthcare Specialty Services and Life Sciences segments. The aggregate purchase price associated with these transactions was approximately $41.1 million , including potential contingent consideration of $1.8 million . Fair Value of Assets Acquired and Liabilities Assumed The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2018, 2017 and 2016 acquisitions. Fiscal Year 2018 Fiscal Year 2017 Fiscal Year 2016 (dollars in thousands) All Acquisitions (1) Medisafe Compass Phoenix Surgical and Endo-Tek Synergy Health plc Gepco Black Diamond Other Acquisitions Cash $ 235 $ 3,751 $ — $ 769 $ 53,057 $ 1,108 $ — $ — Accounts receivable 1,464 3,634 629 1,123 103,093 4,161 2,966 3,859 Inventory 2,289 2,454 659 950 30,074 1,926 3,309 1,108 Property, plant and equipment 3,420 639 13 1,092 496,555 3,421 607 1,979 Other assets 126 — 31 46 19,175 946 54 — Intangible assets 15,318 17,151 5,992 7,824 504,196 61,900 13,500 14,829 Goodwill 35,766 19,599 8,987 5,938 1,685,524 104,485 31,792 20,630 Total Assets 58,618 47,228 16,311 17,742 2,891,674 177,947 52,228 42,405 Current liabilities (2,833 ) (5,562 ) (309 ) (1,373 ) (107,932 ) (1,473 ) (4,525 ) (1,277 ) Long-term indebtedness — — — — (321,082 ) — — — Non-current liabilities (2,622 ) (3,398 ) — (1,263 ) (159,112 ) — (1,548 ) (49 ) Total Liabilities (5,455 ) (8,960 ) (309 ) (2,636 ) (588,126 ) (1,473 ) (6,073 ) (1,326 ) Net Assets $ 53,163 $ 38,268 $ 16,002 $ 15,106 $ 2,303,548 $ 176,474 $ 46,155 $ 41,079 (1) Purchase price allocation is still preliminary as of March 31, 2018, as valuations have not been finalized. Acquisition related transaction and integration costs totaled $16.2 million , $30.1 million , and $82.9 million for the fiscal years ended March 31, 2018 , 2017 , and 2016 , respectively. These costs are included in Selling, general, and administrative expenses in the Consolidated Statements of Income. Divestitures Synergy Health Healthcare Consumable Solutions On November 20, 2017, we sold our Synergy Health Healthcare Consumable Solutions ("HCS") business to Vernacare. Annual revenues for the HCS business were approximately $40.0 million and were included in the Healthcare Products segment. We recorded proceeds of $8.2 million , net of cash divested, and subject to a working capital adjustment. We also recognized a pre-tax loss on the sale, subject to final working capital adjustments, of $13.5 million in Selling, general, and administrative expense in the Consolidated Statement of Income. Netherlands Linen Management Services On February 9, 2017, we sold our Synergy Health Netherlands Linen Management Services business to EMEA B.V. Annual revenues for Synergy Health Netherlands Linen Management Services were approximately $75 million and were included in the Healthcare Specialty Services segment. We recorded a $43.0 million pre-tax loss on the sale in Selling, general, and administrative expense in the Consolidated Statements of Income as a result of the divestiture. In connection with the divestiture, we entered into a loan agreement to provide financing of up to €15 million for a term of up to 15 years . The loan carries an interest rate of 4 percent for the first four years and 12 percent thereafter. Outstanding borrowings under the agreement totaled $3.1 million at March 31, 2018 . U.S. Linen Management Services On November 3, 2016, we sold our Synergy Health U.S. Linen Management Services business to SRI Healthcare LLC. Annual revenues for U.S. Linen Management Services were approximately $50 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $4.5 million and recognized a pre-tax loss on the sale, subject to final adjustments, of $31.2 million in Selling, general, and administrative expense in the Consolidated Statements of Income. Synergy Health Labs On September 2, 2016, we sold Synergy Health Laboratory Services to SYNLAB International. Annual revenues for the Synergy Health Labs were approximately $15.0 million and were included in the Applied Sterilization Technologies segment. We recorded proceeds of $26.3 million , net of cash divested, and recognized a pre-tax gain on the sale of $18.7 million in Selling, general, and administrative expense in the Consolidated Statements of Income. Applied Infection Control On August 31, 2016, we completed the sale of our Applied Infection Control ("AIC") product line to DEB USA, Inc., a wholly-owned subsidiary of S.C. Johnson & Son, Inc. Annual revenues for the AIC product line were typically less than $50.0 million and were included in the Healthcare Products segment. We recorded proceeds of $41.8 million and recognized a pre-tax gain on the sale of $36.2 million in Selling, general, and administrative expense in the Consolidated Statements of Income. UK Linen Management Services On July 1, 2016, we sold our Synergy Health UK Linen Management Services business to STAR Mayan Limited. Annual revenues for UK Linen Management Services were approximately $50.0 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $65.4 million , net of cash divested, and recognized a pre-tax loss on the sale of $66.4 million in Selling, general, and administrative expense in the Consolidated Statements of Income. Fiscal 2017 Acquisitions Compass Medical, Inc. On September 16, 2016, we purchased the assets of Compass Medical, Inc. ("Compass'') for approximately $16.0 million . The purchase price was financed with bank credit facility borrowings. Compass specializes in the sale and repair of flexible endoscopes. On an annual basis, Compass has generated revenues of approximately $6.0 million and is being integrated into our Healthcare Specialty Services segment. Phoenix Surgical Holdings, Ltd. and Endo-Tek LLP On August 31, 2016, we purchased 100% of the shares of Phoenix Surgical Holdings, Ltd. and the assets of Endo-Tek LLP ("Phoenix Surgical and Endo-Tek") for approximately $14.3 million combined, net of cash acquired. The purchase price was financed with cash on hand. On an annual basis, these operations, which specialize in the repair of endoscopes, generated approximately $8.0 million in combined revenue and are being integrated into our Healthcare Specialty Services segment. Medisafe On July 22, 2016, we purchased 100% of the shares of Medisafe Holdings, Ltd. ("Medisafe"), a U.K. manufacturer of washer/disinfector equipment and related consumables and services for approximately $34.5 million , net of cash acquired. The purchase price was financed with cash on hand. On an annual basis, the Medisafe product line has generated $18.0 million in revenue. The acquisition of Medisafe provides washer manufacturing and research and development capabilities in the U.K. Medisafe's products and services are being integrated into our Healthcare Products segment. Fiscal 2016 Acquisitions Synergy Health plc On November 2, 2015, STERIS acquired all outstanding shares of Synergy in a cash and stock transaction valued at £24.80 ( $38.17 ) per Synergy share, or a total of approximately $2.3 billion based on the lowest trading price of Old STERIS’s stock of $73.02 per share on November 2, 2015. The Combination brought together businesses that generate revenues from over 100 countries and that are geographically complementary. Total costs of approximately $63.8 million before tax were incurred during fiscal year 2016 related to the Combination and are reported in Selling, general and administrative expense. During the fiscal 2017 third quarter, adjustments were made to finalize the opening balance sheet fair value estimates. Adjustments related primarily to property, plant and equipment, intangible assets and goodwill. The cumulative impact of the final purchase price allocation resulted in a cumulative decrease in depreciation, amortization and depletion expense of approximately $20.0 million , of which approximately $17.0 million was recorded within Selling, general and administrative expense and approximately $3.0 million was recorded within Cost of revenues in the Consolidated Statements of Income. The cumulative foreign currency translation adjustment recorded as a result of the finalization of purchase accounting was approximately $170.0 million . Actual and Pro Forma Impact Our fiscal 2016 consolidated financial statements include Synergy's results of operations from the date of acquisition on November 2, 2015 through March 31, 2016. Net sales and operating income attributable to Synergy during this period and included in our consolidated financial statements for the fiscal year ended March 31, 2016 total $254.9 million and $3.7 million , respectively. The following unaudited pro forma information gives effect to our acquisition of Synergy as if the acquisition had occurred at the beginning of fiscal 2016 and Synergy had been included in our consolidated results of operations for fiscal year ended March 31, 2016. Fiscal Year Ending Amounts are unaudited March 31, 2016 Net revenues $ 2,619,056 Net income from continuing operations 188,269 The historical consolidated financial information of STERIS and Synergy has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transaction, (2) factually supportable and (3) expected to have a continuing impact on the combined results. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up, the incremental depreciation from the fair value adjustments to property, plant and equipment, and the incremental intangible asset amortization to be incurred based on the valuations of the assets acquired. Adjustments to financing costs and income tax expense also were made to reflect the capital structure and anticipated effective tax rate of the combined entity. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred prior to the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings. Gepco On July 31, 2015, we acquired all of the outstanding shares of General Econopak, Inc. (“Gepco”), since renamed STERIS Barrier Products Solutions, Inc., for a purchase price of $176.5 million in cash, including a customary working capital adjustment. Gepco is a Pennsylvania-based manufacturer of product solutions in the areas of sterility maintenance, barrier protection, and sterile cleanroom products for pharmaceutical, biotechnology and veterinary Customers. Gepco has been integrated into our Life Sciences business segment. The purchase price was financed through a combination of credit facility borrowings and cash on hand. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date. The acquisition qualified for joint election tax benefit under Section 338 (h)(10) of the Internal Revenue Code, which allows goodwill and intangibles to be fully deductible for tax purposes. Black Diamond On June 12, 2015, we acquired the capital stock of Black Diamond Video, Inc. ("Black Diamond"), a California-based developer and provider of operating room integration systems. The purchase price was approximately $46.2 million , which included a working capital adjustment, deferred consideration of $5.9 million and contingent consideration of $0.8 million . The transaction consideration paid at closing was funded with cash on hand. Black Diamond has been integrated into our Healthcare Products business segment. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date. Other 2016 Acquisitions We also completed several other minor purchases that continued to expand our service offerings in the Healthcare Products, Healthcare Specialty Services and Life Sciences segments. The aggregate purchase price associated with these transactions was approximately $41.1 million , including potential contingent consideration of $1.8 million . Fair Value of Assets Acquired and Liabilities Assumed The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2018, 2017 and 2016 acquisitions. Fiscal Year 2018 Fiscal Year 2017 Fiscal Year 2016 (dollars in thousands) All Acquisitions (1) Medisafe Compass Phoenix Surgical and Endo-Tek Synergy Health plc Gepco Black Diamond Other Acquisitions Cash $ 235 $ 3,751 $ — $ 769 $ 53,057 $ 1,108 $ — $ — Accounts receivable 1,464 3,634 629 1,123 103,093 4,161 2,966 3,859 Inventory 2,289 2,454 659 950 30,074 1,926 3,309 1,108 Property, plant and equipment 3,420 639 13 1,092 496,555 3,421 607 1,979 Other assets 126 — 31 46 19,175 946 54 — Intangible assets 15,318 17,151 5,992 7,824 504,196 61,900 13,500 14,829 Goodwill 35,766 19,599 8,987 5,938 1,685,524 104,485 31,792 20,630 Total Assets 58,618 47,228 16,311 17,742 2,891,674 177,947 52,228 42,405 Current liabilities (2,833 ) (5,562 ) (309 ) (1,373 ) (107,932 ) (1,473 ) (4,525 ) (1,277 ) Long-term indebtedness — — — — (321,082 ) — — — Non-current liabilities (2,622 ) (3,398 ) — (1,263 ) (159,112 ) — (1,548 ) (49 ) Total Liabilities (5,455 ) (8,960 ) (309 ) (2,636 ) (588,126 ) (1,473 ) (6,073 ) (1,326 ) Net Assets $ 53,163 $ 38,268 $ 16,002 $ 15,106 $ 2,303,548 $ 176,474 $ 46,155 $ 41,079 (1) Purchase price allocation is still preliminary as of March 31, 2018, as valuations have not been finalized. Acquisition related transaction and integration costs totaled $16.2 million , $30.1 million , and $82.9 million for the fiscal years ended March 31, 2018 , 2017 , and 2016 , respectively. These costs are included in Selling, general, and administrative expenses in the Consolidated Statements of Income. Divestitures Synergy Health Healthcare Consumable Solutions On November 20, 2017, we sold our Synergy Health Healthcare Consumable Solutions ("HCS") business to Vernacare. Annual revenues for the HCS business were approximately $40.0 million and were included in the Healthcare Products segment. We recorded proceeds of $8.2 million , net of cash divested, and subject to a working capital adjustment. We also recognized a pre-tax loss on the sale, subject to final working capital adjustments, of $13.5 million in Selling, general, and administrative expense in the Consolidated Statement of Income. Netherlands Linen Management Services On February 9, 2017, we sold our Synergy Health Netherlands Linen Management Services business to EMEA B.V. Annual revenues for Synergy Health Netherlands Linen Management Services were approximately $75 million and were included in the Healthcare Specialty Services segment. We recorded a $43.0 million pre-tax loss on the sale in Selling, general, and administrative expense in the Consolidated Statements of Income as a result of the divestiture. In connection with the divestiture, we entered into a loan agreement to provide financing of up to €15 million for a term of up to 15 years . The loan carries an interest rate of 4 percent for the first four years and 12 percent thereafter. Outstanding borrowings under the agreement totaled $3.1 million at March 31, 2018 . U.S. Linen Management Services On November 3, 2016, we sold our Synergy Health U.S. Linen Management Services business to SRI Healthcare LLC. Annual revenues for U.S. Linen Management Services were approximately $50 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $4.5 million and recognized a pre-tax loss on the sale, subject to final adjustments, of $31.2 million in Selling, general, and administrative expense in the Consolidated Statements of Income. Synergy Health Labs On September 2, 2016, we sold Synergy Health Laboratory Services to SYNLAB International. Annual revenues for the Synergy Health Labs were approximately $15.0 million and were included in the Applied Sterilization Technologies segment. We recorded proceeds of $26.3 million , net of cash divested, and recognized a pre-tax gain on the sale of $18.7 million in Selling, general, and administrative expense in the Consolidated Statements of Income. Applied Infection Control On August 31, 2016, we completed the sale of our Applied Infection Control ("AIC") product line to DEB USA, Inc., a wholly-owned subsidiary of S.C. Johnson & Son, Inc. Annual revenues for the AIC product line were typically less than $50.0 million and were included in the Healthcare Products segment. We recorded proceeds of $41.8 million and recognized a pre-tax gain on the sale of $36.2 million in Selling, general, and administrative expense in the Consolidated Statements of Income. UK Linen Management Services On July 1, 2016, we sold our Synergy Health UK Linen Management Services business to STAR Mayan Limited. Annual revenues for UK Linen Management Services were approximately $50.0 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $65.4 million , net of cash divested, and recognized a pre-tax loss on the sale of $66.4 million in Selling, general, and administrative expense in the Consolidated Statements of Income.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Changes to the carrying amount of goodwill for the years ended March 31, 2018 , 2017 and 2016 were as follows: Healthcare Products Segment Healthcare Specialty Services Segment Life Sciences Segment Applied Sterilization Technologies Segment Synergy Combination Total Balance at March 31, 2016 363,770 154,272 147,334 83,035 1,408,192 2,156,603 Goodwill acquired or allocated 19,618 21,781 — — — 41,399 Synergy allocation — 376,807 — 1,308,717 (1,411,781 ) 273,743 Divestitures — (85,806 ) — — — (85,806 ) Impairment — (58,356 ) — — — (58,356 ) Foreign currency translation adjustments (5,623 ) (32,819 ) (820 ) (60,607 ) 3,589 (96,280 ) Balance at March 31, 2017 $ 377,765 $ 375,879 $ 146,514 $ 1,331,145 $ — $ 2,231,303 Goodwill acquired or allocated 16,418 3,501 — 15,847 — 35,766 Reassignment — (1,855 ) — 1,855 — — Foreign currency translation adjustments 10,491 10,500 2,302 143,422 — 166,715 Balance at March 31, 2018 $ 404,674 $ 388,025 $ 148,816 $ 1,492,269 $ — $ 2,433,784 The fiscal 2018 goodwill increase was due to our recent business acquisitions, which are discussed in Note 2, titled "Business Acquisitions" and the impact of foreign currency. The fiscal 2018 reassignment between the Healthcare Specialty Services and the Applied Sterilization Technologies segments resulted from certain minor organizational changes that were made to better align with our Customers. The fiscal 2017 goodwill increase within the Healthcare Products segment primarily relates to the acquisition of Medisafe. The fiscal 2017 goodwill increase within the Healthcare Specialty Services and Applied Sterilization Technologies segments was primarily the result of the finalization of purchase accounting related to the Synergy acquisition. The Healthcare Specialty Services segment was also impacted by the fiscal 2017 acquisitions of Compass Medical, Inc., Phoenix Surgical Holdings, Ltd., and Endo-Tek LLP, the Synergy Health UK Linen Management Services divestiture and the Synergy Health Netherlands goodwill impairment discussed below. We evaluate the recoverability of recorded goodwill amounts annually during the third fiscal quarter, or when evidence of potential impairment exists. As a result of our annual goodwill impairment review for fiscal year 2017, we concluded that the carrying value of one of our reporting units exceeded its fair value. The Synergy Health Netherlands linen management unit was reported within our Healthcare Specialty Services segment. Financial forecasts prepared for the annual assessment reflected pricing pressures, volume declines driven by overcapacity in the market, and a decline in the overall market size. These factors resulted in further degradation of the already low operating margin and cash flows of this unit. We incurred a goodwill impairment charge of $58,356 as a result, which is recorded within Goodwill impairment loss in the Consolidated Statements of Income. The fair market value of the reporting unit was determined under an income approach using discounted cash flows and estimated fair market values. Fair value calculated using a discounted cash flow analysis is classified within level 3 of the fair value hierarchy and requires several assumptions including risk adjusted discount rates and financial forecasts. As a result of our annual impairment review for goodwill for fiscal year 2018 and fiscal year 2016, no indicators of impairment were identified. Our fiscal 2018, 2017, and 2016 acquisitions are described in Note 2 to our consolidated financial statements titled, "Business Acquisitions and Divestitures". Information regarding our intangible assets is as follows: 2018 2017 March 31, Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Customer relationships $ 663,532 $ 150,358 $ 597,386 $ 96,648 Non-compete agreements 4,738 3,790 4,722 3,629 Patents and technology 226,318 107,598 211,812 86,665 Trademarks and tradenames 83,509 36,864 80,223 32,547 Supplier relationships 54,800 7,307 54,800 4,567 Other 10 10 10 10 Total $ 1,032,907 $ 305,927 $ 948,953 $ 224,066 Certain trademarks and tradenames obtained as a result of business combinations are indefinite-lived assets. We evaluate our indefinite-lived intangible assets annually during the third quarter, or when evidence of potential impairment exists. No impairment was taken for the fiscal years 2018, 2017 or 2016. The approximate carrying value of these assets at March 31, 2018 and March 31, 2017 was $35,266 and $34,970 , respectively. Total amortization expense for finite-lived intangible assets was $70,195 , $68,607 , and $49,782 for the years ended March 31, 2018 , 2017 , and 2016 , respectively. Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows: 2019 2020 2021 2022 2022 Estimated amortization expense $ 68,447 $ 67,390 $ 66,742 $ 63,832 $ 59,061 The estimated annual amortization expense presented in the preceding table has been calculated based upon March 31, 2018 currency exchange rates. During the third quarter of fiscal 2017, we adopted a new branding strategy change as part of the integration of certain Synergy Health operations into the Healthcare Specialty Services Segment. Under this new branding strategy, hospital sterilization services and instrument repair services will utilize the STERIS Instrument Management Services brand name. The Synergy Health trade name was phased out during the fourth quarter of fiscal 2017. As a result, we shortened the estimated useful life of the Synergy Health trade name and accelerated the corresponding amortization expense over the remainder of fiscal 2017, resulting in an additional expense of $14,444 within the Selling, general and administrative expense line on the Consolidated Statements of Income.

Inventories, Net

Inventories, Net	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Inventories, Net	Inventories, net consisted of the following: March 31, 2018 2017 Raw materials $ 83,741 $ 65,300 Work in process 34,904 26,538 Finished goods 124,005 140,559 LIFO reserve (17,280 ) (16,706 ) Reserve for excess and obsolete inventory (19,639 ) (17,854 ) Inventories, net $ 205,731 $ 197,837

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: March 31, 2018 2017 Land and land improvements (1) $ 55,417 $ 46,848 Buildings and leasehold improvements 449,316 393,692 Machinery and equipment 575,607 508,247 Information systems 145,726 119,920 Radioisotope 476,578 436,787 Construction in progress (1) 87,745 77,421 Total property, plant, and equipment 1,790,389 1,582,915 Less: accumulated depreciation and depletion (779,865 ) (667,007 ) Property, plant, and equipment, net $ 1,010,524 $ 915,908 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service. Depreciation and depletion expense were $108,137 , $119,536 and $93,958 , for the years ended March 31, 2018 , 2017 , and 2016 , respectively. Rental expense for operating leases was $30,474 , $32,740 , and $23,238 for the years ended March 31, 2018 , 2017 , and 2016 , respectively. Operating leases primarily relate to manufacturing, warehouse and office space, service facilities, vehicles, equipment, and communication systems. Certain lease agreements grant us varying renewal and purchase options. Future minimum annual rentals payable under noncancelable operating lease agreements at March 31, 2018 were as follows: Operating Leases 2019 $ 24,116 2020 19,933 2021 14,666 2022 11,051 2023 and thereafter 39,464 Total minimum lease payments $ 109,230 In the preceding table, the future minimum annual rentals payable under noncancelable leases denominated in foreign currencies have been calculated using March 31, 2018 foreign currency exchange rates. Asset Retirement Obligations We provide contract sterilization services including Gamma irradiation which utilizes cobalt-60 in the form of cobalt pencils. We have incurred asset retirement obligations (ARO) associated with the future disposal of these assets once depleted. Recognition of ARO includes: the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and the periodic review of the ARO liability estimates and discount rates used in the analysis. The following table summarizes the activity in the liability for asset retirement obligations. Asset Retirement Obligations Balance at March 31, 2017 $ 9,953 Liabilities incurred during the period 89 Liabilities settled during the period (352 ) Accretion expense 1,198 Foreign currency movement 751 Balance at March 31, 2018 $ 11,639

Debt

Debt	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Debt	Indebtedness as of March 31, 2018 and 2017 was as follows: 2018 2017 Credit Agreement and Swing Line Facility $ 331,206 $ 521,604 Private Placement 988,190 960,684 Deferred financing fees (3,395 ) (3,927 ) Total long term debt $ 1,316,001 $ 1,478,361 On March 23, 2018, we entered into a Credit Agreement (the "Credit Agreement") with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as Administrative Agent. The Credit Agreement replaced a bank credit facility dated March 31, 2015. The Credit Agreement provides up to $1,000,000 of credit, in the form of a revolver facility, which may be utilized for revolving credit borrowings, swing line borrowings and letters of credit, with sublimits for swing line borrowings and letters of credit. The revolver facility may be increased in specified circumstances by up to $500,000 . The Credit Agreement will mature on March 23, 2023, and all unpaid borrowings, together with accrued and unpaid interest thereon, are repayable on that date. The Credit Agreement contains leverage and interest coverage covenants. Borrowings may be taken in U.S. dollars, euros, and pounds sterling and certain other specified currencies and bear interest at our option based upon either the Base Rate or the Eurocurrency Rate, plus the Applicable Margin in effect from time to time under the Credit Agreement. The Applicable Margin is determined based on the ratio of Consolidated Total Debt to Consolidated EBITDA (as such terms are defined in the Credit Agreement). Interest on Base Rate Advances is payable quarterly in arrears and interest on Eurocurrency Rate Advances is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months. Borrowings at closing were used to repay outstanding balances of debt outstanding under the former bank credit facility dated March 31, 2015 that was scheduled to mature on March 31, 2020 and for other general corporate purposes. As of March 31, 2018 a total of $331,206 of Credit Agreement and Swing Line Facility borrowings were outstanding under the Credit Agreement, based on currency exchange rates as of March 31, 2018 . Our outstanding Senior Notes at March 31, 2018 were as follows: Applicable Note Purchase Agreement Maturity Date U.S. Dollar Value at March 31, 2018 U.S. Dollar Value at March 31, 2017 $85,000 Senior notes at 6.33% 2008 Private Placement August 2018 $ 85,000 $ 85,000 $35,000 Senior notes at 6.43% 2008 Private Placement August 2020 35,000 35,000 $91,000 Senior notes at 3.20% 2012 Private Placement December 2022 91,000 91,000 $80,000 Senior notes at 3.35% 2012 Private Placement December 2024 80,000 80,000 $25,000 Senior notes at 3.55% 2012 Private Placement December 2027 25,000 25,000 $125,000 Senior notes at 3.45% 2015 Private Placement May 2025 125,000 125,000 $125,000 Senior notes at 3.55% 2015 Private Placement May 2027 125,000 125,000 $100,000 Senior notes at 3.70% 2015 Private Placement May 2030 100,000 100,000 $50,000 Senior notes at 3.93% 2017 Private Placement February 2027 50,000 50,000 €60,000 Senior notes at 1.86% 2017 Private Placement February 2027 73,912 64,414 $45,000 Senior notes at 4.03% 2017 Private Placement February 2029 45,000 45,000 €20,000 Senior notes at 2.04% 2017 Private Placement February 2029 24,637 21,472 £45,000 Senior notes at 3.04% 2017 Private Placement February 2029 63,141 56,040 €19,000 Senior notes at 2.30% 2017 Private Placement February 2032 23,406 20,398 £30,000 Senior notes at 3.17% 2017 Private Placement February 2032 42,094 37,360 Total Senior Notes $ 988,190 $ 960,684 On February 27, 2017, we issued and sold an aggregate principal amount of $95,000 , €99,000 , and £75,000 , of senior notes in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. These notes have maturities of between 10 and 15 years from the issue date. The agreement governing these notes contains leverage and interest coverage covenants. On May 15, 2015, Old STERIS issued and sold $350,000 of senior notes, in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. These notes have maturities of 10 to 15 years from the issue date. The agreement governing these notes contains leverage and interest coverage covenants. The agreements governing certain senior notes issued and sold in February 2013, December 2012, and August 2008, were amended and restated in their entirety on March 31, 2015. All of these notes were issued and sold in private placements to certain institutional investors in offerings that were exempt from the registration requirements of the Securities Act of 1933. The amended and restated agreements, which have been consolidated into a single agreement for the 2013 and 2012 notes, and a separate single agreement for the 2008 notes, contain leverage and interest coverage covenants. At March 31, 2018 , we were in compliance with all financial covenants associated with our indebtedness. The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows: 2019 $ 85,000 2020 — 2021 35,000 2022 — 2023 and thereafter 1,199,396 Total $ 1,319,396

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional information related to our Consolidated Balance Sheet is as follows: March 31, 2018 2017 Accrued payroll and other related liabilities: Compensation and related items $ 30,270 $ 29,777 Accrued vacation/paid time off 11,011 8,651 Accrued bonuses 31,716 20,715 Accrued employee commissions 17,168 16,201 Other post-retirement benefits obligations-current portion 1,906 2,187 Other employee benefit plans' obligations-current portion 1,929 1,044 Total accrued payroll and other related liabilities $ 94,000 $ 78,575 Accrued expenses and other: Deferred revenues $ 74,698 $ 71,020 Self-insured risk reserves-current portion 7,349 6,633 Accrued dealer commissions 16,121 16,122 Accrued warranty 6,872 6,861 Asset retirement obligation-current portion 1,798 — Other 61,379 54,253 Total accrued expenses and other $ 168,217 $ 154,889 Other liabilities: Self-insured risk reserves-long-term portion $ 15,008 $ 15,584 Other post-retirement benefits obligations-long-term portion 12,194 13,821 Defined benefit pension plans obligations-long-term portion 29,407 27,234 Other employee benefit plans obligations-long-term portion 3,221 3,661 Accrued long-term income taxes 18,922 2,089 Asset retirement obligation-long-term portion 9,841 9,953 Other 20,007 10,331 Total other liabilities $ 108,600 $ 82,673

Income Tax Expense

Income Tax Expense	12 Months Ended
	Mar. 31, 2018
Income Tax Expense [Abstract]
Income Tax Expense (Benefit)	Income from continuing operations before income taxes was as follows: Years Ended March 31, 2018 2017 2016 United States operations $ 203,872 $ 189,429 $ 105,758 United Kingdom operations 3,253 (36,420 ) (20,553 ) Other locations operations 147,857 31,637 86,679 $ 354,982 $ 184,646 $ 171,884 The components of the provision for income taxes related to income from continuing operations consisted of the following: Years Ended March 31, 2018 2017 2016 Current: United States federal $ 47,728 $ 43,900 $ 41,653 United States state and local 7,727 8,171 7,943 United Kingdom 6,671 362 2,194 Other locations 22,667 21,094 13,924 84,793 73,527 65,714 Deferred: United States federal (15,728 ) 10,293 1,427 United States state and local 2,656 2,131 299 United Kingdom (2,968 ) (2,292 ) (6,973 ) Other locations (5,393 ) (9,644 ) (168 ) (21,433 ) 488 (5,415 ) Total Provision for Income Taxes $ 63,360 $ 74,015 $ 60,299 The total provision for income taxes can be reconciled to the tax computed at the United Kingdom federal statutory tax rate for 2018 and 2017 and the United States federal statutory tax rate for 2016 as follows: Years Ended March 31, 2018 2017 2016 National statutory tax rate 19.0 % 20.0 % 35.0 % Increase in accruals for uncertain tax positions 0.1 % 0.3 % 0.2 % U.S. state and local taxes, net of federal income tax benefit 2.3 % 3.8 % 3.3 % Increase in valuation allowances 0.1 % 0.1 % 1.0 % U.S. research and development credit (0.5 )% (1.1 )% — % U.S. foreign income tax credit (0.2 )% — % (0.6 )% Difference in non-United States tax rates — % — % (8.5 )% Difference in non-United Kingdom tax rates 4.1 % 6.0 % — % Excise tax gross-up — % — % 3.4 % U.S. manufacturing deduction (0.8 )% (2.5 )% (2.5 )% Excess tax benefit for equity compensation (1.8 )% (2.8 )% — % Tax rate changes on deferred tax assets and liabilities (10.3 )% (2.3 )% — % U.S. transition tax on foreign earnings 4.9 % — % — % Acquisitions and divestitures 0.5 % 9.0 % — % Goodwill impairment on divestitures — % 7.9 % — % Capitalized acquisition costs — % 0.2 % 5.3 % All other, net 0.4 % 1.5 % (1.5 )% Total Provision for Income Taxes 17.8 % 40.1 % 35.1 % Unrecognized Tax Benefits. We classify uncertain tax positions and related interest and penalties as long-term liabilities within “Other liabilities” in our accompanying Consolidated Balance Sheets, unless they are expected to be paid within 12 months, in which case, the uncertain tax positions would be classified as current liabilities within “Accrued income taxes.” We recognize interest and penalties related to unrecognized tax benefits within “Income tax expense” in our accompanying Consolidated Statements of Income. A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows: 2018 2017 Unrecognized Tax Benefits Balance at April 1 $ 1,884 $ 3,527 Increases for tax provisions of current year 356 510 Balances related to acquired/disposed businesses — (1,502 ) Other, including currency translation 260 (651 ) Unrecognized Tax Benefits Balance at March 31 $ 2,500 $ 1,884 We recognized interest and penalties related to uncertain tax positions in the provision for income taxes. As of March 31, 2018 , and 2017 we had $295 and $184 accrued for interest and penalties, respectively. The increase during fiscal 2018 is primarily associated with the addition of current year uncertain tax positions. If all unrecognized tax benefits were recognized, the net impact on the provision for income tax expense would be $2,795 . It is reasonably possible that during the next 12 months, there will be no material reductions in unrecognized tax benefits as a result of the expiration of various statutes of limitations or matters related to transfer pricing. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2015 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2011. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse effect on our consolidated financial statements. We estimate that the tax benefit from our Costa Rican Tax Holiday is $945 (or $0.01 per fully diluted share), annually. The Tax Holiday runs fully exempt, from income tax, through 2025 and partially exempt through 2029. Deferred Taxes. The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2018 and 2017 were as follows: March 31, 2018 2017 Deferred Tax Assets: Post-retirement benefit accrual $ 3,505 $ 6,116 Compensation 12,334 17,196 Net operating loss carryforwards 26,217 35,129 Accrued expenses 5,795 7,807 Insurance 3,417 4,957 Deferred income 4,632 8,962 Bad debt 1,426 1,740 Pension 5,247 4,647 Other 1,668 781 Deferred Tax Assets 64,241 87,335 Less: Valuation allowance 13,596 16,366 Total Deferred Tax Assets 50,645 70,969 Deferred Tax Liabilities: Depreciation and depletion 61,171 74,092 Intangibles 140,398 156,291 Other 2,774 3,631 Total Deferred Tax Liabilities 204,343 234,014 Net Deferred Tax Assets (Liabilities) $ (153,698 ) $ (163,045 ) At March 31, 2018 , we had U.S. federal operating loss carryforwards of $34,866 , which remain subject to a 20 year carryforward period. Additionally, we had non-U.S. operating loss carry forwards of $51,309 . Although the majority of the non-U.S. carryforwards have indefinite expiration periods, those carryforwards that have definite expiration periods will expire if unused between fiscal years 2019 and 2027. In addition, we have recorded tax benefits of $3,863 related to state operating loss carryforwards. If unused, these state operating loss carryforwards will expire between fiscal years 2019 and 2038. At March 31, 2018 , we had $129 of tax credit carryforwards. These credit carryforwards can be used through fiscal 2027. We review the need for a valuation allowance against our deferred tax assets. A valuation allowance of $13,596 has been applied to a portion of the net deferred tax assets because we do not believe it is more-likely-than-not that we will receive future benefit. The valuation allowance decreased during fiscal 2018 by $2,770 . Other than the provisional tax expense recorded for the one-time transition tax on unremitted earnings of non-US subsidiaries, no additional provision has been made for income taxes on undistributed earnings of foreign subsidiaries as the amounts continue to be indefinitely reinvested. The Company is still evaluating whether to change its indefinite reinvestment assertion in light of U.S. Tax Reform and considers this conclusion to be incomplete. If the Company subsequently changes its assertion, it will account for the change in the quarter of fiscal year 2019 when the analysis is complete. The amount of undistributed earnings of subsidiaries was approximately $1,100,000 at March 31, 2018. It is not practicable to estimate the additional income taxes and applicable withholding taxes that would be payable on the remittance of such undistributed earnings. In October 2015, the Organization for Economic Cooperation and Development (OECD), in conjunction with the G20, finalized broad-based international tax policy guidelines that involve transfer pricing and other international tax subjects. While some member jurisdictions automatically adopt the new OECD guidelines, most member countries can adopt the guidelines only by new law or regulations. We are currently adopting processes to comply with the reporting requirements specified by the guidelines and are evaluating the other parts of the guidelines.

Benefit Plans

Benefit Plans	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Benefit Plans	In the United States, we sponsor an unfunded post-retirement benefits plan for two groups of United States retirees. Benefits under this plan include retiree life insurance and retiree medical insurance, including prescription drug coverage. During the second quarter of fiscal 2009, we amended our United States post-retirement welfare benefits plan, reducing the benefits to be provided to retirees under the plan and increasing their share of the costs. The amendments resulted in a decrease of $46,001 in the accumulated post-retirement benefit obligation. The impact of this change was recognized in our Consolidated Balance Sheets in fiscal 2009 and is being amortized as a component of the annual net periodic benefit cost over a period of approximately thirteen years. In July 2014, the Board of Directors of American Sterilizer Company (“AMSCO”) approved the termination of the American Sterilizer Company Retirement Income Plan (“Plan”) effective October 1, 2014. An Application for Determination was filed with the Internal Revenue Service (IRS) on August 22, 2014, with respect to the Plan termination. A Form 500 Standard Termination Notice was filed with the Pension Benefit Guaranty Corporation ("PBGC") on November 17, 2014. The 60-day PBGC waiting period lapsed without objection by the PBGC. AMSCO received a favorable determination from the IRS regarding the termination. On August 19, 2015, an annuity contract was purchased from Massachusetts Mutual Life Insurance Company to provide Plan benefits. Plan assets were converted to cash to fund the purchase. The purchase price of the annuity contract was $51,805 . An additional employer contribution of $4,641 was made to the Plan to fund the annuity purchase obligation on August 26, 2015. As a result of the purchase of the annuity, we recognized a pension settlement of $26,470 . In addition, plan benefits and benefit administration became the responsibility of the annuity provider. The assumptions used to measure the benefit obligation as of March 31, 2015 reflected this effort. As a result of the combination with Synergy, we now participate in five defined benefit pension schemes outside the United States: one in the UK, one in the Netherlands, two in Germany, and one in Switzerland. Unfunded obligations of $23,507 were recorded as of the November 2, 2015 closing date. The Synergy Health plc Retirement Benefit Scheme is a defined benefit (final salary) funded pension scheme. In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long-term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013. The Synergy Radeberg and Synergy Allershausen Schemes are unfunded defined pension schemes and are closed to new entrants. The Synergy Daniken Scheme is a defined benefit funded pension scheme. As a result of our fiscal 2018 acquisition of Harwell Dosimeters Ltd, we now participate in the Harwell Dosimeters Ltd Retirement Benefits Scheme which is a defined benefit funded pension scheme. We recognize the funded status of our defined benefit pension and post-retirement benefit plans in our Consolidated Balance Sheets, with a corresponding adjustment to accumulated other comprehensive income, net of tax. The funded status is measured as of March 31 each year and is calculated as the difference between the fair value of plan assets and the benefit obligation (which is the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for post-retirement benefit plans). Accumulated comprehensive income (loss) represents the net unrecognized actuarial losses and unrecognized prior service cost. These amounts will be recognized in net periodic benefit cost as they are amortized. We will recognize future changes to the funded status of these plans in the year the change occurs, through other comprehensive income. Obligations and Funded Status. The following table reconciles the funded status of the defined benefit pension plans and the other post-retirement benefits plan to the amounts recorded on our Consolidated Balance Sheets at March 31, 2018 and 2017 , respectively. Benefit obligation balances presented in the following table reflect the projected benefit obligations for our defined benefit pension plans and the accumulated other post-retirement benefit obligation for our post-retirement benefits plan. The measurement date of our defined benefit pension plans and other post-retirement benefits plan is March 31, for both periods presented. Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2018 2017 2018 2017 Change in Benefit Obligations: Benefit Obligations at Beginning of Year $ 128,897 $ 128,942 $ 16,008 $ 18,380 Obligation assumed in business acquisition 3,843 — — — Service cost 2,402 1,650 — — Interest cost 3,262 3,434 519 554 Actuarial loss (gain) (697 ) 16,633 (501 ) (531 ) Benefits and expenses (6,075 ) (7,190 ) (1,926 ) (2,395 ) Employee contributions 765 629 — — Impact of foreign currency exchange rate changes 16,451 (15,201 ) — — Benefit Obligations at End of Year 148,848 128,897 14,100 16,008 Change in Plan Assets: Fair Value of Plan Assets at Beginning of Year 101,663 104,353 — — Assets assumed in business acquisition 4,462 — — — Actual return on plan assets 1,052 11,910 — — Employer contributions 5,150 4,838 1,926 2,395 Employee contributions 765 629 — — Benefits and expenses paid (6,078 ) (7,190 ) (1,926 ) (2,395 ) Impact of foreign currency exchange rate changes 12,427 (12,877 ) — — Fair Value of Plan Assets at End of Year 119,441 101,663 — — Funded Status of the Plans $ (29,407 ) $ (27,234 ) $ (14,100 ) $ (16,008 ) Amounts recognized in the consolidated balance sheets consist of the following: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2018 2017 2018 2017 Current liabilities $ — $ — $ (1,906 ) $ (2,187 ) Noncurrent liabilities (29,407 ) (27,234 ) (12,194 ) (13,821 ) $ (29,407 ) $ (27,234 ) $ (14,100 ) $ (16,008 ) The pre-tax amount of unrecognized actuarial net loss and unamortized prior service cost included in accumulated other comprehensive (loss) income at March 31, 2018 , was approximately $23,568 and $13,825 , respectively. During fiscal 2019, we will amortize the following pre-tax amounts from accumulated other comprehensive income: Defined Benefit Pension Plans Other Post-Retirement Benefits Plan Actuarial loss $ 507 $ 648 Prior Service Cost — (3,263 ) Defined benefit plans with an accumulated benefit obligation and projected benefit obligation exceeding the fair value of plan assets had the following plan assets and obligations at March 31, 2018 and 2017 : Other Defined Benefit Pension Plans 2018 2017 Aggregate fair value of plan assets $ 119,441 $ 101,663 Aggregate accumulated benefit obligations 148,848 128,897 Aggregate projected benefit obligations 148,848 128,897 Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Income. Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan AMSCO Plan 2018 2017 2016 2018 2017 2016 2018 2017 2016 Service cost $ 2,402 $ 1,650 $ 961 $ — $ — $ — $ — $ — $ 27 Interest cost 3,262 3,434 1,659 519 554 593 — — 560 Expected return on plan assets (4,835 ) (2,853 ) (1,324 ) — — — — — (1,008 ) Prior service cost recognition — — (142 ) (3,263 ) (3,263 ) (3,263 ) — — — Net amortization and deferral 126 — — 648 739 828 — — 602 Curtailments/settlements — — (326 ) — — — — — 26,470 Net periodic benefit cost $ 955 $ 2,231 $ 828 $ (2,096 ) $ (1,970 ) $ (1,842 ) $ — $ — $ 26,651 Recognized in other comprehensive loss (income) before tax: Net loss (gain) occurring during year $ (697 ) $ (7,553 ) $ (3,733 ) $ 501 $ 531 $ 673 $ — $ — $ — Amortization of prior service credit — — — 3,263 3,263 3,263 — — — Amortization of net loss (126 ) — — (648 ) (739 ) (721 ) — — (602 ) Total recognized in other comprehensive loss (income) (823 ) (7,553 ) (3,733 ) 3,116 3,055 3,215 — — (602 ) Total recognized in total benefits cost and other comprehensive loss (income) $ 132 $ (5,322 ) $ (2,905 ) $ 1,020 $ 1,085 $ 1,373 $ — $ — $ 26,049 Assumptions Used in Calculating Benefit Obligations and Net Periodic Benefit Cost. The following table presents significant assumptions used to determine the projected benefit obligations at March 31: 2018 2017 Discount Rate: Synergy Health plc Retirement Benefits Scheme 2.50 % 2.60 % Isotron BV Pension Plan 1.60 % 1.60 % Synergy Health Daniken AG 0.95 % 0.65 % Synergy Health Radeberg 1.60 % 1.50 % Synergy Health Allershausen 1.60 % 1.50 % Harwell Dosimeters Ltd Retirement Benefits Scheme 2.55 % n/a Other post-retirement plan 3.50 % 3.50 % The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31: 2018 2017 2016 Discount Rate: Defined benefit pension plans Synergy Health plc Retirement Benefits Scheme 2.60 % 3.50 % 3.20 % Isotron BV Pension Plan 1.60 % 1.60 % 2.10 % Synergy Health Daniken AG 0.65 % 0.65 % 0.40 % Synergy Health Radeberg 1.50 % 1.50 % 1.60 % Synergy Health Allershausen 1.50 % 1.50 % 1.60 % Harwell Dosimeters Ltd Retirement Benefits Scheme 2.55 % n/a n/a Other post-retirement plan 3.50 % 3.50 % 3.25 % Expected Return on Plan Assets: Synergy Health plc Retirement Benefits Scheme 4.97 % 4.87 % 5.19 % Isotron BV Pension Plan 1.60 % 1.60 % 2.10 % Synergy Health Daniken AG 1.40 % 1.40 % 1.40 % The net periodic benefit cost and the actuarial present value of projected benefit obligations are based upon assumptions that we review on an annual basis. These assumptions may be revised annually based upon an evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing benefits. We develop our expected long-term rate of return on plan assets assumptions by evaluating input from third-party professional advisers, taking into consideration the asset allocation of the portfolios and the long-term asset class return expectations. We develop our discount rate assumptions by evaluating input from third-party professional advisers, taking into consideration the current yield on country specific investment grade long-term bonds which provide for similar cash flow streams as our projected obligations. We have made assumptions regarding healthcare costs in computing our other post-retirement benefit obligation. The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below. 2018 2017 2016 Healthcare cost trend rate – medical 7.0 % 7.0 % 7.0 % Healthcare cost trend rate – prescription drug 7.0 % 7.0 % 7.0 % Long-term healthcare cost trend rate 4.5 % 4.5 % 4.5 % To determine the healthcare cost trend rates, we evaluate a combination of information, including ongoing claims cost monitoring, annual statistical analyses of claims data, reconciliation of forecasted claims against actual claims, review of trend assumptions of other plan sponsors and national health trends, and adjustments for plan design changes, workforce changes, and changes in plan participant behavior. A one-percentage-point change in assumed healthcare cost trend rates (including medical, prescription drug, and long-term rates) would have had the following effect on our other post-retirement benefit obligation at March 31, 2018 : One-Percentage Point Increase Decrease Effect on total service and interest cost components $ 1 $ (1 ) Effect on other post-retirement benefit obligation 21 (20 ) Plan Assets. The investment policies for our plans are generally established by the local pension plan trustees and seek to maintain the plans' ability to meet liabilities and to comply with local minimum funding requirements. Plan assets are invested in diversified portfolios that provide adequate levels of return at an acceptable level of risk. The investment policies are reviewed at least annually and revised, as deemed appropriate to ensure that the objectives are being met. At March 31, 2018 , the targeted allocation for the plans were approximately 75% equity investments and 25% fixed income investments. Financial instruments included in pension plan assets are categorized into three tiers. These tiers include a fair value hierarchy of three levels, based on the degree of subjectivity inherent in the valuation methodology as follows: Level 1 - Quoted prices for identical assets in active markets. Level 2 - Quoted prices for similar assets in active markets with inputs that are observable, either directly or indirectly. Level 3 - Unobservable prices or inputs in which little or no market data exists. The fair value of our pension benefits plan assets at March 31, 2018 and 2017 by asset category is as follows: Fair Value Measurements at March 31, 2018 (In thousands) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Cash $ 67 $ 67 $ — $ — Insured annuities 15,228 — 15,228 — Insurance contracts 5,484 — — 5,484 Common and collective trusts valued at net asset value: Equity security trusts 74,081 Debt security trusts 24,581 Total Plan Assets $ 119,441 $ 67 $ 15,228 $ 5,484 Fair Value Measurements at March 31, 2017 (In thousands) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Cash $ 182 $ 182 $ — $ — Insured annuities 10,813 — 10,813 — Insurance contracts 3,959 — — 3,959 Common and collective trusts valued at net asset value: Equity security trusts 64,922 Debt security trusts 21,787 Total Plan Assets $ 101,663 $ 182 $ 10,813 $ 3,959 Collective investment trusts are measured at fair value using the net asset value per share practical expedient. These trusts have not been categorized in the fair value hierarchy and are being presented in the tables above to permit a reconciliation of the fair value hierarchy to the total plan assets. The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2018 due to the following: Insurance contracts Balance at March 31, 2016 $ 4,192 Gains (losses) related to assets still held at year-end 116 Purchases, sales, settlements - net (208 ) Foreign currency (141 ) Balance at March 31, 2017 $ 3,959 Gains (losses) related to assets still held at year-end (43 ) Additions from business acquisition 2,231 Transfers out of Level 3 (852 ) Foreign currency 189 Balance at March 31, 2018 $ 5,484 Cash Flows. We contribute amounts to our defined benefit pension plans at least equal to the minimum amounts required by applicable employee benefit laws and local tax laws. We expect to make contributions of approximately $5,630 , during fiscal year 2019. Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2018 , the following benefit payments are expected to be made to plan participants: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2019 $ 3,899 $ 1,907 2020 3,903 1,694 2021 4,143 1,548 2022 4,608 1,436 2023 5,611 1,293 2024-2029 27,108 4,741 The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the “Act”) provides a prescription drug benefit for Medicare beneficiaries, a benefit we provide to Medicare eligible retirees covered by our post-retirement benefits plan. We have concluded that the prescription drug benefit provided in our post-retirement benefit plan is considered to be actuarially equivalent to the benefit provided under the Act and thus qualifies for the subsidy under the Act. Benefits are subject to a per capita per month cost cap and any costs above the cap become the responsibility of the retiree. The subsidy is applied to reduce the retiree responsibility. As a result, the expected future subsidy no longer reduces our accumulated post-retirement benefit obligation and net periodic benefit cost. We collected subsidies totaling approximately $383 and $326 , during fiscal 2018 and fiscal 2017 , respectively, which reduced the retiree responsibility for costs in excess of the caps established in the post-retirement benefit plan. Defined Contribution Plans. We maintain a 401(k) defined contribution plan for eligible U.S. employees, a 401(k) defined contribution plan for eligible Puerto Rico employees and similar savings plans for certain employees in Canada, United Kingdom, Ireland, and Finland. We provide a match on a specified portion of an employee’s contribution. The U.S. plan assets are held in trust and invested as directed by the plan participants. The Canadian plan assets are held by insurance companies. The aggregate fair value of the U.S. plan assets was $655,031 at March 31, 2018 . At March 31, 2018 , the U.S. plan held 645,854 STERIS ordinary shares with a fair value of $60,297 . We paid dividends of $781 , $734 , and $669 to the plan and participants on STERIS shares held by the plan for the years ended March 31, 2018 , 2017 , and 2016 , respectively. We contributed approximately $24,037 , $22,676 , and $21,897 , to the defined contribution plans for the years ended March 31, 2018 , 2017 , and 2016 , respectively. We also maintain a domestic non-qualified deferred compensation plan covering certain employees, which formerly allowed for the deferral of compensation for an employee-specified term or until retirement or termination. There have been no employee contributions made to this plan since fiscal 2012. The Plan was amended in fiscal 2012 to disallow deferrals of salary payable in 2012 and subsequent calendar years and of commissions and other incentive compensation payable in respect of the 2013 and subsequent fiscal years. We hold investments in mutual funds to satisfy future obligations of the plan. We account for these assets as available-for-sale securities and they are included in “Other assets” on our accompanying Consolidated Balance Sheets, with a corresponding liability for the plan’s obligation recorded in “Accrued expenses and other.” The aggregate value of the assets was $1,583 and $1,604 at March 31, 2018 and March 31, 2017 , respectively. Realized gains and losses on these investments are recorded in “Interest and miscellaneous income” within “Non-operating expenses” on our accompanying Consolidated Statements of Income. Changes in the fair value of the assets are recorded in other comprehensive income on our accompanying balance sheets.

Contingencies

Contingencies	12 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency [Text Block]	We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the risks and uncertainties described under the title "product related regulations and claims" in Item 1A. of this Annual Report on Form 10-K. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes” in this Annual Report on Form 10-K. Additional information regarding our contingencies is included in Item 7 of Part II titled, “Management’s Discussion and Analysis of Financial Conditions and Results of Operations under "Contingencies". As of March 31, 2018 and 2017 , our commercial commitments totaled $66,992 and $57,709 , respectively. Commercial commitments include standby letters of credit, letters of credit required as security under our self-insured risk retention policies, and other potential cash outflows resulting from an event that requires payment by us. Approximately $7,694 of the March 31, 2018 and 2017 totals relate to letters of credit required as security under our self-insured risk retention policies. As of March 31, 2018 , we had minimum purchase commitments with suppliers for raw material purchases totaling $126,758 . As of March 31, 2018 , we also had commitments of $1,713 for long term construction contracts.

Business Segment Information

Business Segment Information	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Business Segment Information	. Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs. Linen Management Services were divested in fiscal 2017. Our Life Sciences segment offers consumable products, equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and capital equipment. Our Applied Sterilization Technologies segment offers contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. Certain minor organizational changes were made to better align with our Customers, resulting in several smaller operations shifting among the segments. The prior period measures have been recast for comparability. For the year ended March 31, 2018 , revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. The accounting policies for reportable segments are the same as those for the consolidated Company. Management evaluates performance and allocates resources based on a segment operating income measure. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which result in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate includes certain non-allocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Segment operating income excludes certain adjustments which include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making. Years Ended March 31, 2018 2017 2016 Revenues: Healthcare Products $ 1,276,054 $ 1,266,517 $ 1,203,884 Healthcare Specialty Services 469,065 539,536 421,110 Life Sciences 361,590 328,866 297,733 Applied Sterilization Technologies 513,287 477,837 316,037 Total revenues $ 2,619,996 $ 2,612,756 $ 2,238,764 Operating income (loss): Healthcare Products 221,795 227,707 181,009 Healthcare Specialty Services 28,910 10,573 24,555 Life Sciences 106,737 97,180 84,564 Applied Sterilization Technologies 173,375 158,379 99,854 Total reportable segments 530,817 493,839 389,982 Corporate (17,439 ) (17,307 ) (11,320 ) Total operating income before adjustments $ 513,378 $ 476,532 $ 378,662 Less: Adjustments Goodwill impairment loss (1) — 58,356 — Amortization of inventory and property "step up" to fair value (2) 1,599 4,743 9,907 Amortization of purchased intangible assets (2) 67,793 66,398 47,704 Acquisition and integration related transaction charges (3) 16,211 30,082 82,891 Loss (gain) on fair value adjustment of acquisition related contingent consideration (593 ) 2,569 (736 ) Net loss on divestiture of businesses (2) 14,547 86,574 — Settlement of pension obligation (4) — — 26,470 Impact of the U.S. Tax Cuts and Jobs Act (5) 10,264 — — Restructuring charges 103 215 (501 ) Total operating income $ 403,454 $ 227,595 $ 212,927 (1) For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets". (2) For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures". (3) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (4) See Note 9 titled, "Benefit Plans" for more information related to the settlement of the pension obligation. (5) Represents a one-time special employee bonus paid to most U.S. employees and associated professional fees. Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare Products and Life Sciences segments. Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare Products and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare Products and Life Sciences segments. Therefore, their respective amounts are reported together. March 31, 2018 2017 Assets: Healthcare Products and Life Sciences $ 1,621,156 $ 1,576,923 Healthcare Specialty Services 813,909 809,596 Applied Sterilization Technologies 2,765,269 2,537,936 Total assets $ 5,200,334 $ 4,924,455 Years Ended March 31, 2018 2017 2016 Capital Expenditures: Healthcare Products and Life Sciences $ 52,767 $ 39,253 $ 34,581 Healthcare Specialty Services 16,497 42,408 31,308 Applied Sterilization Technologies 96,193 91,240 60,518 Total Capital Expenditures $ 165,457 $ 172,901 $ 126,407 Depreciation, Depletion, and Amortization: Healthcare Products and Life Sciences $ 52,025 $ 46,709 $ 49,142 Healthcare Specialty Services 29,269 56,860 36,114 Applied Sterilization Technologies 97,038 84,573 58,484 Total Depreciation, Depletion, and Amortization $ 178,332 $ 188,142 $ 143,740 Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant and equipment, net are those assets that are identified within the operations in each geographic area. Years Ended March 31, 2018 2017 2016 Revenues: United Kingdom $ 207,514 $ 229,603 $ 144,577 United States 1,836,414 1,803,457 1,662,050 Other locations 576,068 579,696 432,137 Total Revenues $ 2,619,996 $ 2,612,756 $ 2,238,764 March 31, 2018 2017 Property, Plant, and Equipment, Net United Kingdom $ 97,586 $ 76,695 United States 530,591 499,760 Other locations 382,347 339,453 Property, Plant, and Equipment, Net $ 1,010,524 $ 915,908

Common Shares

Common Shares	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Earnings Per Share [Text Block]	Common and Ordinary Shares In connection with the Combination, each Old STERIS common shareholder received one ordinary share, par value 10 pence, of the Company for each Old STERIS common share held, and each Synergy ordinary shareholder received 0.4308 ordinary shares, par value 10 pence, of the Company and 439 pence in cash, for each Synergy ordinary share held. We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Years ended March 31, 2018 2017 2016 Denominator ( shares in thousands ): Weighted average shares outstanding—basic 85,028 85,473 70,698 Dilutive effect of share equivalents 685 621 486 Weighted average shares outstanding and share equivalents—diluted 85,713 86,094 71,184 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Years ended March 31, 2018 2017 2016 Number of ordinary share options ( shares in thousands ) 393 576 263 Preferred Shares Pursuant to an engagement letter dated October 23, 2015, we issued 100,000 preferred shares, par value of £0.10 each, for an aggregate consideration of approximately $15 , in satisfaction of debt owed to a service provider. The holders of the preferred shares are entitled to a fixed cumulative preferential annual dividend of 5 percent on the amount paid periodically on the preferred shares respectively held by them. On a return of capital of the Company whether on liquidation or otherwise, the holders of the preferred shares shall be entitled to receive out of the assets of the Company available for distribution to its shareholders the sum of £0.10 per preferred share plus any accrued but unpaid dividend, but will not be entitled to any further participation in the assets of the Company. The holders of the preferred shares will have no right to attend, speak or vote, whether in person or by proxy, at any general meeting of the Company or any meeting of a class of members of the Company in respect of the preferred shares and will not be entitled to receive any notice of meetings.

Repurchases of Common Shares

Repurchases of Common Shares	12 Months Ended
	Mar. 31, 2018
Repurchases of Common Shares [Abstract]
Schedule of Treasury Stock by Class [Text Block]	On August 9, 2016, the Company announced that its Board of Directors had authorized the purchase of up to $300 million of our ordinary shares. We may enter into share repurchase contracts until August 2, 2021 to effect these purchases. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at any time. We repurchased 664,963 of our ordinary shares during fiscal 2018 for the aggregate amount of $59,234 . We repurchased 1,286,183 of our ordinary shares during fiscal 2017 for the aggregate amount of $90,475 . Prior to the Combination, the Company’s Board of Directors provided authorization to repurchase up to $300 million of STERIS common shares. Under this authorization, we were able to purchase shares from time to time through open market purchases, including transactions pursuant to Rule 10b5-1 plans, or privately negotiated transactions. The authorization was no longer applicable after the Combination with Synergy. We did not make any purchases during fiscal year 2016 under the prior stock repurchase authorization. We obtained 127,903 of our shares during fiscal 2018 in the aggregate amount of $7,014 in connection with stock based compensation award programs. We obtained 168,906 of our shares during fiscal 2017 in the aggregate amount of $7,034 in connection with these programs. We obtained 267,696 of our shares during fiscal 2016 in the aggregate amount of $14,369 in connection with these programs.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	We maintain a long-term incentive plan which we assumed from Old STERIS, that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. Prior to the Combination, awards were made in respect of common shares of Old STERIS. In conjunction with the Combination all outstanding common share denominated awards were converted into an equivalent number of Company ordinary share denominated awards, with the same terms and conditions as applied to the replaced awards. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our ordinary shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or earlier if the option holder is no longer employed by us (subject to an extended exercise period in some cases for optionees who are age 55 and have at least five years of service). Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of March 31, 2018 , 4,985,756 shares remained available for grant under the long-term incentive plan. The fair value of share-based stock option compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during fiscal 2018, fiscal 2017 and fiscal 2016: Fiscal 2018 Fiscal 2017 Fiscal 2016 Risk-free interest rate 2.01 % 1.29 % 1.51 % Expected life of options 5.7 years 5.7 years 5.7 years Expected dividend yield of stock 1.58 % 1.54 % 1.40 % Expected volatility of stock 22.08 % 22.92 % 25.06 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.25% , 1.85% and 1.55% was applied in fiscal 2018 , 2017 and 2016 , respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2017 1,945,274 $ 50.28 Granted 429,360 77.75 Exercised (329,733 ) 34.01 Forfeited (23,239 ) 68.29 Outstanding at March 31, 2018 2,021,662 $ 58.56 6.6 years $ 70,350 Exercisable at March 31, 2018 1,139,722 $ 48.81 5.3 years $ 50,772 We estimate that 867,996 of the non-vested stock options outstanding at March 31, 2018 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $93.36 closing price of our ordinary shares on March 29, 2018 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our ordinary shares. The total intrinsic value of stock options exercised during the years ended March 31, 2018 , 2017 and 2016 was $16,096 , $6,454 and $13,000 , respectively. Net cash proceeds from the exercise of stock options were $11,093 , $4,955 and $11,240 for the years ended March 31, 2018 , 2017 and 2016 , respectively. The tax benefit from stock option exercises was $6,581 , $5,058 and $6,281 for the years ended March 31, 2018 , 2017 and 2016 , respectively. The weighted average grant date fair value of stock option grants was $15.51 , $13.42 and $14.66 for the years ended March 31, 2018 , 2017 and 2016 , respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of March 31, 2018 , 2017 and 2016 was $1,437 , $1,622 , $2,165 , respectively. The fair value of outstanding SARS is revalued at each reporting date and the related liability and expense are adjusted appropriately. A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2017 780,526 34,013 $ 60.87 Granted 251,300 23,259 78.60 Vested (231,107 ) (21,181 ) 54.41 Forfeited (37,518 ) (660 ) 68.57 Non-vested at March 31, 2018 763,201 35,431 $ 68.65 Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during fiscal 2018 was $13,727 . As of March 31, 2018 , there was a total of $36,514 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.14 years.

Financial and Other Guarantees

Financial and Other Guarantees	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Product Warranty Disclosure [Text Block]	We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the periods presented are as follows: Years Ended March 31, 2018 2017 2016 Balance, Beginning of Year $ 6,861 $ 5,909 $ 5,579 Warranties issued during the period 12,305 11,823 11,194 Settlements made during the period (12,294 ) (10,871 ) (10,864 ) Balance, End of Year $ 6,872 $ 6,861 $ 5,909 We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance Sheets within “Accrued expenses and other.” The liability recorded for such deferred service revenue was $35,204 , $34,264 and $33,416 as of March 31, 2018 , 2017 and 2016 , respectively. Such deferred revenue is then amortized on a straight-line basis over the contract term and recognized as service revenue on our accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenues is excluded from the table presented above.

Forward and Swap Contracts

Forward and Swap Contracts	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At March 31, 2018 , we held foreign currency forward contracts to buy 13.0 million Canadian dollars. At March 31, 2018 , we held commodity swap contracts to buy 592.5 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance Sheet Location March 31, 2018 March 31, 2017 March 31, 2018 March 31, 2017 Prepaid & Other $ 187 $ 160 $ — $ — Accrued expenses and other $ — $ — $ — $ 35 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of (loss) gain recognized in income Amount of (loss) gain recognized in income Years Ended March 31, 2018 2017 2016 Foreign currency forward contracts Selling, general and administrative $ (1,357 ) $ (1,886 ) $ (683 ) Commodity swap contracts Cost of revenues $ 373 $ 376 $ (461 ) Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of non-functional currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $57,161 at March 31, 2018 . These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Fair Value Disclosures [Text Block]	Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at March 31, 2018 and March 31, 2017 : Fair Value Measurements At March 31, Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 2018 2017 2018 2017 2018 2017 2018 2017 Assets: Cash and cash equivalents (1) $ 201,534 $ 282,918 $ 201,534 $ 282,918 $ — $ — $ — $ — Forward and swap contracts (2) 187 160 — — 187 160 — — Investments (3) 16,382 12,552 16,382 12,552 — — — — Liabilities: Forward and swap contracts (2) $ — $ 35 $ — $ — $ — $ 35 $ — $ — Deferred compensation plans (3) 1,694 1,677 1,694 1,677 — — — — Long term debt (4) 1,316,001 1,478,361 — — 1,305,181 1,496,966 — — Contingent consideration obligations (5) 8,068 4,451 — — — — 8,068 4,451 (1) Money market fund holdings are valued at fair value using the net asset value per share practical expedient and are not included within the fair value hierarchy. These money market funds are being presented in the table above to permit a reconciliation of the fair value hierarchy to total cash and cash equivalents. (2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment. (4) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at March 31, 2018 are summarized as follows: Contingent Consideration Balance at March 31, 2016 $ 5,886 Additions 3,592 Payments (5,416 ) Foreign currency translation adjustments 389 Balance at March 31, 2017 $ 4,451 Additions 5,774 Payments (1,735 ) Reductions (593 ) Foreign currency translation adjustments 171 Balance at March 31, 2018 $ 8,068 Additions and payments of contingent consideration obligations during fiscal year 2018 were primarily related to our fiscal year 2018 and 2017 acquisitions. Additions and payments for contingent consideration obligations during fiscal year 2017 were primarily related to Black Diamond Video, Inc. and Sercon. Refer to Note 2 , Business Acquisitions and Divestitures for more information. Information regarding our investments is as follows: Investments At March 31, Cost Unrealized Gains (1) Unrealized Losses (1) Fair Value 2018 2017 2018 2017 2018 2017 2018 2017 Available-for-sale securities: Marketable equity securities and other (1) $ 11,037 $ 11,037 $ 3,762 $ — $ — $ (72 ) $ 14,799 $ 10,965 Mutual funds 1,000 1,091 583 496 — — 1,583 1,587 Total available-for-sale securities $ 12,037 $ 12,128 $ 4,345 $ 496 $ — $ (72 ) $ 16,382 $ 12,552 (1) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	12 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity consists of the following: Years Ended March 31, 2018 2017 2016 Cumulative foreign currency translation adjustment $ 16,457 $ (238,525 ) $ (72,594 ) Amortization of pension and postretirement benefit plans costs, net of taxes (6,742 ) (2,355 ) 5,108 Unrealized gain (loss) on available for sale securities 1,970 178 (673 ) Total $ 11,685 $ (240,702 ) $ (68,159 )

Reclassifications out of AOCI (

Reclassifications out of AOCI (Notes)	12 Months Ended
	Mar. 31, 2018
Reclassifications out of AOCI Equity [Abstract]
Reclassifications of out AOCI [Text Block]	Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity consists of the following: Years Ended March 31, 2018 2017 2016 Cumulative foreign currency translation adjustment $ 16,457 $ (238,525 ) $ (72,594 ) Amortization of pension and postretirement benefit plans costs, net of taxes (6,742 ) (2,355 ) 5,108 Unrealized gain (loss) on available for sale securities 1,970 178 (673 ) Total $ 11,685 $ (240,702 ) $ (68,159 )
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the years ended March 31, 2018 and March 31, 2017 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income (Loss) 2018 2017 2018 2017 2018 2017 2018 2017 Beginning Balance $ 178 $ (673 ) $ (2,355 ) $ 5,108 $ (238,525 ) $ (72,594 ) $ (240,702 ) $ (68,159 ) Other Comprehensive Income (Loss) before reclassifications 1,703 745 (2,291 ) (5,491 ) 254,982 (165,931 ) 254,394 (170,677 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 89 106 (2,096 ) (1,972 ) — — (2,007 ) (1,866 ) Net current-period Other Comprehensive Income (Loss) 1,792 851 (4,387 ) (7,463 ) 254,982 (165,931 ) 252,387 (172,543 ) Ending Balance $ 1,970 $ 178 $ (6,742 ) $ (2,355 ) $ 16,457 $ (238,525 ) $ 11,685 $ (240,702 ) (1) Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated other comprehensive income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Quarterly Results (Unaudited)

Quarterly Results (Unaudited)	12 Months Ended
	Mar. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	Quarters Ended March 31, December 31, September 30, June 30, Fiscal 2018 Revenues: Product $ 351,010 $ 309,461 $ 286,557 $ 273,605 Service 364,963 352,439 347,602 334,359 Total Revenues 715,973 661,900 634,159 607,964 Cost of Revenues: Product 187,710 162,611 152,611 143,245 Service 235,510 220,701 214,787 208,598 Total Cost of Revenues 423,220 383,312 367,398 351,843 Gross Profit 292,753 278,588 266,761 256,121 Percentage of Revenues 40.9 % 42.1 % 42.1 % 42.1 % Restructuring Expenses (53 ) 78 27 51 Net Income Attributable to Shareholders $ 73,598 $ 94,781 $ 64,459 $ 58,077 Basic Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.87 $ 1.12 $ 0.76 $ 0.68 Diluted Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.86 $ 1.11 $ 0.75 $ 0.68 Fiscal 2017 Revenues: Product $ 332,093 $ 302,260 $ 292,216 $ 271,750 Service 349,096 344,514 354,199 366,628 Total Revenues 681,189 646,774 646,415 638,378 Cost of Revenues: Product 173,333 152,879 155,110 142,698 Service 227,731 236,286 243,397 255,690 Total Cost of Revenues 401,064 389,165 398,507 398,388 Gross Profit 280,125 257,609 247,908 239,990 Percentage of Revenues 41.1 % 39.8 % 38.4 % 37.6 % Restructuring Expenses (5 ) 18 48 154 Net Income Attributable to Shareholders $ 26,143 $ (4,996 ) $ 40,416 $ 48,401 Basic Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.31 $ (0.06 ) $ 0.47 $ 0.56 Diluted Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.31 $ (0.06 ) $ 0.47 $ 0.56

Nature of Operations and Summ29

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Consolidation, Policy	Principles of Consolidation. We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. In prior periods, we presented income attributable to noncontrolling interests in the "Interest income and miscellaneous expense" line of our Consolidated Statements of Income and the amounts were not material.
Use of Estimates, Policy	Use of Estimates. We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available.
Cash and Cash Equivalents, Policy	Cash Equivalents and Supplemental Cash Flow Information. Cash equivalents are all highly liquid investments with a maturity of three months or less when purchased. We invest our excess cash in short-term instruments including money market funds and time deposits with major banks and financial institutions. We select investments in accordance with the criteria established in our investment policy. Our investment policy specifies, among other things, maturity, credit quality and concentration restrictions with the objective of preserving capital and maintaining adequate liquidity. Information supplementing our Consolidated Statements of Cash Flows is as follows: Years Ended March 31, 2018 2017 2016 Cash paid during the year for: Interest $ 48,663 $ 42,797 $ 37,165 Income taxes 85,629 78,009 60,885 Cash received during the year for income tax refunds 7,747 2,002 1,697
Revenue Recognition, Policy	Revenue Recognition. We recognize revenue for products when ownership passes to the Customer, which is based on contract or shipping terms and for services when the service is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor. We have no further obligations related to bringing about resale and our standard return and restocking fee policies are applied. Revenues are reported net of sales and value-added taxes collected from Customers. We also have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. Returns, rebates, and similar allowances are estimated based on historical experience and trend analysis. In transactions that contain multiple elements, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each element based on its relative selling price, based on the price for the product or service when it is sold separately. We offer preventive maintenance agreements to our Customers with contract terms of one to five years which require us to maintain and repair our products during this time. Amounts received under these Customer contracts are initially recorded as deferred service revenues and then recognized as service revenues ratably over the contract term.
Trade and Other Accounts Receivable, Policy	Accounts Receivable. Accounts receivable are presented at their face amount, less allowances for sales returns and uncollectible accounts. Accounts receivable consist of amounts billed and currently due from Customers and amounts earned but unbilled. We generally obtain and perfect security interest in products sold in the United States when we have a concern with the Customer's risk profile. We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed by Customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, Customer payment practices, and general economic conditions. We also analyze significant Customer accounts on a regular basis and record a specific allowance when we become aware of a specific Customer’s inability to pay. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible. We maintain an allowance for sales returns based upon known returns and estimated returns for both capital equipment and consumables. We estimate returns of capital equipment and consumables based upon recent historical experience
Inventory, Policy	Inventories, net. Inventories are stated at the lower of their cost or market value. We determine cost based upon a combination of the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods. For inventories valued using the LIFO method, we believe that the use of the LIFO method results in a matching of current costs and revenues. Inventories valued using the LIFO method represented approximately 26.0% and 29.0% of total inventories at March 31, 2018 and 2017 , respectively. Inventory costs include material, labor, and overhead. If we had used only the FIFO method of inventory costing, inventories would have been $17,280 and $16,706 higher than those reported at March 31, 2018 and 2017 , respectively. We review inventory on an ongoing basis, considering factors such as deterioration, obsolescence, and other items. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to cost of revenues.
Property, Plant and Equipment, Policy	Property, Plant, and Equipment. Our property, plant, and equipment consists of land and land improvements, buildings and leasehold improvements, machinery and equipment, information systems, radioisotope (cobalt-60), and construction in progress. Property, plant, and equipment are presented at cost less accumulated depreciation and depletion. We capitalize additions and improvements. Repairs and maintenance are charged to expense as they are incurred. Land is not depreciated and construction in progress is not depreciated until placed in service. Depreciation of most assets is computed on the cost less the estimated salvage value by using the straight-line method over the estimated remaining useful lives. Depletion of radioisotope is computed using the annual decay factor of the material, which is similar to the sum-of-the-years-digits method. We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table: Asset Type Useful Life (years) Land improvements 3-40 Buildings and leasehold improvements 2-50 Machinery and equipment 2-20 Information Systems 2-20 Radioisotope (cobalt-60) 20 When we sell, retire, or dispose of property, plant, and equipment, we remove the asset’s cost and accumulated depreciation from our Consolidated Balance Sheet. We recognize the net gain or loss on the sale or disposition in the Consolidated Statements of Income in the period when the transaction occurs.
Goodwill and Intangible Assets, Policy	Goodwill. We perform our annual impairment test for goodwill in the third quarter of each year. We may consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. We may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. We review the book value compared to the fair value at the reporting unit level. We calculate the fair value of our reporting units based on the present value of estimated future cash flows. Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows to measure fair value. Assumptions used in our impairment evaluations, such as forecasted growth rates and cost of capital, are consistent with internal projections, strategic plans, and operating plans. We believe such assumptions and estimates are also comparable to those that would be used by other market place participants. Identifiable Intangible Assets. Our identifiable intangible assets include product technology rights, trademarks, licenses, and Customer and vendor relationships. We record these assets at cost, or when acquired as part of a business acquisition, at estimated fair value. We generally amortize identifiable intangible assets over periods ranging from 5 to 20 years using the straight-line method. Our intangible assets also include indefinite lived assets including certain trademarks and tradenames that were acquired in connection with business combinations. These assets are tested at least annually for impairment.
Investment, Policy	Investments. Investments in marketable securities are stated at fair value and are included in "Other assets" on the Consolidated Balance Sheets. Unrealized gains and losses on marketable securities classified as available-for-sale are recorded in Accumulated Other Comprehensive Income (Loss).
Impairment or Disposal of Long-Lived Assets, Policy	Asset Impairment Losses. Property, plant, equipment, and identifiable intangible assets are reviewed for impairment when indicators of impairment exist and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We monitor for such indicators on an ongoing basis and if an impairment exists, we record the loss in the Consolidated Statements of Income during that period.
Asset Retirement Obligation [Policy Text Block]	Asset Retirement Obligations. We incur retirement obligations for certain assets. We record initial liabilities for the asset retirement obligations ("ARO") at fair value. Recognition of ARO includes: estimating the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and a periodic review of the ARO liability estimates and discount rates used in the analysis. We provide additional information about our asset retirement obligations in Note 5 to our consolidated financial statements titled, “Property, Plant and Equipment.”
Business Combinations Policy	Acquisitions of Business. Assets acquired and liabilities assumed in a business combination are accounted for at fair value on the date of acquisition. Costs related to the acquisition are expensed as incurred.
Liability Reserve Estimate, Policy	Self-Insurance Liabilities. We record a liability for self-insured risks that we retain for general and product liabilities, workers’ compensation, and automobile liabilities based on actuarial calculations. We use our historical loss experience and actuarial methods to calculate the liability. This liability includes estimates for both losses and incurred but not reported claims. We review the assumptions used to calculate the estimated liability at least annually to evaluate the adequacy of the amount recorded. We maintain insurance policies to cover losses greater than our estimated liability, which are subject to the terms and conditions of those policies. We are also self-insured for certain employee medical claims. We estimate a liability for incurred but not reported claims based upon recent claims experience.
Pension and Other Postretirement Plans, Policy	Benefit Plans. We sponsor defined benefit pension plans. We also sponsor a post-retirement benefits plan for certain former employees. We determine our costs and obligations related to these plans by evaluating input from third-party professional advisers. These costs and obligations are affected by assumptions including the discount rate, expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other factors. We review the assumptions used on an annual basis. We recognize an asset for the overfunded status or a liability for the underfunded status of defined benefit pension and post-retirement benefits plans in our consolidated balance sheets. This amount is measured as the difference between the fair value of plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for other post-retirement benefit plans). Changes in the funded status of the plans are recorded in other comprehensive income in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 9 to our consolidated financial statements titled, “Benefit Plans.”
Fair Value of Financial Instruments, Policy	Fair Value of Financial Instruments. Except for long-term debt, our financial instruments are highly liquid or have short-term maturities. We provide additional information about the fair value of our financial instruments in Note 17 titled, “Fair Value Measurements.”
Foreign Currency Transactions and Translations Policy	Foreign Currency Translation. Most of our operations use their local currency as their functional currency. Financial statements of subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate for each period for revenues, expenses, gains and losses. Translation adjustments for subsidiaries whose local currency is their functional currency are recorded as a component of accumulated other comprehensive income (loss) within equity. Transaction gains and losses resulting from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized as incurred in the accompanying Consolidated Statement of Income, except for certain inter-company balances designated as long-term in nature.
Derivatives, Policy	Forward and Swap Contracts. We enter into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies, including inter-company transactions.We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are marked to market, with gains and losses recognized within “Selling, general, and administrative expenses” or "Cost of revenues" in the accompanying Consolidated Statements of Income.
Standard Product Warranty, Policy	Warranty. Warranties are provided on the sale of certain of our products and services and an accrual for estimated future claims is recorded at the time revenue is recognized. We estimate warranty expense based primarily on historical warranty claim experience.
Shipping and Handling Cost, Policy	Shipping and Handling. We record shipping and handling costs in costs of revenues. Shipping and handling costs charged to Customers are recorded as revenues in the period the product revenues are recognized.
Advertising Costs, Policy	Advertising Expenses. Costs incurred for communicating, advertising and promoting our products are generally expensed when incurred as a component of Selling, General and Administrative Expense. We incurred $10,886 , $12,622 , and $10,785 of advertising costs during the years ended March 31, 2018 , 2017 , and 2016 , respectively.
Research and Development Expense, Policy	Research and Development. We incur research and development costs associated with commercial products and expense these costs as incurred. If a Customer reimburses us for research and development costs, the costs are charged to the related contracts as costs of revenues.
Income Tax, Policy	Income Taxes. We defer income taxes for all temporary differences between pre-tax financial and taxable income and between the book and tax basis of assets and liabilities. We record valuation allowances to reduce net deferred tax assets to an amount that we expect will more-likely-than-not be realized. In making such a determination, we consider all available information, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and if applicable, any carryback claims that can be filed. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes and the effective tax rate. We evaluate uncertain tax positions in accordance with a two-step process. The first step is recognition: The determination of whether or not it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate tax authority and that the tax authority will have full knowledge of all relevant information. The second step is measurement: A tax position that meets the more-likely-than-not threshold is measured to determine the amount of benefit to recognize in the financial statements. The measurement process requires the determination of the range of possible settlement amounts and the probability of achieving each of the possible settlements. The tax position is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. No tax benefits are recognized for positions that do not meet the more-likely-than-not threshold. Tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not recognition threshold are derecognized in the first subsequent financial reporting period in which the threshold is no longer met. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes.”
Medical Device Excise Tax	Medical Device Excise Tax. The Medical Device Excise Tax became effective January 1, 2013. The excise tax was mandated by the 2010 health care reform legislation and assesses a 2.3% tax on the sale or use of certain medical devices that are sold or manufactured in the United States. Many of our products are subject to the excise tax. Late in 2015, Congress enacted legislation that suspended the excise tax for 2016 and 2017. Early in 2018, U.S. Congress enacted legislation that extended the suspension of the excise tax for 2018 and 2019. Therefore, we did not incur Medical Device Excise taxes during fiscal 2018 or 2017. Should the U.S. Congress take no further action with regard to this tax we will begin to incur excise tax in the fourth quarter of fiscal 2020. We incurred Medical Device Excise taxes of $5,802 during fiscal year 2016, which was included in cost of revenues in the period of sale.
Share-based Compensation, Option and Incentive Plans Policy	Share-Based Compensation. We describe share-based compensation in Note 14 to our consolidated financial statements titled, “Share-Based Compensation.” We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. We record liability awards at fair value each reporting period and the change in fair value is reflected as share-based compensation expense in our Consolidated Statements of Income. The expense is classified as cost of goods sold, selling, general and administrative expenses or research and development expenses in a manner consistent with the employee’s compensation and benefits. These costs are recognized in the Consolidated Statement of Income over the period during which an employee is required to provide service in exchange for the award.
Costs Associated with Exit or Disposal Activities or Restructurings, Policy	Restructuring. We recognize restructuring expenses as incurred. Asset impairment and accelerated depreciation expenses primarily relate to inventory write-downs for rationalized products and adjustments in the carrying value of the related facilities and machinery and equipment to their estimated fair value. In addition, the remaining useful lives of other property, plant, and equipment associated with the related operations are reevaluated based on the respective restructuring plan, which may result in the acceleration of depreciation and amortization of certain assets
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323) March 2016 The standard replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2018 The prospective adoption of this standard did not have a material impact on our consolidated financial statements. ASU 2015-11, "Inventory - Simplifying the Measurement of Inventory" (Topic 330) July 2015 The standard requires an entity to measure inventory within the scope of this update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years and should be applied prospectively. Early adoption is permitted. First Quarter Fiscal 2018 The prospective adoption of this standard did not have a material impact on our consolidated financial statements. ASU 2017-04, "Intangibles - Goodwill and Other, Simplifying the Test for Goodwill Impairment" (Topic 350) January 2017 This standard eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedures that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, under the amendments of this standard, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The loss should not exceed the total amount of goodwill allocated to that reporting unit. Tax effects should be considered. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. Third Quarter Fiscal 2018 The prospective adoption of this standard did not have a material impact on our consolidated financial statements. ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718) March 2016 The standard simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2017 As a result of the adoption of this standard, we recorded $6.6 million and $5.1 million of excess tax benefits associated with share based compensation in the Consolidated Statements of Income for the years ended March 31, 2018 and 2017, respectively, and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated. Standards that have not yet been adopted ASU 2014-09, "Revenue from Contracts with Customers" and subsequently issued amendments May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We have completed our evaluation of our revenue streams and contracts and have adopted this standard on April 1, 2018 using the modified retrospective method. We have identified certain historical revenue transactions for which the timing of recognition would have been different under this standard. The amount of the cumulative adjustment required to defer revenue based on these transactions at the end of fiscal 2018 represents less than 0.5% of fiscal 2018 revenues, which will reduce retained earnings as of April 1, 2018. We are in the process of finalizing our revenue accounting policy and implementing changes to our business processes, disclosures and controls. Additionally, we expect to provide the required additional disclosures in periods subsequent to the adoption. ASU 2016-01, "Financial Instruments - Overall - Recognition and Measurement of Financial Assets and Liabilities" (Subtopic 825-10) January 2016 The standard changes how equity investments are measured and presents changes in the fair value of financial liabilities measured under the fair value option. Presentation and disclosure requirements for financial instruments are also affected. Entities will be required to measure equity investments that do not result in consolidation and are not recorded under the equity method at fair value with changes in fair value recognized in net income. The standard clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. N/A The impact that the standard will have on our consolidated financial statements will depend on the future variability in the fair values of our equity investments. However, based on current investment holdings, the impact is not expected to be material. ASU 2016-02, "Leases" (Topic 842) February 2016 The standard will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are currently evaluating the impact that the standard will have on our consolidated financial statements. We are also evaluating our lease portfolio, software packages, process and policy change requirements. We anticipate that most of our operating leases will result in the recognition of additional assets and corresponding liabilities in our Consolidated Balance Sheet, however we do not expect the standard to have a material impact on our financial position. The actual impact will depend on our lease portfolio at the time of adoption. More information regarding our total operating lease commitments at March 31, 2018, is disclosed in Note 5, "Property, Plant and Equipment". ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" June 2016 The standard requires a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2016-15, "Statement of Cash Flows" (Topic 230) August 2016 This standard provides guidance on the following specific cash flow issues: Debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. The standard is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is permitted. N/A The impact that the standard will have will depend on the future occurrence of the relevant transactions or conditions addressed by the standard. ASU 2016-16, "Income Taxes, Intra-Entity Transfers of Assets Other Than Inventory" (Topic 740) October 2016 The standard improves the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. The new standard requires the recognition of income tax consequences resulting from an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard is effective for annual periods beginning after December 15, 2017. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. The impact will depend on the value of future intra-entity transfers. ASU 2017-07 "Compensation - Retirement Benefits - Improving the Presentation of Net Periodic Pension and Net Periodic Postretirement Benefit Cost" (Topic 715) March 2017 This standard requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside the subtotal of income from operations, if one is presented. The standard is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. N/A The adoption of this standard is not expected to have a material impact on our consolidated financial statements as it principally relates to classification of costs within our Consolidated Statements of Income. The components of our net periodic benefit costs are disclosed in Note 9, "Benefit Plans". ASU 2017-09 "Compensation - Stock Compensation" (Topic 718) May 2017 The standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This standard is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. N/A The impact will depend on the future occurrence of the relevant terms or conditions addressed by the standard. ASU 2017-12 "Targeted Improvements to Accounting for Hedging Activities" (Topic 815) August 2017 The standard provides targeted improvements to accounting for hedging activities by expanding an entity’s ability to hedge non-financial and financial risk components and reduce complexity in fair value hedges of interest rate risk. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. The guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted in any interim period after issuance of the standard. The standard should be applied using a modified retrospective approach for cash flow and net investment hedge relationships that exist on the date of adoption, and prospectively for presentation and disclosure requirements. N/A We do not expect this standard to have a material impact on our consolidated financial statements. ASU 2018-02 "Income Statement - Reporting Comprehensive Income" (Topic 220) February 2018 The standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and requires certain disclosures about stranded tax effects. The underlying guidance requiring that the effect of a change in tax laws or rates be in included in income form continuing operations is not affected. This standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

Nature of Operations and Summ30

Nature of Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Cash Flow, Supplemental Disclosures	Information supplementing our Consolidated Statements of Cash Flows is as follows: Years Ended March 31, 2018 2017 2016 Cash paid during the year for: Interest $ 48,663 $ 42,797 $ 37,165 Income taxes 85,629 78,009 60,885 Cash received during the year for income tax refunds 7,747 2,002 1,697
Property, Plant and Equipment	We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table: Asset Type Useful Life (years) Land improvements 3-40 Buildings and leasehold improvements 2-50 Machinery and equipment 2-20 Information Systems 2-20 Radioisotope (cobalt-60) 20 Information related to the major categories of our depreciable assets is as follows: March 31, 2018 2017 Land and land improvements (1) $ 55,417 $ 46,848 Buildings and leasehold improvements 449,316 393,692 Machinery and equipment 575,607 508,247 Information systems 145,726 119,920 Radioisotope 476,578 436,787 Construction in progress (1) 87,745 77,421 Total property, plant, and equipment 1,790,389 1,582,915 Less: accumulated depreciation and depletion (779,865 ) (667,007 ) Property, plant, and equipment, net $ 1,010,524 $ 915,908 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Business Acquisitions and Div31

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)	12 Months Ended
	Mar. 31, 2018
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2018, 2017 and 2016 acquisitions. Fiscal Year 2018 Fiscal Year 2017 Fiscal Year 2016 (dollars in thousands) All Acquisitions (1) Medisafe Compass Phoenix Surgical and Endo-Tek Synergy Health plc Gepco Black Diamond Other Acquisitions Cash $ 235 $ 3,751 $ — $ 769 $ 53,057 $ 1,108 $ — $ — Accounts receivable 1,464 3,634 629 1,123 103,093 4,161 2,966 3,859 Inventory 2,289 2,454 659 950 30,074 1,926 3,309 1,108 Property, plant and equipment 3,420 639 13 1,092 496,555 3,421 607 1,979 Other assets 126 — 31 46 19,175 946 54 — Intangible assets 15,318 17,151 5,992 7,824 504,196 61,900 13,500 14,829 Goodwill 35,766 19,599 8,987 5,938 1,685,524 104,485 31,792 20,630 Total Assets 58,618 47,228 16,311 17,742 2,891,674 177,947 52,228 42,405 Current liabilities (2,833 ) (5,562 ) (309 ) (1,373 ) (107,932 ) (1,473 ) (4,525 ) (1,277 ) Long-term indebtedness — — — — (321,082 ) — — — Non-current liabilities (2,622 ) (3,398 ) — (1,263 ) (159,112 ) — (1,548 ) (49 ) Total Liabilities (5,455 ) (8,960 ) (309 ) (2,636 ) (588,126 ) (1,473 ) (6,073 ) (1,326 ) Net Assets $ 53,163 $ 38,268 $ 16,002 $ 15,106 $ 2,303,548 $ 176,474 $ 46,155 $ 41,079 he table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2018, 2017 and 2016 acquisitions. Fiscal Year 2018 Fiscal Year 2017 Fiscal Year 2016 (dollars in thousands) All Acquisitions (1) Medisafe Compass Phoenix Surgical and Endo-Tek Synergy Health plc Gepco Black Diamond Other Acquisitions Cash $ 235 $ 3,751 $ — $ 769 $ 53,057 $ 1,108 $ — $ — Accounts receivable 1,464 3,634 629 1,123 103,093 4,161 2,966 3,859 Inventory 2,289 2,454 659 950 30,074 1,926 3,309 1,108 Property, plant and equipment 3,420 639 13 1,092 496,555 3,421 607 1,979 Other assets 126 — 31 46 19,175 946 54 — Intangible assets 15,318 17,151 5,992 7,824 504,196 61,900 13,500 14,829 Goodwill 35,766 19,599 8,987 5,938 1,685,524 104,485 31,792 20,630 Total Assets 58,618 47,228 16,311 17,742 2,891,674 177,947 52,228 42,405 Current liabilities (2,833 ) (5,562 ) (309 ) (1,373 ) (107,932 ) (1,473 ) (4,525 ) (1,277 ) Long-term indebtedness — — — — (321,082 ) — — — Non-current liabilities (2,622 ) (3,398 ) — (1,263 ) (159,112 ) — (1,548 ) (49 ) Total Liabilities (5,455 ) (8,960 ) (309 ) (2,636 ) (588,126 ) (1,473 ) (6,073 ) (1,326 ) Net Assets $ 53,163 $ 38,268 $ 16,002 $ 15,106 $ 2,303,548 $ 176,474 $ 46,155 $ 41,079 (1) Purchase price allocation is still preliminary as of March 31, 2018, as valuations have not been finalized. Acquisition related transaction and integration costs totaled $16.2 million , $30.1 million , and $82.9 million for the fiscal years ended March 31, 2018 , 2017 , and 2016 , respectively. These costs are included in Selling, general, and administrative expenses in the Consolidated Statements of Income. Divestitures Synergy Health Healthcare Consumable Solutions On November 20, 2017, we sold our Synergy Health Healthcare Consumable Solutions ("HCS") business to Vernacare. Annual revenues for the HCS business were approximately $40.0 million and were included in the Healthcare Products segment. We recorded proceeds of $8.2 million , net of cash divested, and subject to a working capital adjustment. We also recognized a pre-tax loss on the sale, subject to final working capital adjustments, of $13.5 million in Selling, general, and administrative expense in the Consolidated Statement of Income. Netherlands Linen Management Services On February 9, 2017, we sold our Synergy Health Netherlands Linen Management Services business to EMEA B.V. Annual revenues for Synergy Health Netherlands Linen Management Services were approximately $75 million and were included in the Healthcare Specialty Services segment. We recorded a $43.0 million pre-tax loss on the sale in Selling, general, and administrative expense in the Consolidated Statements of Income as a result of the divestiture. In connection with the divestiture, we entered into a loan agreement to provide financing of up to €15 million for a term of up to 15 years . The loan carries an interest rate of 4 percent for the first four years and 12 percent thereafter. Outstanding borrowings under the agreement totaled $3.1 million at March 31, 2018 . U.S. Linen Management Services On November 3, 2016, we sold our Synergy Health U.S. Linen Management Services business to SRI Healthcare LLC. Annual revenues for U.S. Linen Management Services were approximately $50 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $4.5 million and recognized a pre-tax loss on the sale, subject to final adjustments, of $31.2 million in Selling, general, and administrative expense in the Consolidated Statements of Income. Synergy Health Labs On September 2, 2016, we sold Synergy Health Laboratory Services to SYNLAB International. Annual revenues for the Synergy Health Labs were approximately $15.0 million and were included in the Applied Sterilization Technologies segment. We recorded proceeds of $26.3 million , net of cash divested, and recognized a pre-tax gain on the sale of $18.7 million in Selling, general, and administrative expense in the Consolidated Statements of Income. Applied Infection Control On August 31, 2016, we completed the sale of our Applied Infection Control ("AIC") product line to DEB USA, Inc., a wholly-owned subsidiary of S.C. Johnson & Son, Inc. Annual revenues for the AIC product line were typically less than $50.0 million and were included in the Healthcare Products segment. We recorded proceeds of $41.8 million and recognized a pre-tax gain on the sale of $36.2 million in Selling, general, and administrative expense in the Consolidated Statements of Income. UK Linen Management Services On July 1, 2016, we sold our Synergy Health UK Linen Management Services business to STAR Mayan Limited. Annual revenues for UK Linen Management Services were approximately $50.0 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $65.4 million , net of cash divested, and recognized a pre-tax loss on the sale of $66.4 million in Selling, general, and administrative expense in the Consolidated Statements of Income.
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information gives effect to our acquisition of Synergy as if the acquisition had occurred at the beginning of fiscal 2016 and Synergy had been included in our consolidated results of operations for fiscal year ended March 31, 2016. Fiscal Year Ending Amounts are unaudited March 31, 2016 Net revenues $ 2,619,056 Net income from continuing operations 188,269

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Table Text Block]	Information regarding our intangible assets is as follows: 2018 2017 March 31, Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Customer relationships $ 663,532 $ 150,358 $ 597,386 $ 96,648 Non-compete agreements 4,738 3,790 4,722 3,629 Patents and technology 226,318 107,598 211,812 86,665 Trademarks and tradenames 83,509 36,864 80,223 32,547 Supplier relationships 54,800 7,307 54,800 4,567 Other 10 10 10 10 Total $ 1,032,907 $ 305,927 $ 948,953 $ 224,066
Schedule of Goodwill [Table Text Block]	Changes to the carrying amount of goodwill for the years ended March 31, 2018 , 2017 and 2016 were as follows: Healthcare Products Segment Healthcare Specialty Services Segment Life Sciences Segment Applied Sterilization Technologies Segment Synergy Combination Total Balance at March 31, 2016 363,770 154,272 147,334 83,035 1,408,192 2,156,603 Goodwill acquired or allocated 19,618 21,781 — — — 41,399 Synergy allocation — 376,807 — 1,308,717 (1,411,781 ) 273,743 Divestitures — (85,806 ) — — — (85,806 ) Impairment — (58,356 ) — — — (58,356 ) Foreign currency translation adjustments (5,623 ) (32,819 ) (820 ) (60,607 ) 3,589 (96,280 ) Balance at March 31, 2017 $ 377,765 $ 375,879 $ 146,514 $ 1,331,145 $ — $ 2,231,303 Goodwill acquired or allocated 16,418 3,501 — 15,847 — 35,766 Reassignment — (1,855 ) — 1,855 — — Foreign currency translation adjustments 10,491 10,500 2,302 143,422 — 166,715 Balance at March 31, 2018 $ 404,674 $ 388,025 $ 148,816 $ 1,492,269 $ — $ 2,433,784
Schedule of Expected Amortization Expense	Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows: 2019 2020 2021 2022 2022 Estimated amortization expense $ 68,447 $ 67,390 $ 66,742 $ 63,832 $ 59,061

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Inventory, Current	Inventories, net consisted of the following: March 31, 2018 2017 Raw materials $ 83,741 $ 65,300 Work in process 34,904 26,538 Finished goods 124,005 140,559 LIFO reserve (17,280 ) (16,706 ) Reserve for excess and obsolete inventory (19,639 ) (17,854 ) Inventories, net $ 205,731 $ 197,837

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Change in Asset Retirement Obligation [Table Text Block]	The following table summarizes the activity in the liability for asset retirement obligations. Asset Retirement Obligations Balance at March 31, 2017 $ 9,953 Liabilities incurred during the period 89 Liabilities settled during the period (352 ) Accretion expense 1,198 Foreign currency movement 751 Balance at March 31, 2018 $ 11,639
Schedule of Future Minimum Lease Payments for Capital Leases	Future minimum annual rentals payable under noncancelable operating lease agreements at March 31, 2018 were as follows: Operating Leases 2019 $ 24,116 2020 19,933 2021 14,666 2022 11,051 2023 and thereafter 39,464 Total minimum lease payments $ 109,230
Property, Plant and Equipment	We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table: Asset Type Useful Life (years) Land improvements 3-40 Buildings and leasehold improvements 2-50 Machinery and equipment 2-20 Information Systems 2-20 Radioisotope (cobalt-60) 20 Information related to the major categories of our depreciable assets is as follows: March 31, 2018 2017 Land and land improvements (1) $ 55,417 $ 46,848 Buildings and leasehold improvements 449,316 393,692 Machinery and equipment 575,607 508,247 Information systems 145,726 119,920 Radioisotope 476,578 436,787 Construction in progress (1) 87,745 77,421 Total property, plant, and equipment 1,790,389 1,582,915 Less: accumulated depreciation and depletion (779,865 ) (667,007 ) Property, plant, and equipment, net $ 1,010,524 $ 915,908 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Senior Notes in Private Placement [Table Text Block]	Applicable Note Purchase Agreement Maturity Date U.S. Dollar Value at March 31, 2018 U.S. Dollar Value at March 31, 2017 $85,000 Senior notes at 6.33% 2008 Private Placement August 2018 $ 85,000 $ 85,000 $35,000 Senior notes at 6.43% 2008 Private Placement August 2020 35,000 35,000 $91,000 Senior notes at 3.20% 2012 Private Placement December 2022 91,000 91,000 $80,000 Senior notes at 3.35% 2012 Private Placement December 2024 80,000 80,000 $25,000 Senior notes at 3.55% 2012 Private Placement December 2027 25,000 25,000 $125,000 Senior notes at 3.45% 2015 Private Placement May 2025 125,000 125,000 $125,000 Senior notes at 3.55% 2015 Private Placement May 2027 125,000 125,000 $100,000 Senior notes at 3.70% 2015 Private Placement May 2030 100,000 100,000 $50,000 Senior notes at 3.93% 2017 Private Placement February 2027 50,000 50,000 €60,000 Senior notes at 1.86% 2017 Private Placement February 2027 73,912 64,414 $45,000 Senior notes at 4.03% 2017 Private Placement February 2029 45,000 45,000 €20,000 Senior notes at 2.04% 2017 Private Placement February 2029 24,637 21,472 £45,000 Senior notes at 3.04% 2017 Private Placement February 2029 63,141 56,040 €19,000 Senior notes at 2.30% 2017 Private Placement February 2032 23,406 20,398 £30,000 Senior notes at 3.17% 2017 Private Placement February 2032 42,094 37,360 Total Senior Notes $ 988,190 $ 960,684
Schedule of Maturities of Long-term Debt [Table Text Block]	The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows: 2019 $ 85,000 2020 — 2021 35,000 2022 — 2023 and thereafter 1,199,396 Total $ 1,319,396
Schedule of Debt	Indebtedness as of March 31, 2018 and 2017 was as follows: 2018 2017 Credit Agreement and Swing Line Facility $ 331,206 $ 521,604 Private Placement 988,190 960,684 Deferred financing fees (3,395 ) (3,927 ) Total long term debt $ 1,316,001 $ 1,478,361

Additional Consolidated Balan36

Additional Consolidated Balance Sheets Information (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities	Additional information related to our Consolidated Balance Sheet is as follows: March 31, 2018 2017 Accrued payroll and other related liabilities: Compensation and related items $ 30,270 $ 29,777 Accrued vacation/paid time off 11,011 8,651 Accrued bonuses 31,716 20,715 Accrued employee commissions 17,168 16,201 Other post-retirement benefits obligations-current portion 1,906 2,187 Other employee benefit plans' obligations-current portion 1,929 1,044 Total accrued payroll and other related liabilities $ 94,000 $ 78,575 Accrued expenses and other: Deferred revenues $ 74,698 $ 71,020 Self-insured risk reserves-current portion 7,349 6,633 Accrued dealer commissions 16,121 16,122 Accrued warranty 6,872 6,861 Asset retirement obligation-current portion 1,798 — Other 61,379 54,253 Total accrued expenses and other $ 168,217 $ 154,889 Other liabilities: Self-insured risk reserves-long-term portion $ 15,008 $ 15,584 Other post-retirement benefits obligations-long-term portion 12,194 13,821 Defined benefit pension plans obligations-long-term portion 29,407 27,234 Other employee benefit plans obligations-long-term portion 3,221 3,661 Accrued long-term income taxes 18,922 2,089 Asset retirement obligation-long-term portion 9,841 9,953 Other 20,007 10,331 Total other liabilities $ 108,600 $ 82,673

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Mar. 31, 2018
Income Tax Expense [Abstract]
Schedule of Deferred Tax Assets and Liabilities	The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2018 and 2017 were as follows: March 31, 2018 2017 Deferred Tax Assets: Post-retirement benefit accrual $ 3,505 $ 6,116 Compensation 12,334 17,196 Net operating loss carryforwards 26,217 35,129 Accrued expenses 5,795 7,807 Insurance 3,417 4,957 Deferred income 4,632 8,962 Bad debt 1,426 1,740 Pension 5,247 4,647 Other 1,668 781 Deferred Tax Assets 64,241 87,335 Less: Valuation allowance 13,596 16,366 Total Deferred Tax Assets 50,645 70,969 Deferred Tax Liabilities: Depreciation and depletion 61,171 74,092 Intangibles 140,398 156,291 Other 2,774 3,631 Total Deferred Tax Liabilities 204,343 234,014 Net Deferred Tax Assets (Liabilities) $ (153,698 ) $ (163,045 )
Schedule of Income before Income Tax, Domestic and Foreign	Income from continuing operations before income taxes was as follows: Years Ended March 31, 2018 2017 2016 United States operations $ 203,872 $ 189,429 $ 105,758 United Kingdom operations 3,253 (36,420 ) (20,553 ) Other locations operations 147,857 31,637 86,679 $ 354,982 $ 184,646 $ 171,884
Schedule of Components of Income Tax Expense (Benefit)	The components of the provision for income taxes related to income from continuing operations consisted of the following: Years Ended March 31, 2018 2017 2016 Current: United States federal $ 47,728 $ 43,900 $ 41,653 United States state and local 7,727 8,171 7,943 United Kingdom 6,671 362 2,194 Other locations 22,667 21,094 13,924 84,793 73,527 65,714 Deferred: United States federal (15,728 ) 10,293 1,427 United States state and local 2,656 2,131 299 United Kingdom (2,968 ) (2,292 ) (6,973 ) Other locations (5,393 ) (9,644 ) (168 ) (21,433 ) 488 (5,415 ) Total Provision for Income Taxes $ 63,360 $ 74,015 $ 60,299
provision for taxes rate reconciliation	The total provision for income taxes can be reconciled to the tax computed at the United Kingdom federal statutory tax rate for 2018 and 2017 and the United States federal statutory tax rate for 2016 as follows: Years Ended March 31, 2018 2017 2016 National statutory tax rate 19.0 % 20.0 % 35.0 % Increase in accruals for uncertain tax positions 0.1 % 0.3 % 0.2 % U.S. state and local taxes, net of federal income tax benefit 2.3 % 3.8 % 3.3 % Increase in valuation allowances 0.1 % 0.1 % 1.0 % U.S. research and development credit (0.5 )% (1.1 )% — % U.S. foreign income tax credit (0.2 )% — % (0.6 )% Difference in non-United States tax rates — % — % (8.5 )% Difference in non-United Kingdom tax rates 4.1 % 6.0 % — % Excise tax gross-up — % — % 3.4 % U.S. manufacturing deduction (0.8 )% (2.5 )% (2.5 )% Excess tax benefit for equity compensation (1.8 )% (2.8 )% — % Tax rate changes on deferred tax assets and liabilities (10.3 )% (2.3 )% — % U.S. transition tax on foreign earnings 4.9 % — % — % Acquisitions and divestitures 0.5 % 9.0 % — % Goodwill impairment on divestitures — % 7.9 % — % Capitalized acquisition costs — % 0.2 % 5.3 % All other, net 0.4 % 1.5 % (1.5 )% Total Provision for Income Taxes 17.8 % 40.1 % 35.1 %
Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible	A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows: 2018 2017 Unrecognized Tax Benefits Balance at April 1 $ 1,884 $ 3,527 Increases for tax provisions of current year 356 510 Balances related to acquired/disposed businesses — (1,502 ) Other, including currency translation 260 (651 ) Unrecognized Tax Benefits Balance at March 31 $ 2,500 $ 1,884

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Expected Benefit Payments	Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2018 , the following benefit payments are expected to be made to plan participants: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2019 $ 3,899 $ 1,907 2020 3,903 1,694 2021 4,143 1,548 2022 4,608 1,436 2023 5,611 1,293 2024-2029 27,108 4,741
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	During fiscal 2019, we will amortize the following pre-tax amounts from accumulated other comprehensive income: Defined Benefit Pension Plans Other Post-Retirement Benefits Plan Actuarial loss $ 507 $ 648 Prior Service Cost — (3,263 )
Schedule of Accrued Liabilities	Amounts recognized in the consolidated balance sheets consist of the following: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2018 2017 2018 2017 Current liabilities $ — $ — $ (1,906 ) $ (2,187 ) Noncurrent liabilities (29,407 ) (27,234 ) (12,194 ) (13,821 ) $ (29,407 ) $ (27,234 ) $ (14,100 ) $ (16,008 )
Schedule of Accumulated and Projected Benefit Obligations	Defined benefit plans with an accumulated benefit obligation and projected benefit obligation exceeding the fair value of plan assets had the following plan assets and obligations at March 31, 2018 and 2017 : Other Defined Benefit Pension Plans 2018 2017 Aggregate fair value of plan assets $ 119,441 $ 101,663 Aggregate accumulated benefit obligations 148,848 128,897 Aggregate projected benefit obligations 148,848 128,897
Components of Net Periodic Benefits Cost and Other Amounts Recognized in Other Comprehensive Income [Table Text Block]	Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan AMSCO Plan 2018 2017 2016 2018 2017 2016 2018 2017 2016 Service cost $ 2,402 $ 1,650 $ 961 $ — $ — $ — $ — $ — $ 27 Interest cost 3,262 3,434 1,659 519 554 593 — — 560 Expected return on plan assets (4,835 ) (2,853 ) (1,324 ) — — — — — (1,008 ) Prior service cost recognition — — (142 ) (3,263 ) (3,263 ) (3,263 ) — — — Net amortization and deferral 126 — — 648 739 828 — — 602 Curtailments/settlements — — (326 ) — — — — — 26,470 Net periodic benefit cost $ 955 $ 2,231 $ 828 $ (2,096 ) $ (1,970 ) $ (1,842 ) $ — $ — $ 26,651 Recognized in other comprehensive loss (income) before tax: Net loss (gain) occurring during year $ (697 ) $ (7,553 ) $ (3,733 ) $ 501 $ 531 $ 673 $ — $ — $ — Amortization of prior service credit — — — 3,263 3,263 3,263 — — — Amortization of net loss (126 ) — — (648 ) (739 ) (721 ) — — (602 ) Total recognized in other comprehensive loss (income) (823 ) (7,553 ) (3,733 ) 3,116 3,055 3,215 — — (602 ) Total recognized in total benefits cost and other comprehensive loss (income) $ 132 $ (5,322 ) $ (2,905 ) $ 1,020 $ 1,085 $ 1,373 $ — $ — $ 26,049
Schedule of Net Benefit Costs	The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31: 2018 2017 2016 Discount Rate: Defined benefit pension plans Synergy Health plc Retirement Benefits Scheme 2.60 % 3.50 % 3.20 % Isotron BV Pension Plan 1.60 % 1.60 % 2.10 % Synergy Health Daniken AG 0.65 % 0.65 % 0.40 % Synergy Health Radeberg 1.50 % 1.50 % 1.60 % Synergy Health Allershausen 1.50 % 1.50 % 1.60 % Harwell Dosimeters Ltd Retirement Benefits Scheme 2.55 % n/a n/a Other post-retirement plan 3.50 % 3.50 % 3.25 % Expected Return on Plan Assets: Synergy Health plc Retirement Benefits Scheme 4.97 % 4.87 % 5.19 % Isotron BV Pension Plan 1.60 % 1.60 % 2.10 % Synergy Health Daniken AG 1.40 % 1.40 % 1.40 %
Schedule of Assumptions Used	The following table presents significant assumptions used to determine the projected benefit obligations at March 31: 2018 2017 Discount Rate: Synergy Health plc Retirement Benefits Scheme 2.50 % 2.60 % Isotron BV Pension Plan 1.60 % 1.60 % Synergy Health Daniken AG 0.95 % 0.65 % Synergy Health Radeberg 1.60 % 1.50 % Synergy Health Allershausen 1.60 % 1.50 % Harwell Dosimeters Ltd Retirement Benefits Scheme 2.55 % n/a Other post-retirement plan 3.50 % 3.50 %
Schedule of Health Care Cost Trend Rates	The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below. 2018 2017 2016 Healthcare cost trend rate – medical 7.0 % 7.0 % 7.0 % Healthcare cost trend rate – prescription drug 7.0 % 7.0 % 7.0 % Long-term healthcare cost trend rate 4.5 % 4.5 % 4.5 % To determine the healthcare cost trend rates, we evaluate a combination of information, including ongoing claims cost monitoring, annual statistical analyses of claims data, reconciliation of forecasted claims against actual claims, review of trend assumptions of other plan sponsors and national health trends, and adjustments for plan design changes, workforce changes, and changes in plan participant behavior. A one-percentage-point change in assumed healthcare cost trend rates (including medical, prescription drug, and long-term rates) would have had the following effect on our other post-retirement benefit obligation at March 31, 2018 : One-Percentage Point Increase Decrease Effect on total service and interest cost components $ 1 $ (1 ) Effect on other post-retirement benefit obligation 21 (20 )
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The fair value of our pension benefits plan assets at March 31, 2018 and 2017 by asset category is as follows: Fair Value Measurements at March 31, 2018 (In thousands) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Cash $ 67 $ 67 $ — $ — Insured annuities 15,228 — 15,228 — Insurance contracts 5,484 — — 5,484 Common and collective trusts valued at net asset value: Equity security trusts 74,081 Debt security trusts 24,581 Total Plan Assets $ 119,441 $ 67 $ 15,228 $ 5,484 Fair Value Measurements at March 31, 2017 (In thousands) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Cash $ 182 $ 182 $ — $ — Insured annuities 10,813 — 10,813 — Insurance contracts 3,959 — — 3,959 Common and collective trusts valued at net asset value: Equity security trusts 64,922 Debt security trusts 21,787 Total Plan Assets $ 101,663 $ 182 $ 10,813 $ 3,959
Schedule of Defined Benefit Plans Disclosures	Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2018 2017 2018 2017 Change in Benefit Obligations: Benefit Obligations at Beginning of Year $ 128,897 $ 128,942 $ 16,008 $ 18,380 Obligation assumed in business acquisition 3,843 — — — Service cost 2,402 1,650 — — Interest cost 3,262 3,434 519 554 Actuarial loss (gain) (697 ) 16,633 (501 ) (531 ) Benefits and expenses (6,075 ) (7,190 ) (1,926 ) (2,395 ) Employee contributions 765 629 — — Impact of foreign currency exchange rate changes 16,451 (15,201 ) — — Benefit Obligations at End of Year 148,848 128,897 14,100 16,008 Change in Plan Assets: Fair Value of Plan Assets at Beginning of Year 101,663 104,353 — — Assets assumed in business acquisition 4,462 — — — Actual return on plan assets 1,052 11,910 — — Employer contributions 5,150 4,838 1,926 2,395 Employee contributions 765 629 — — Benefits and expenses paid (6,078 ) (7,190 ) (1,926 ) (2,395 ) Impact of foreign currency exchange rate changes 12,427 (12,877 ) — — Fair Value of Plan Assets at End of Year 119,441 101,663 — — Funded Status of the Plans $ (29,407 ) $ (27,234 ) $ (14,100 ) $ (16,008 )
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]	The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2018 due to the following: Insurance contracts Balance at March 31, 2016 $ 4,192 Gains (losses) related to assets still held at year-end 116 Purchases, sales, settlements - net (208 ) Foreign currency (141 ) Balance at March 31, 2017 $ 3,959 Gains (losses) related to assets still held at year-end (43 ) Additions from business acquisition 2,231 Transfers out of Level 3 (852 ) Foreign currency 189 Balance at March 31, 2018 $ 5,484

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Mar. 31, 2018
Segment Reporting Information [Line Items]
Reconciliation of Assets from Segment to Consolidated	March 31, 2018 2017 Property, Plant, and Equipment, Net United Kingdom $ 97,586 $ 76,695 United States 530,591 499,760 Other locations 382,347 339,453 Property, Plant, and Equipment, Net $ 1,010,524 $ 915,908
Schedule of Segment Reporting Information, by Segment	Years Ended March 31, 2018 2017 2016 Revenues: Healthcare Products $ 1,276,054 $ 1,266,517 $ 1,203,884 Healthcare Specialty Services 469,065 539,536 421,110 Life Sciences 361,590 328,866 297,733 Applied Sterilization Technologies 513,287 477,837 316,037 Total revenues $ 2,619,996 $ 2,612,756 $ 2,238,764 Operating income (loss): Healthcare Products 221,795 227,707 181,009 Healthcare Specialty Services 28,910 10,573 24,555 Life Sciences 106,737 97,180 84,564 Applied Sterilization Technologies 173,375 158,379 99,854 Total reportable segments 530,817 493,839 389,982 Corporate (17,439 ) (17,307 ) (11,320 ) Total operating income before adjustments $ 513,378 $ 476,532 $ 378,662 Less: Adjustments Goodwill impairment loss (1) — 58,356 — Amortization of inventory and property "step up" to fair value (2) 1,599 4,743 9,907 Amortization of purchased intangible assets (2) 67,793 66,398 47,704 Acquisition and integration related transaction charges (3) 16,211 30,082 82,891 Loss (gain) on fair value adjustment of acquisition related contingent consideration (593 ) 2,569 (736 ) Net loss on divestiture of businesses (2) 14,547 86,574 — Settlement of pension obligation (4) — — 26,470 Impact of the U.S. Tax Cuts and Jobs Act (5) 10,264 — — Restructuring charges 103 215 (501 ) Total operating income $ 403,454 $ 227,595 $ 212,927
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area	Years Ended March 31, 2018 2017 2016 Revenues: United Kingdom $ 207,514 $ 229,603 $ 144,577 United States 1,836,414 1,803,457 1,662,050 Other locations 576,068 579,696 432,137 Total Revenues $ 2,619,996 $ 2,612,756 $ 2,238,764
Other Expense
Segment Reporting Information [Line Items]
Schedule of Segment Reporting Information, by Segment	Years Ended March 31, 2018 2017 2016 Capital Expenditures: Healthcare Products and Life Sciences $ 52,767 $ 39,253 $ 34,581 Healthcare Specialty Services 16,497 42,408 31,308 Applied Sterilization Technologies 96,193 91,240 60,518 Total Capital Expenditures $ 165,457 $ 172,901 $ 126,407 Depreciation, Depletion, and Amortization: Healthcare Products and Life Sciences $ 52,025 $ 46,709 $ 49,142 Healthcare Specialty Services 29,269 56,860 36,114 Applied Sterilization Technologies 97,038 84,573 58,484 Total Depreciation, Depletion, and Amortization $ 178,332 $ 188,142 $ 143,740
Assets
Segment Reporting Information [Line Items]
Schedule of Segment Reporting Information, by Segment	March 31, 2018 2017 Assets: Healthcare Products and Life Sciences $ 1,621,156 $ 1,576,923 Healthcare Specialty Services 813,909 809,596 Applied Sterilization Technologies 2,765,269 2,537,936 Total assets $ 5,200,334 $ 4,924,455

Common Shares (Tables)

Common Shares (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	Years ended March 31, 2018 2017 2016 Denominator ( shares in thousands ): Weighted average shares outstanding—basic 85,028 85,473 70,698 Dilutive effect of share equivalents 685 621 486 Weighted average shares outstanding and share equivalents—diluted 85,713 86,094 71,184
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Years ended March 31, 2018 2017 2016 Number of ordinary share options ( shares in thousands ) 393 576 263

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during fiscal 2018, fiscal 2017 and fiscal 2016: Fiscal 2018 Fiscal 2017 Fiscal 2016 Risk-free interest rate 2.01 % 1.29 % 1.51 % Expected life of options 5.7 years 5.7 years 5.7 years Expected dividend yield of stock 1.58 % 1.54 % 1.40 % Expected volatility of stock 22.08 % 22.92 % 25.06 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2017 1,945,274 $ 50.28 Granted 429,360 77.75 Exercised (329,733 ) 34.01 Forfeited (23,239 ) 68.29 Outstanding at March 31, 2018 2,021,662 $ 58.56 6.6 years $ 70,350 Exercisable at March 31, 2018 1,139,722 $ 48.81 5.3 years $ 50,772
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2017 780,526 34,013 $ 60.87 Granted 251,300 23,259 78.60 Vested (231,107 ) (21,181 ) 54.41 Forfeited (37,518 ) (660 ) 68.57 Non-vested at March 31, 2018 763,201 35,431 $ 68.65

Financial and Other Guarantees

Financial and Other Guarantees (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Guarantor Obligations	Changes in our warranty liability during the periods presented are as follows: Years Ended March 31, 2018 2017 2016 Balance, Beginning of Year $ 6,861 $ 5,909 $ 5,579 Warranties issued during the period 12,305 11,823 11,194 Settlements made during the period (12,294 ) (10,871 ) (10,864 ) Balance, End of Year $ 6,872 $ 6,861 $ 5,909

Forward and Swap Contracts (Tab

Forward and Swap Contracts (Tables)	12 Months Ended
	Mar. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance Sheet Location March 31, 2018 March 31, 2017 March 31, 2018 March 31, 2017 Prepaid & Other $ 187 $ 160 $ — $ — Accrued expenses and other $ — $ — $ — $ 35
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of (loss) gain recognized in income Amount of (loss) gain recognized in income Years Ended March 31, 2018 2017 2016 Foreign currency forward contracts Selling, general and administrative $ (1,357 ) $ (1,886 ) $ (683 ) Commodity swap contracts Cost of revenues $ 373 $ 376 $ (461 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement Inputs, Disclosure [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at March 31, 2018 and March 31, 2017 : Fair Value Measurements At March 31, Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 2018 2017 2018 2017 2018 2017 2018 2017 Assets: Cash and cash equivalents (1) $ 201,534 $ 282,918 $ 201,534 $ 282,918 $ — $ — $ — $ — Forward and swap contracts (2) 187 160 — — 187 160 — — Investments (3) 16,382 12,552 16,382 12,552 — — — — Liabilities: Forward and swap contracts (2) $ — $ 35 $ — $ — $ — $ 35 $ — $ — Deferred compensation plans (3) 1,694 1,677 1,694 1,677 — — — — Long term debt (4) 1,316,001 1,478,361 — — 1,305,181 1,496,966 — — Contingent consideration obligations (5) 8,068 4,451 — — — — 8,068 4,451 (1) Money market fund holdings are valued at fair value using the net asset value per share practical expedient and are not included within the fair value hierarchy. These money market funds are being presented in the table above to permit a reconciliation of the fair value hierarchy to total cash and cash equivalents. (2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment. (4) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Fair Value, by Balance Sheet Grouping [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at March 31, 2018 are summarized as follows: Contingent Consideration Balance at March 31, 2016 $ 5,886 Additions 3,592 Payments (5,416 ) Foreign currency translation adjustments 389 Balance at March 31, 2017 $ 4,451 Additions 5,774 Payments (1,735 ) Reductions (593 ) Foreign currency translation adjustments 171 Balance at March 31, 2018 $ 8,068
Unrealized Gain (Loss) on Investments [Table Text Block]	Information regarding our investments is as follows: Investments At March 31, Cost Unrealized Gains (1) Unrealized Losses (1) Fair Value 2018 2017 2018 2017 2018 2017 2018 2017 Available-for-sale securities: Marketable equity securities and other (1) $ 11,037 $ 11,037 $ 3,762 $ — $ — $ (72 ) $ 14,799 $ 10,965 Mutual funds 1,000 1,091 583 496 — — 1,583 1,587 Total available-for-sale securities $ 12,037 $ 12,128 $ 4,345 $ 496 $ — $ (72 ) $ 16,382 $ 12,552

Accumulated Other Comprehensi45

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Schedule of Reclassification out of AOCI [Table Text Block]	ounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the years ended March 31, 2018 and March 31, 2017 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income (Loss) 2018 2017 2018 2017 2018 2017 2018 2017 Beginning Balance $ 178 $ (673 ) $ (2,355 ) $ 5,108 $ (238,525 ) $ (72,594 ) $ (240,702 ) $ (68,159 ) Other Comprehensive Income (Loss) before reclassifications 1,703 745 (2,291 ) (5,491 ) 254,982 (165,931 ) 254,394 (170,677 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 89 106 (2,096 ) (1,972 ) — — (2,007 ) (1,866 ) Net current-period Other Comprehensive Income (Loss) 1,792 851 (4,387 ) (7,463 ) 254,982 (165,931 ) 252,387 (172,543 ) Ending Balance $ 1,970 $ 178 $ (6,742 ) $ (2,355 ) $ 16,457 $ (238,525 ) $ 11,685 $ (240,702 ) (1) Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated other comprehensive income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity consists of the following: Years Ended March 31, 2018 2017 2016 Cumulative foreign currency translation adjustment $ 16,457 $ (238,525 ) $ (72,594 ) Amortization of pension and postretirement benefit plans costs, net of taxes (6,742 ) (2,355 ) 5,108 Unrealized gain (loss) on available for sale securities 1,970 178 (673 ) Total $ 11,685 $ (240,702 ) $ (68,159 )

Reclassifications out of AOCI46

Reclassifications out of AOCI (Tables)	12 Months Ended
	Mar. 31, 2018
Reclassifications out of AOCI Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	ounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the years ended March 31, 2018 and March 31, 2017 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income (Loss) 2018 2017 2018 2017 2018 2017 2018 2017 Beginning Balance $ 178 $ (673 ) $ (2,355 ) $ 5,108 $ (238,525 ) $ (72,594 ) $ (240,702 ) $ (68,159 ) Other Comprehensive Income (Loss) before reclassifications 1,703 745 (2,291 ) (5,491 ) 254,982 (165,931 ) 254,394 (170,677 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 89 106 (2,096 ) (1,972 ) — — (2,007 ) (1,866 ) Net current-period Other Comprehensive Income (Loss) 1,792 851 (4,387 ) (7,463 ) 254,982 (165,931 ) 252,387 (172,543 ) Ending Balance $ 1,970 $ 178 $ (6,742 ) $ (2,355 ) $ 16,457 $ (238,525 ) $ 11,685 $ (240,702 ) (1) Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated other comprehensive income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Quarterly Results (Unaudited) (

Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Mar. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Effect of Fourth Quarter Events [Table Text Block]	Quarters Ended March 31, December 31, September 30, June 30, Fiscal 2018 Revenues: Product $ 351,010 $ 309,461 $ 286,557 $ 273,605 Service 364,963 352,439 347,602 334,359 Total Revenues 715,973 661,900 634,159 607,964 Cost of Revenues: Product 187,710 162,611 152,611 143,245 Service 235,510 220,701 214,787 208,598 Total Cost of Revenues 423,220 383,312 367,398 351,843 Gross Profit 292,753 278,588 266,761 256,121 Percentage of Revenues 40.9 % 42.1 % 42.1 % 42.1 % Restructuring Expenses (53 ) 78 27 51 Net Income Attributable to Shareholders $ 73,598 $ 94,781 $ 64,459 $ 58,077 Basic Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.87 $ 1.12 $ 0.76 $ 0.68 Diluted Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.86 $ 1.11 $ 0.75 $ 0.68 Fiscal 2017 Revenues: Product $ 332,093 $ 302,260 $ 292,216 $ 271,750 Service 349,096 344,514 354,199 366,628 Total Revenues 681,189 646,774 646,415 638,378 Cost of Revenues: Product 173,333 152,879 155,110 142,698 Service 227,731 236,286 243,397 255,690 Total Cost of Revenues 401,064 389,165 398,507 398,388 Gross Profit 280,125 257,609 247,908 239,990 Percentage of Revenues 41.1 % 39.8 % 38.4 % 37.6 % Restructuring Expenses (5 ) 18 48 154 Net Income Attributable to Shareholders $ 26,143 $ (4,996 ) $ 40,416 $ 48,401 Basic Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.31 $ (0.06 ) $ 0.47 $ 0.56 Diluted Income Per Ordinary Share Attributable to Shareholders: Net income $ 0.31 $ (0.06 ) $ 0.47 $ 0.56

Nature of Operations and Summ48

Nature of Operations and Summary of Siginificant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Loss Contingencies [Line Items]
Medical Device Excise Tax Rate	2.30%
Excise and Sales Taxes			$ 5,802
Percentage of LIFO Inventory	26.00%	29.00%
FIFO Inventory Amount	$ 17,280	$ 16,706
Interest Costs, Capitalized During Period	528	1,141
Interest Costs Incurred	50,629	44,520	42,708
Interest Paid	48,663	42,797	37,165
Income Taxes Paid, Net	85,629	78,009	60,885
Advertising Expense	10,886	12,622	10,785
Proceeds from Income Tax Refunds	7,747	$ 2,002	$ 1,697
Excess tax benefits from share-based compensation	$ 5,100
Land Improvements [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3-40
Building [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2-50
Machinery and Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2-20
Computer Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2-20
Property, Plant and Equipment, Other Types [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	20
Minimum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	5 years
Maximum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	20 years

Business Acquisitions and Div49

Business Acquisitions and Divestitures Business Acquisitions and Divestitures Narrative (Details) $ / shares in Units, $ in Thousands, € in Millions

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Sep. 30, 2017USD ($)

Jun. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Sep. 30, 2016USD ($)

Jun. 30, 2016USD ($)

Sep. 30, 2016USD ($)

Dec. 31, 2016USD ($)

Mar. 31, 2018USD ($)

Mar. 31, 2017USD ($)

Mar. 31, 2016USD ($)

Feb. 09, 2017EUR (€)

Sep. 16, 2016USD ($)

Aug. 31, 2016USD ($)

Jul. 22, 2016USD ($)

Nov. 02, 2015£ / shares

Nov. 02, 2015USD ($)$ / shares

Jul. 31, 2015USD ($)

Jun. 12, 2015USD ($)

Business Acquisition [Line Items]

acquisition and integration related charges

[1]

$ 16,211

$ 30,082

$ 82,891

Business Combination, Contingent Consideration, Liability

$ 8,068

$ 4,451

8,068

4,451

5,886

Amortization of Intangible Assets

70,195

68,607

49,782

Translation adjustment on net assets

$ 170,000

Depreciation, amortization and depletion adjustment from purchase price allocation

20,000

Revenues

715,973

$ 661,900

$ 634,159

$ 607,964

$ 681,189

$ 646,774

$ 638,378

$ 646,415

2,619,996

2,612,756

2,238,764

STERIS Closing Stock Price at 11/02/2015 | $ / shares

$ 73.02

Operating Income (Loss)

403,454

227,595

212,927

Proceeds from Divestiture of Businesses

8,888

135,713

0

Gain (Loss) on Disposition of Business

[2]

(14,547)

$ (86,574)

0

Other Loan Receivable | €

€ 15

Loan term

P15Y

Principal outstanding on loan receivable

3,000

3,000

Selling, General and Administrative Expenses [Member]

Business Acquisition [Line Items]

Depreciation, amortization and depletion adjustment from purchase price allocation

17,000

Cost of revenue [Member]

Business Acquisition [Line Items]

Depreciation, amortization and depletion adjustment from purchase price allocation

$ 3,000

Fiscal 2018 [Member] [Member]

Business Acquisition [Line Items]

Purchase price of acquired entity

52,900

52,900

Series of Individually Immaterial Business Acquisitions [Member]

Business Acquisition [Line Items]

Business Combination, Contingent Consideration, Liability

$ 5,400

5,400

Netherlands Linen Management [Domain]

Business Acquisition [Line Items]

Revenues

75,000

Gain (Loss) on Disposition of Business

43,000

US Linen Management Services [Member]

Business Acquisition [Line Items]

Revenues

50,000

Proceeds from Divestiture of Businesses

4,500

Gain (Loss) on Disposition of Business

$ 31,200

Black Diamond [Member]

Business Acquisition [Line Items]

Business Combination, Contingent Consideration, Liability

$ 800

Compass Medical [Member]

Business Acquisition [Line Items]

Purchase price of acquired entity

$ 16,000

Revenues

6,000

Phoenix and Endo-Tek [Member]

Business Acquisition [Line Items]

Purchase price of acquired entity

$ 14,300

Revenues

8,000

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Medisafe [Member]

Business Acquisition [Line Items]

Purchase price of acquired entity

$ 34,500

Revenues

18,000

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Synergy Health plc [Member]

Business Acquisition [Line Items]

Revenues

254,911

Approximate purchase price of entity

$ 2,300,000

Business Combination, Acquisition Related Costs

63,789

Operating Income (Loss)

3,695

Other Acquisitions [Member]

Business Acquisition [Line Items]

Business Combination, Contingent Consideration, Liability

1,760

Synergy Health Labs [Member]

Business Acquisition [Line Items]

Revenues

15,000

Proceeds from Divestiture of Businesses

$ 26,300

Gain (Loss) on Disposition of Business

18,700

Applied Infection Control [Member]

Business Acquisition [Line Items]

Revenues

50,000

Proceeds from Divestiture of Businesses

41,800

Gain (Loss) on Disposition of Business

36,200

UK Linen Management Services [Member]

Business Acquisition [Line Items]

Revenues

50,000

Proceeds from Divestiture of Businesses

65,400

Gain (Loss) on Disposition of Business

$ 66,400

United Kingdom, Pounds

Business Acquisition [Line Items]

Value of transaction per Synergy Share | £ / shares

£ 24.80

United States of America, Dollars

Business Acquisition [Line Items]

Value of transaction per Synergy Share | $ / shares

$ 38.17

Econopak [Member] [Member]

Business Acquisition [Line Items]

Approximate purchase price of entity

$ 176,474

Other Acquisitions [Member]

Business Acquisition [Line Items]

Approximate purchase price of entity

$ 41,079

Black Diamond [Member]

Business Acquisition [Line Items]

Approximate purchase price of entity

46,155

Deferred Purchase Price of Acquired Entity

$ 5,870

Years 1-4, 4% Int Rate [Member]

Business Acquisition [Line Items]

Loan Receivable Interest Rate

4.00%

4.00%

Years 5-15, 12% Int Rate [Member]

Business Acquisition [Line Items]

Loan Receivable Interest Rate

12.00%

12.00%

HCS [Member]

Business Acquisition [Line Items]

Revenues

$ 40,000

Proceeds from Divestiture of Businesses

8,200

Gain (Loss) on Disposition of Business

$ (13,500)

[1]

Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions

[2]

For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".

Business Acquisitions and Div50

Business Acquisitions and Divestitures Synergy Acquisition (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 2,433,784	$ 2,231,303	$ 2,156,603

Business Acquisitions and Div51

Business Acquisitions and Divestitures Synergy Finite-Lived Intangibles (Details) $ in Thousands	Mar. 31, 2016USD ($)
Synergy Health plc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 504,196

Business Acquisitions and Div52

Business Acquisitions and Divestitures Synergy Pro Forma (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2016USD ($)
Business Combinations [Abstract]
Business Acquisition, Pro Forma Revenue	$ 2,619,056
Business Acquisition, Pro Forma Net Income (Loss)	$ 188,269

Business Acquisitions and Div53

Business Acquisitions and Divestitures Business Acquisition Summary (Details) - USD ($) $ / shares in Units, $ in Thousands		Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Nov. 02, 2015
Business Acquisition [Line Items]
STERIS Closing Stock Price at 11/02/2015					$ 73.02
Goodwill		$ 2,433,784	$ 2,231,303	$ 2,156,603
Fiscal 2018 Acquisitions [Domain]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	[1]	235
Medisafe [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			3,751
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			3,634
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			2,454
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			639
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			17,151
Goodwill			19,599
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			47,228
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			(5,562)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			(3,398)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(8,960)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			38,268
Compass Medical [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			629
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			659
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			13
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			31
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			5,992
Goodwill			8,987
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			16,311
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			(309)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(309)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			16,002
Phoenix and Endo-Tek [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			769
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			1,123
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			950
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			1,092
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			46
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			7,824
Goodwill			5,938
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			17,742
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			(1,373)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			(1,263)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(2,636)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 15,106
Fiscal 2018 [Member] [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	[1]	1,464
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	[1]	2,289
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	[1]	3,420
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	[1]	126
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[1]	15,318
Goodwill	[1]	35,766
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	[1]	58,618
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	[1]	(2,833)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	[1]	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	[1]	(2,622)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	[1]	(5,455)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	[1]	$ 53,163
Synergy Health plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents				53,057
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables				103,093
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory				30,074
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				496,555
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other				19,175
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				504,196
Goodwill				1,685,524
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets				2,891,674
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(107,932)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt				(321,082)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities				(159,112)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				(588,126)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				2,303,548
Econopak [Member] [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents				1,108
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables				4,161
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory				1,926
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				3,421
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other				946
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				61,900
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets				177,947
Business Acquisition, Goodwill, Expected Tax Deductible Amount				104,485
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(1,473)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt				0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities				0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				(1,473)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				176,474
Black Diamond [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents				0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables				2,966
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory				3,309
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				607
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other				54
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				13,500
Goodwill				31,792
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets				52,228
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(4,525)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt				0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities				(1,548)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				(6,073)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				46,155
Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents				0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables				3,859
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory				1,108
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				1,979
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other				0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				14,829
Goodwill				20,630
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets				42,405
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(1,277)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt				0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities				(49)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				(1,326)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				$ 41,079
[1]	(1) Purchase price allocation is still preliminary as of March 31, 2018, as valuations have not been finalized.

Goodwill and Intangible Asset54

Goodwill and Intangible Assets Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016
Goodwill [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 35,266	$ 34,970
Goodwill	2,433,784	2,231,303		$ 2,156,603
Goodwill allocation related to Synergy		(273,743)
Goodwill, Written off Related to Sale of Business Unit		(85,806)
Goodwill, Impairment Loss	0	(58,356)	[1]	0
Finite-Lived Intangible Assets, Amortization Expense	70,195	68,607		49,782
Finite-Lived Intangible Assets, Gross	1,032,907	948,953
Finite-Lived Intangible Assets, Accumulated Amortization	305,927	224,066
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		(1,308,717)
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
Life Science Member [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		0
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
Healthcare Specialty Services [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		(376,807)
Goodwill, Written off Related to Sale of Business Unit		(85,806)
Goodwill, Impairment Loss		(58,356)
goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	35,766	41,399
Healthcare Products [Member] [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		0
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	166,715	(96,280)
Healthcare Specialty Services [Member]
Goodwill [Line Items]
Goodwill	388,025	375,879		154,272
Healthcare Specialty Services [Member] | goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	3,501	21,781
Healthcare Specialty Services [Member] | Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	10,500	(32,819)
Life Science Member [Member]
Goodwill [Line Items]
Goodwill	148,816	146,514		147,334
Life Science Member [Member] | goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	0	0
Life Science Member [Member] | Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	2,302	(820)
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill	1,492,269	1,331,145		83,035
Applied Sterilization Technologies [Member] | goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	15,847	0
Applied Sterilization Technologies [Member] | Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	143,422	(60,607)
Healthcare Products [Member] [Member]
Goodwill [Line Items]
Goodwill	404,674	377,765		363,770
Healthcare Products [Member] [Member] | goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	16,418	19,618
Healthcare Products [Member] [Member] | Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	10,491	(5,623)
synergy [Member]
Goodwill [Line Items]
Goodwill	0	0		$ 1,408,192
Goodwill allocation related to Synergy		(1,411,781)
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
synergy [Member] | goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	0	0
synergy [Member] | Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	0	3,589
Trademarks and Trade Names [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Amortization Expense		14,444
Finite-Lived Intangible Assets, Gross	83,509	80,223
Finite-Lived Intangible Assets, Accumulated Amortization	$ 36,864	$ 32,547
[1]	For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".

Goodwill and Intangible Asset55

Goodwill and Intangible Assets Goodwill Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016
Goodwill [Line Items]
Goodwill	$ 2,433,784	$ 2,231,303		$ 2,156,603
Goodwill allocation related to Synergy		273,743
Goodwill, Written off Related to Sale of Business Unit		85,806
Goodwill, Impairment Loss	0	58,356	[1]	0
Life Science Member [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		0
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
Healthcare Specialty Services [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		376,807
Goodwill, Written off Related to Sale of Business Unit		85,806
Goodwill, Impairment Loss		58,356
Healthcare Products [Member] [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		0
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy		1,308,717
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	35,766	41,399
transfers [Member] [Member]
Goodwill [Line Items]
Goodwill, Transfers	0
Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	166,715	(96,280)
synergy [Member]
Goodwill [Line Items]
Goodwill	0	0		1,408,192
Goodwill allocation related to Synergy		1,411,781
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill, Impairment Loss		0
synergy [Member] | goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	0	0
synergy [Member] | transfers [Member] [Member]
Goodwill [Line Items]
Goodwill, Transfers	0
synergy [Member] | Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	0	3,589
Healthcare Specialty Services [Member]
Goodwill [Line Items]
Goodwill	388,025	375,879		154,272
Healthcare Specialty Services [Member] | goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	3,501	21,781
Healthcare Specialty Services [Member] | transfers [Member] [Member]
Goodwill [Line Items]
Goodwill, Transfers	(1,855)
Healthcare Specialty Services [Member] | Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	10,500	(32,819)
Life Science Member [Member]
Goodwill [Line Items]
Goodwill	148,816	146,514		147,334
Life Science Member [Member] | goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	0	0
Life Science Member [Member] | transfers [Member] [Member]
Goodwill [Line Items]
Goodwill, Transfers	0
Life Science Member [Member] | Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	2,302	(820)
Healthcare Products [Member] [Member]
Goodwill [Line Items]
Goodwill	404,674	377,765		363,770
Healthcare Products [Member] [Member] | goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	16,418	19,618
Healthcare Products [Member] [Member] | transfers [Member] [Member]
Goodwill [Line Items]
Goodwill, Transfers	0
Healthcare Products [Member] [Member] | Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	10,491	(5,623)
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill	1,492,269	1,331,145		$ 83,035
Applied Sterilization Technologies [Member] | goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	15,847	0
Applied Sterilization Technologies [Member] | transfers [Member] [Member]
Goodwill [Line Items]
Goodwill, Transfers	1,855
Applied Sterilization Technologies [Member] | Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	$ 143,422	$ (60,607)
[1]	For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".

Goodwill and Intangible Asset56

Goodwill and Intangible Assets Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 1,032,907	$ 948,953
Finite-Lived Intangible Assets, Accumulated Amortization	305,927	224,066
Customer Relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	663,532	597,386
Finite-Lived Intangible Assets, Accumulated Amortization	150,358	96,648
Noncompete Agreements [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,738	4,722
Finite-Lived Intangible Assets, Accumulated Amortization	3,790	3,629
Patented Technology [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	226,318	211,812
Finite-Lived Intangible Assets, Accumulated Amortization	107,598	86,665
Trademarks and Trade Names [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	83,509	80,223
Finite-Lived Intangible Assets, Accumulated Amortization	36,864	32,547
supplier relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	54,800	54,800
Finite-Lived Intangible Assets, Accumulated Amortization	7,307	4,567
Other Intangible Assets [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	10	10
Finite-Lived Intangible Assets, Accumulated Amortization	$ 10	$ 10

Goodwill and Intangible Asset57

Goodwill and Intangible Assets Future Amortization of Intangible Assets (Details) $ in Thousands	Mar. 31, 2018USD ($)
Other Intangible Assets [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 68,447
Finite-Lived Intangible Assets, Amortization Expense, Year Two	67,390
Finite-Lived Intangible Assets, Amortization Expense, Year Three	66,742
Finite-Lived Intangible Assets, Amortization Expense, Year Four	63,832
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 59,061

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Notes To Financial Statements [Abstract]
Inventory, Raw Materials	$ 83,741	$ 65,300
Inventory, Work in Process	34,904	26,538
Inventory, Finished Goods	124,005	140,559
Inventory, LIFO Reserve	(17,280)	(16,706)
Inventory Valuation Reserves	(19,639)	(17,854)	$ (18,707)	$ (17,597)
Inventories, net	$ 205,731	$ 197,837

Property, Plant and Equipment59

Property, Plant and Equipment (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Asset Retirement Obligation		$ 11,639	$ 9,953
Asset Retirement Obligation, Liabilities Incurred		89
Asset Retirement Obligation, Liabilities Settled		(352)
Asset Retirement Obligation, Accretion Expense		1,198
Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)		751
Land	[1]	55,417	46,848
Buildings and Improvements, Gross		449,316	393,692
Machinery and Equipment, Gross		575,607	508,247
Capitalized Computer Software, Gross		145,726	119,920
Materials, Supplies, and Other		476,578	436,787
Construction in Progress, Gross	[1]	87,745	77,421
Property, Plant and Equipment, Gross		1,790,389	1,582,915
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment		(779,865)	(667,007)
Property, Plant and Equipment, Net		1,010,524	915,908
Depreciation		108,137	119,536	$ 93,958
Operating Leases, Rent Expense		30,474	$ 32,740	$ 23,238
Operating Leases, Future Minimum Payments Due, Current		24,116
Operating Leases, Future Minimum Payments, Due in Two Years		19,933
Operating Leases, Future Minimum Payments, Due in Three Years		14,666
Operating Leases, Future Minimum Payments, Due in Four Years		11,051
Operating Leases, Future Minimum Payments, Due Thereafter		39,464
Operating Leases, Future Minimum Payments Due		$ 109,230
[1]	Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Details)

Debt (Details) € in Thousands, £ in Thousands, $ in Thousands		3 Months Ended	12 Months Ended
		Jun. 30, 2015USD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Feb. 27, 2017GBP (£)	Feb. 27, 2017USD ($)	Feb. 27, 2017EUR (€)
Debt Instrument [Line Items]
Long-term Debt, Current Maturities			$ 85,000
Line of Credit Facility, Maximum Borrowing Capacity			1,000,000
Debt Instrument, Face Amount	[1]		988,190	$ 960,684
Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net			(3,395)	(3,927)
Line of Credit Facility, Amount Outstanding			331,206	521,604
Long-term Debt			1,319,396
Proceeds from Issuance of Private Placement		$ 350,000	0	293,730	$ 350,000
Long-term Debt			1,316,001	$ 1,478,361
Long-term Debt, Maturities, Repayments of Principal in Year Two			0
Long-term Debt, Maturities, Repayments of Principal in Year Three			35,000
Long-term Debt, Maturities, Repayments of Principal in Year Four			0
Long-term Debt, Maturities, Repayments of Principal after Year Five			1,199,396
12 year maturity
Debt Instrument [Line Items]
Debt Instrument, Maturity Date, Description		10
15 year maturity
Debt Instrument [Line Items]
Debt Instrument, Maturity Date, Description		15
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 500,000
United States of America, Dollars
Debt Instrument [Line Items]
Senior Notes							$ 95,000
United Kingdom, Pounds
Debt Instrument [Line Items]
Senior Notes | £						£ 75,000
Euro Member Countries, Euro
Debt Instrument [Line Items]
Senior Notes | €								€ 99,000
[1]	2018 2017Credit Agreement and Swing Line Facility $331,206 $521,604Private Placement 988,190 960,684Deferred financing fees (3,395) (3,927)Total long term debt $1,316,001 $1,478,361

Debt 2017 Senior Notes (Details

Debt 2017 Senior Notes (Details) € in Thousands, £ in Thousands		Mar. 31, 2018GBP (£)	Mar. 31, 2018USD ($)	Mar. 31, 2018EUR (€)	Mar. 31, 2017USD ($)
Debt Instrument [Line Items]
Debt Instrument, Face Amount	[1]		$ 988,190,000		$ 960,684,000
Long-term Debt			1,316,001,000		1,478,361,000
STE 6.83% due 2018 Senior Notes [Member] [Domain] [Domain] [Domain] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 85,000,000		85,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.33%	6.33%	6.33%
STE 6.93% due 2020 Senior Notes [Member] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 35,000,000		35,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.43%	6.43%	6.43%
STE 3.70% due 2030 Senior Notes [Member] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 100,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.70%	3.70%	3.70%
STE 3.70% due 2022 Senior Notes [Member] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 91,000,000		91,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.20%	3.20%	3.20%
STE 3.85% due 2024 Senior Notes [Member] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 80,000,000		80,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.35%	3.35%	3.35%
STE 4.05% due 2027 Senior Notes [Member] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 25,000,000		25,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.55%	3.55%	3.55%
STE 3.45% due 2025 Senior Notes [Member] [Domain] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 125,000,000		125,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.45%	3.45%	3.45%
STE 3.55% due 2027 Senior Notes [Member] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 125,000,000		125,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.55%	3.55%	3.55%
STE 3.70% due 2030 Senior Notes [Member] [Domain] [Domain] [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 100,000,000		100,000,000
STE 3.93% due 2027 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 50,000,000		50,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.93%	3.93%	3.93%
STE 1.86% due 2027 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 73,912,000	€ 60,000	64,414,000
Debt Instrument, Interest Rate, Stated Percentage		1.86%	1.86%	1.86%
STE 4.03% due 2029 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 45,000,000		45,000,000
Debt Instrument, Interest Rate, Stated Percentage		4.03%	4.03%	4.03%
STE 2.04% due 2029 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 24,637,000	€ 20,000	21,472,000
Debt Instrument, Interest Rate, Stated Percentage		2.04%	2.04%	2.04%
STE 3.04% due 2029 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		£ 45,000	$ 63,141,000		56,040,000
Debt Instrument, Interest Rate, Stated Percentage		3.04%	3.04%	3.04%
STE 2.30% due 2032 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 23,406,000	€ 19,000	20,398,000
Debt Instrument, Interest Rate, Stated Percentage		2.30%	2.30%	2.30%
STE 3.17% due 2032 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		£ 30,000	$ 42,094,000		37,360,000
Debt Instrument, Interest Rate, Stated Percentage		3.17%	3.17%	3.17%
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt			$ 988,190,000		$ 960,684,000
[1]	2018 2017Credit Agreement and Swing Line Facility $331,206 $521,604Private Placement 988,190 960,684Deferred financing fees (3,395) (3,927)Total long term debt $1,316,001 $1,478,361

Additional Consolidated Balan62

Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Notes To Financial Statements [Abstract]
Employee-related Liabilities	$ 30,270	$ 29,777
Accrued Vacation	11,011	8,651
Accrued Bonuses	31,716	20,715
Accrued Liabilities for Commissions, Expense and Taxes	17,168	16,201
Liability, Other Retirement Benefits	1,906	2,187
Liability, Retirement and Postemployment Benefits	1,929	1,044
Employee-related Liabilities, Current	94,000	78,575
Deferred Revenue	74,698	71,020
Self Insurance Reserve, Current	7,349	6,633
Accrued Sales Commission	16,121	16,122
Standard and Extended Product Warranty Accrual	6,872	6,861	$ 5,909	$ 5,579
Asset Retirement Obligation, Current	1,798	0
Other Accrued Liabilities	61,379	54,253
Accrued Liabilities	168,217	154,889
Self Insurance Reserve, Noncurrent	15,008	15,584
Liability, Other Retirement Benefits, Noncurrent	12,194	13,821
Liability, Defined Benefit Pension Plan, Noncurrent	29,407	27,234
Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent	3,221	3,661
Accrued Income Taxes, Noncurrent	18,922	2,089
Asset Retirement Obligations, Noncurrent	9,841	9,953
Other Liabilities	20,007	10,331
Other Liabilities, Noncurrent	$ 108,600	$ 82,673

Income Tax Expense (Details)

Income Tax Expense (Details) - USD ($) $ / shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Operating Loss Carryforwards [Line Items]
Tax Adjustments, Settlements, and Unusual Provisions	$ 18,913
Income Tax Examination, Penalties and Interest Accrued	295	$ 184
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	2,795
Deferred Tax Assets, Tax Credit Carryforwards	129
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits	$ 3,505	$ 6,116
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	19.00%	20.00%	35.00%
Current Federal Tax Expense (Benefit)	$ 6,671	$ 362	$ 2,194
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ 3,253	$ (36,420)	$ (20,553)
Effective Income Tax Rate, Continuing Operations	17.80%	40.10%	35.10%
Unrecognized Tax Benefits	$ 2,500	$ 1,884	$ 3,527
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	354,982	184,646	171,884
Current State and Local Tax Expense (Benefit)	7,727	8,171	7,943
Current Income Tax Expense (Benefit)	84,793	73,527	65,714
Deferred Federal Income Tax Expense (Benefit)	(2,968)	(2,292)	(6,973)
Deferred State and Local Income Tax Expense (Benefit)	2,656	2,131	299
Increase (Decrease) in Deferred Income Taxes	(21,433)	488	(5,415)
Income Tax Expense (Benefit)	$ 63,360	$ 74,015	$ 60,299
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate	0.10%	0.30%	0.20%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes	2.30%	3.80%	3.30%
Increase (decrease) in Valuation Allowances	0.10%	0.10%	1.00%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	(0.50%)	(1.10%)	(0.00%)
Effective Income Tax Rate Reconciliation, Tax Credits, Foreign	(0.20%)	(0.00%)	(0.60%)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	0.00%	0.00%	(8.50%)
Effective Tax Rate Reconciliation, UK Tax Rate Differential	4.10%	6.00%	0.00%
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent	0.00%	0.00%	3.00%
Effective Income Tax Rate Reconciliation, Deductions, Qualified Production Activities	(0.80%)	(2.50%)	(2.50%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent	(1.80%)	2.80%	(0.00%)
Effective Tax Reconciliation, deferred tax assets and liabilities	(10.30%)	2.30%	(0.00%)
Change in Effective Income Tax US Transition tax	4.90%	(0.00%)	(0.00%)
Effective Tax Rate Reconciliation, acquisitions and divestitures	0.50%	9.00%	0.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent	0.00%	7.90%	0.00%
Capitalized Interest Costs- Effective tax rate	0.00%	0.20%	5.30%
Effective Income Tax Rate Reconciliation, Other Adjustments	0.40%	1.50%	(1.50%)
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	$ 356	$ 510
Unrecognized Tax Benefits, Increase Resulting from Acquisition	0
Unrecognized Tax Benefits, Decrease Resulting from Acquisition		(1,502)
Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation	260	651
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	12,334	17,196
Deferred Tax Assets, Operating Loss Carryforwards	34,866
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	5,795	7,807
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance	3,417	4,957
Deferred Tax Assets, Deferred Income	4,632	8,962
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	1,426	1,740
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Pensions	5,247	4,647
Deferred Tax Assets, Other	1,668	781
Deferred Tax Assets, Gross, Current	64,241	87,335
Deferred Tax Assets, Valuation Allowance	13,596	16,366	$ 16,435	$ 14,380
Deferred Tax Assets, Net	50,645	70,969
Deferred Tax Liabilities, Property, Plant and Equipment	61,171	74,092
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	140,398	156,291
Deferred Tax and Other Liabilities, Noncurrent	2,774	3,631
Deferred Tax Liabilities	204,343	234,014
Deferred Tax Assets (Liabilities), Net	(153,698)	(163,045)
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	51,309
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	3,863
Valuation Allowance, Deferred Tax Asset, Change in Amount	2,770
Deferred Tax Assets, Operating Loss Carryforwards	26,217	35,129
Undistributed Earnings of Foreign Subsidiaries	$ 1,100,000
Anticipated Tax rate Remeasurement Assets Liab	21.00%
Tax Cuts and Jobs Act Remeasurement of Deferreds Impact	$ 36,422
Tax Cuts and Jobs Act Transition Tax Impact	17,509
Costa Rica Exempt thorugh 2025 and partially exempt through 2029 [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ 945
Income Tax Holiday, Income Tax Benefits Per Share	$ 0
UNITED STATES
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	$ 203,872	189,429	105,758
Current Foreign Tax Expense (Benefit)	47,728	43,900	41,653
Deferred Foreign Income Tax Expense (Benefit)	(15,728)	10,293	1,427
Other Foreign Entities [Member] [Member]
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	147,857	31,637	86,679
Current Foreign Tax Expense (Benefit)	22,667	21,094	13,924
Deferred Foreign Income Tax Expense (Benefit)	$ (5,393)	$ (9,644)	$ (168)

Benefit Plans (Change in benefi

Benefit Plans (Change in benefit obligations funded status) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Business Combination	$ 2,231
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	189	$ (141)
Defined benefit plan repayment of obligation [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	5,630
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	3,899
Defined Benefit Plan, Benefit Obligation	148,848	128,897	$ 128,942
Defined Benefit Plan, Benefit Obligation, Business Combination	3,843
Defined Benefit Plan, Service Cost	2,402	1,650	961
Defined Benefit Plan, Interest Cost	3,262	3,434	1,659
Defined Benefit Plan, Actuarial Net (Gains) Losses	(697)	16,633
Defined Benefit Plan, Benefit Obligation, Benefits Paid	6,075	7,190
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	765	629
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(6,078)	(7,190)
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	765	629
Defined Benefit Plan, Fair Value of Plan Assets	119,441	101,663	104,353
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	1,052	11,910
Defined Benefit Plan, Plan Assets, Contributions by Employer	5,150	4,838
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(29,407)	(27,234)
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	12,427	(12,877)
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	16,451	(15,201)
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	1,907
Defined Benefit Plan, Benefit Obligation	14,100	16,008	18,380
Defined Benefit Plan, Service Cost	0	0	0
Defined Benefit Plan, Interest Cost	519	554	593
Defined Benefit Plan, Actuarial Net (Gains) Losses	(501)	(531)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	1,926	2,395
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(1,926)	(2,395)
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Fair Value of Plan Assets	0	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	1,926	2,395
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(14,100)	(16,008)
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	0	27
Defined Benefit Plan, Interest Cost	$ 0	$ 0	$ 560

Benefit Plans (Amounts recogniz

Benefit Plans (Amounts recognized in balance sheets) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	$ 0	$ 0
Liability, Defined Benefit Plan, Noncurrent	(29,407)	(27,234)
Liability, Defined Benefit Pension Plan	(29,407)	(27,234)
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	(1,906)	(2,187)
Liability, Defined Benefit Plan, Noncurrent	(12,194)	(13,821)
Liability, Defined Benefit Pension Plan	$ (14,100)	$ (16,008)

Benefit Plans (Amortize pre-tax

Benefit Plans (Amortize pre-tax amount AOCI) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	$ 23,568
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0
Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax	13,825
Other Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Actuarial Net (Gains) Losses	648
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	$ (3,263)
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax		$ 0

Benefit Plans (Projected benefi

Benefit Plans (Projected benefit obligation exceeding the fair value of plan assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation				$ 46,001
Defined Benefit Plan, Plan Assets, Business Combination	$ 2,231
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	$ 0	$ 27
Defined Benefit Plan, Interest Cost	0	0	560
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	148,848	128,897	128,942
Defined Benefit Plan, Fair Value of Plan Assets	119,441	101,663	104,353
Defined Benefit Plan Assets assumed in Business Combination	4,462
Defined Benefit Plan, Benefit Obligation, Business Combination	3,843
Defined Benefit Plan, Service Cost	2,402	1,650	961
Defined Benefit Plan, Interest Cost	3,262	3,434	1,659
Defined Benefit Plan, Actuarial Net (Gains) Losses	(697)	16,633
Defined Benefit Plan, Benefit Obligation, Benefits Paid	6,075	7,190
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	765	629
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	16,451	(15,201)
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	1,052	11,910
Defined Benefit Plan, Plan Assets, Contributions by Employer	5,150	4,838
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	765	629
Defined Benefit Plan, Plan Assets, Benefits Paid	6,078	7,190
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(29,407)	(27,234)
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	14,100	16,008	18,380
Defined Benefit Plan, Fair Value of Plan Assets	0	0	0
Defined Benefit Plan, Service Cost	0	0	0
Defined Benefit Plan, Interest Cost	519	554	$ 593
Defined Benefit Plan, Actuarial Net (Gains) Losses	(501)	(531)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	1,926	2,395
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	1,926	2,395
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Plan Assets, Benefits Paid	1,926	2,395
Defined Benefit Plan, Funded (Unfunded) Status of Plan	$ (14,100)	$ (16,008)

Benefit Plans (Components of th

Benefit Plans (Components of the annual net periodic benefit cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	$ 23,568
Amortization of prior service cost next fiscal year	0
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(501)	$ (531)
Defined Benefit Plan, Service Cost	0	0	$ 0
Defined Benefit Plan, Interest Cost	519	554	593
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(3,263)	(3,263)	(3,263)
Defined Benefit Plan, Accumulated Benefit Obligation, (Increase) Decrease for Settlement and Curtailment	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	(2,096)	(1,970)	(1,842)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	648	739	828
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	501	531	673
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	3,263	3,263	3,263
Defined Benefit Plan, Amortization of Net Gains (Losses)	(648)	(739)	(721)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	3,116	3,055	3,215
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	1,020	1,085	1,373
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	0	27
Defined Benefit Plan, Interest Cost	0	0	560
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	0	(1,008)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0
Defined Benefit Plan, Accumulated Benefit Obligation, (Increase) Decrease for Settlement and Curtailment	0	0	26,470
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	0	0	26,651
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	0	0	602
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold	0	0
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax			0
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	0	0	0
Defined Benefit Plan, Amortization of Net Gains (Losses)	0	0	(602)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	0	0	(602)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	0	0	26,049
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(697)	16,633
Defined Benefit Plan, Service Cost	2,402	1,650	961
Defined Benefit Plan, Interest Cost	3,262	3,434	1,659
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(4,835)	(2,853)	(1,324)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	(142)
Defined Benefit Plan, Accumulated Benefit Obligation, (Increase) Decrease for Settlement and Curtailment	0	0	(326)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	955	2,231	828
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	126	0	0
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	(697)	(7,553)	(3,733)
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	0	0	0
Defined Benefit Plan, Amortization of Net Gains (Losses)	(126)	0	0
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	(823)	(7,553)	(3,733)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	132	$ (5,322)	$ (2,905)
Other Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	648
Amortization of prior service cost next fiscal year	$ (3,263)

Benefit Plans (Assumptions used

Benefit Plans (Assumptions used in calculating benefit obligations and net periodic benefit cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	2.50%	2.60%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	4.97%	4.87%	5.19%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.60%	1.60%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.60%	1.60%	2.10%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	0.95%	0.65%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.40%	1.40%	1.40%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.60%	1.50%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.60%	1.50%
Harwell Dosimeters [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	2.55%
Other Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	3.50%	3.50%
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	$ 2,402	$ 1,650	$ 961

Benefit Plans (Significant assu

Benefit Plans (Significant assumptions used to determine the net periodic benefit costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Amortization of prior service cost next fiscal year	$ 0
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	$ 507
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.60%	3.50%	3.20%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	4.97%	4.87%	5.19%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.60%	1.60%	2.10%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.60%	1.60%	2.10%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	0.65%	0.65%	0.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.40%	1.40%	1.40%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.50%	1.50%	1.60%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.50%	1.50%	1.60%
Harwell Dosimeters [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.55%
Other Post-Retirement Benefit Plans, Net
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	3.50%	3.50%	3.25%
Other Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	$ 648
Amortization of prior service cost next fiscal year	$ (3,263)

Benefit Plans (Assumed long-ter

Benefit Plans (Assumed long-term healthcare cost trend rate) (Details)	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Postemployment Benefits [Abstract]
Healthcare cost trend rate medical	7.00%	7.00%	7.00%
Healthcare prescription drug	7.00%	7.00%	7.00%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	4.50%	4.50%	4.50%

Benefit Plans (Effect of one-pe

Benefit Plans (Effect of one-percentage-point change in assumed healthcare cost trend rates) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2018USD ($)
Postemployment Benefits [Abstract]
Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components	$ 1
Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components	(1)
Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation	21
Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation	$ (20)

Benefit Plans (Targeted asset a

Benefit Plans (Targeted asset allocation of plan assets and the actual allocation of plan assets) (Details)	Mar. 31, 2018
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	75.00%
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	25.00%

Benefit Plans (Fair value of ou

Benefit Plans (Fair value of our pension benefits plan assets) (Details) - USD ($) $ in Thousands		Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Other Investments		$ 5,484	$ 3,959	$ 4,192
Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[1]	201,534	282,918
Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[1]	0	0
Fair Value, Inputs, Level 3
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		0	0
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract		5,484	3,959
Cash and Cash Equivalents, Fair Value Disclosure		67	182
Other Investments		15,228	10,813
Marketable Securities, Equity Securities		74,081	64,922
Defined Benefit Plan, Fair Value of Plan Assets		119,441	101,663	$ 104,353
Marketable Securities, Fixed Maturities		24,581	21,787
Other Defined Benefit Pension Plans [Domain] | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract		0	0
Cash and Cash Equivalents, Fair Value Disclosure		67	182
Other Investments		0	0
Defined Benefit Plan, Fair Value of Plan Assets		67	182
Other Defined Benefit Pension Plans [Domain] | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract		0	0
Cash and Cash Equivalents, Fair Value Disclosure		0	0
Other Investments		15,228	10,813
Defined Benefit Plan, Fair Value of Plan Assets		15,228	10,813
Other Defined Benefit Pension Plans [Domain] | Fair Value, Inputs, Level 3
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract		5,484	3,959
Cash and Cash Equivalents, Fair Value Disclosure		0	0
Other Investments		0	0
Defined Benefit Plan, Fair Value of Plan Assets		$ 5,484	$ 3,959
[1]	Money market fund holdings are valued at fair value using the net asset value per share practical expedient and are not included within the fair value hierarchy. These money market funds are being presented in the table above to permit a reconciliation of the fair value hierarchy to total cash and cash equivalents.

Benefit Plans (Expected payment

Benefit Plans (Expected payments to be made to plan participants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Gross Prescription Drug Subsidy Receipts Received (Deprecated 2017-01-31)	$ 383	$ 326
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(501)	(531)
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	1,907
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	1,694
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	1,548
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	1,436
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	1,293
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	4,741
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(3,263)	(3,263)	$ (3,263)
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(697)	16,633
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	3,899
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	3,903
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	4,143
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	4,608
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	5,611
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	27,108
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	$ 0	$ 0	$ (142)

Benefit Plans (Details Textual)

Benefit Plans (Details Textual) - USD ($) $ in Thousands		Aug. 26, 2015	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Nov. 02, 2015	Sep. 30, 2015
DBP Purchase Price of Annuity Contract							$ 51,805
Defined Contribution Plan, Employer Discretionary Contribution Amount		$ 4,641	$ 24,037	$ 22,676	$ 21,897
Unfunded Benefit Obligation - Synergy Plan						$ 23,507
Defined Contribution Plan, Fair Value of Plan Assets			$ 655,031
STERIS Corporation shares held in defined contribution plan			645,854
Fair value of STERIS Corporatio stock held in defined contribution plan			$ 60,297
Defined Contribution Plan, Dividends Paid			781	734	669
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement	[1]		0	0	$ 26,470
Deferred Compensation Plan Assets			$ 1,583	$ 1,604
Equity Securities [Member]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage			75.00%
Debt Securities
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage			25.00%
[1]	See Note 9 titled, "Benefit Plans" for more information related to the settlement of the pension obligation.

Benefit Plans Benefit Plans (Ro

Benefit Plans Benefit Plans (Rollforward of Level 3 assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Period Increase (Decrease)	$ (43)	$ 116
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements		(208)
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements	2,231
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	189	(141)
Other Investments	5,484	$ 3,959	$ 4,192
Fair Value, Inputs, Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3	$ (852)

Contingencies (Details)

Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Loss Contingencies [Line Items]
Commitments and Contingencies
Letters of credit as security for self insurance risk and retention policies	7,694	7,694
Purchase Commitment, Remaining Minimum Amount Committed	126,758
long term construction contracts	1,713
Commercial commitments [Member]
Loss Contingencies [Line Items]
Commitments and Contingencies	$ 66,992	$ 57,709

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended							6 Months Ended	12 Months Ended
		Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Sep. 30, 2016	Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenues		$ 715,973	$ 661,900	$ 634,159	$ 607,964	$ 681,189	$ 646,774	$ 638,378	$ 646,415	$ 2,619,996	$ 2,612,756		$ 2,238,764
Operating Income (Loss)										403,454	227,595		212,927
Goodwill, Impairment Loss										0	58,356	[1]	0
amortization of inventory and property step up to fair value	[1]									1,599	4,743		9,907
amortization and impairment of acquired intangible assets	[2]									67,793	66,398		47,704
acquisition and integration related charges	[2]									16,211	30,082		82,891
loss (gain) on fair value contingent consideration adjustments										(593)	2,569		(736)
Gain (Loss) on Disposition of Business	[1]									14,547	86,574		0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement	[3]									0	0		26,470
Impact of TCJA on Operating Income	[4]									10,264
Restructuring expenses		(53)	$ 78	$ 27	$ 51	(5)	$ 18	$ 154	$ 48	103	215		(501)
Assets		5,200,334				4,924,455				5,200,334	4,924,455
Payments to Acquire Productive Assets										165,457	172,901		126,407
Depreciation, Depletion and Amortization										178,332	188,142		143,740
Property, Plant and Equipment, Net		1,010,524				915,908				1,010,524	915,908
Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues										513,287	477,837		316,037
Operating Income (Loss)										173,375	158,379		99,854
Goodwill, Impairment Loss											0
Assets		2,765,269				2,537,936				2,765,269	2,537,936
Payments to Acquire Productive Assets										96,193	91,240		60,518
Depreciation, Depletion and Amortization										97,038	84,573		58,484
Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues										361,590	328,866		297,733
Operating Income (Loss)										106,737	97,180		84,564
Goodwill, Impairment Loss											0
OperatingSegmentAllExceptCorpandOther [Member]
Segment Reporting Information [Line Items]
Revenues										2,619,996	2,612,756		2,238,764
Operating Income (Loss)										530,817	493,839		389,982
OperatingSegmentCorpandOther [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)										(17,439)	(17,307)		(11,320)
OperatingSegmentAll [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)										513,378	476,532		378,662
Healthcare and Life Sciences [Member]
Segment Reporting Information [Line Items]
Assets		1,621,156				1,576,923				1,621,156	1,576,923
Payments to Acquire Productive Assets										52,767	39,253		34,581
Depreciation, Depletion and Amortization										52,025	46,709		49,142
Healthcare Specialty Services [Member]
Segment Reporting Information [Line Items]
Revenues										469,065	539,536		421,110
Operating Income (Loss)										28,910	10,573		24,555
Goodwill, Impairment Loss											58,356
Assets		813,909				809,596				813,909	809,596
Payments to Acquire Productive Assets										16,497	42,408		31,308
Depreciation, Depletion and Amortization										29,269	56,860		36,114
Healthcare Products [Member] [Member]
Segment Reporting Information [Line Items]
Revenues										1,276,054	1,266,517		1,203,884
Operating Income (Loss)										221,795	227,707		181,009
Goodwill, Impairment Loss											0
United Kingdom [Member]
Segment Reporting Information [Line Items]
Revenues										207,514	229,603		144,577
Property, Plant and Equipment, Net		97,586				76,695				97,586	76,695
UNITED STATES
Segment Reporting Information [Line Items]
Revenues										1,836,414	1,803,457		1,662,050
Property, Plant and Equipment, Net		530,591				499,760				530,591	499,760
Other Foreign Entities [Member] [Member]
Segment Reporting Information [Line Items]
Revenues										576,068	579,696		$ 432,137
Property, Plant and Equipment, Net		$ 382,347				$ 339,453				$ 382,347	$ 339,453
[1]	For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".
[2]	Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions
[3]	See Note 9 titled, "Benefit Plans" for more information related to the settlement of the pension obligation.
[4]	Represents a one-time special employee bonus paid to most U.S. employees and associated professional fees.

Common Shares (Details)

Common Shares (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018£ / shares	Mar. 31, 2018£ / sharesshares	Mar. 31, 2017£ / sharesshares	Mar. 31, 2016USD ($)shares	Mar. 31, 2018USD ($)shares	Mar. 31, 2017USD ($)shares	Dec. 31, 2015£ / shares	Dec. 31, 2015USD ($)shares	Nov. 02, 2015£ / sharesshares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Stock, Par or Stated Value Per Share | £ / shares	£ 0.10	£ 0.10	£ 0.10
Ordinary shares, with £0.10 par value; £17,006 aggregate par amount authorized; 84,747 and 84,948 ordinary shares issued and outstanding, respectively | $					$ 2,048,037	$ 2,085,134
Preferred Stock, Dividend Rate, Percentage	5.00%
Preferred Stock, Shares Issued | shares					100,000	100,000		100,000
Preferred Stock, Par or Stated Value Per Share | £ / shares	£ 0.10	£ 0.10	£ 0.10
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding | $				$ 15	$ 15	$ 15
Preferred Stock, Redemption Price Per Share | £ / shares							£ 0.10
Weighted Average Number of Shares Outstanding, Basic | shares		85,028,000	85,473,000	70,698,000
Weighted Average Number Diluted Shares Outstanding Adjustment | shares		685,000	621,000	486,000
Weighted Average Number of Shares Outstanding, Diluted | shares		85,713,000	86,094,000	71,184,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		393,000	576,000	263,000
United Kingdom, Pounds
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Par or Stated Value Per Share | £ / shares							£ 0.10
United States of America, Dollars
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding | $								$ 15
Synergy Health plc [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Stock, Par or Stated Value Per Share | £ / shares									£ 0.10
Total Shares Received by Synergy Shareholders for Combination | shares									0.4308
Cash Value per share paid to Synergy Shareholders for Combination | £ / shares									£ 439

Repurchases of Common Shares (D

Repurchases of Common Shares (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Aug. 09, 2016	Mar. 31, 2008
Schedule of Available-for-sale Securities [Line Items]
Stock Repurchase Program, Authorized Amount				$ 300,000	$ 300,000
Stock Repurchased During Period, Shares	664,963	1,286,183
Ordinary Stock Repurchases Not Including Shares Withheld for Taxes	$ 59,234	$ 90,475
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	127,903	168,906	267,696
Payments Related to Tax Withholding for Share-based Compensation	$ 7,014	$ 7,034	$ 14,369

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	4,985,756
Weighted-average assumptions used for options granted:
Risk-free interest rate	2.01%	1.29%	1.51%
Expected life of options	5 years 8 months 16 days	5 years 7 months 28 days	5 years 7 months 28 days
Exptected dividend yield of stock	1.58%	1.54%	1.40%
Expected volatility of stock	22.08%	22.92%	25.06%
Estimated forfeiture rate	2.25%	1.85%	1.55%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,945,274
Weighted Average Exercise Price, Outstanding, Beginning of Period	$ 50.28
Number of Options, Granted	429,360
Weighted Average Exercise Price, Granted	$ 77.75
Number of Options, Exercised	(329,733)
Weighted Average Exercise Price, Exercised	$ 34.01
Number of Options, Forfeited	(23,239)
Weighted Average Exercise Price, Forfeited	$ 68.29
Number of Options, Outstanding, End of Period	2,021,662	1,945,274
Weighted Average Exercise Price, Outstanding, End of Period	$ 58.56	$ 50.28
Average Remaining Contractual Term, Outstanding	6 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding	$ 70,350
Number of Options, Exercisable	1,139,722
Weighted Average Exercise Price, Exercisable	$ 48.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 3 months 18 days
Aggregate Intrinsic Value, Exercisable	$ 50,772
Non-vested stock options outstanding expected to vest	867,996
Common Stock, Fair Market Value Per Share	$ 93.36
Total intrinsic value of stock options exercised	$ 16,096	$ 6,454	$ 13,000
Net cash proceeds from the exercise of stock options	11,093	4,955	11,240
Tax benefit from stock option exercises	$ 6,581	$ 5,058	$ 6,281
Weighted average grant date fair value of stock option grants, per share	$ 15.51	$ 13.42	$ 14.66
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	34,013
Number of Restricted Shares, Granted	23,259
Number of Restricted Shares, Vested	(21,181)
Number of Restricted Shares, Canceled	(660)
Number of Restricted Shares, Non-vested at End of Period	35,431	34,013
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 36,514
Weighted average period for recognition of unrecognized compensation cost	2 years 1 month 21 days
Stock Appreciation Rights (SARs)
Summary of non-vested restricted share activity:
FairValueOfOutstandingStockAppreciationRights	$ 1,437	$ 1,622	$ 2,165
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	780,526
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 60.87
Number of Restricted Shares, Granted	251,300
Weighted-Average Grant Date Fair Value, Granted	$ 78.60
Number of Restricted Shares, Vested	(231,107)
Weighted-Average Grant Date Fair Value, Vested	$ 54.41
Number of Restricted Shares, Canceled	(37,518)
Weighted-Average Grant Date Fair Value, Canceled	$ 68.57
Number of Restricted Shares, Non-vested at End of Period	763,201	780,526
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 68.65	$ 60.87
Fair Value, Share-based Payment Awards, Other than Options	$ 13,727

Financial and Other Guarantee83

Financial and Other Guarantees (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Standard and Extended Product Warranty Accrual	$ 6,872	$ 6,861	$ 5,909	$ 5,579
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	12,305	11,823	11,194
Standard Product Warranty Accrual, Decrease for Payments	(12,294)	(10,871)	(10,864)
Service Agreements [Member]
ERROR in label resolution.	$ 35,204	$ 34,264	$ 33,416

Forward and Swap Contracts (Det

Forward and Swap Contracts (Details) $ in Thousands, $ in Millions	12 Months Ended
	Mar. 31, 2018USD ($)lbs	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2018CAD ($)lbs
Derivative [Line Items]
Non-derivative Net Investment Hedge	$ 57,161
Investment Contract Weight | lbs	592,500			592,500
Other Assets
Derivative [Line Items]
Derivative Assets	$ 187	$ 160
Derivative Liabilities	0	0
Accrued Liabilities
Derivative [Line Items]
Derivative Assets	0	0
Derivative Liabilities	0	35
Selling, General and Administrative Expenses
Derivative [Line Items]
Foreign Currency Transaction Loss, before Tax	1,357	1,886	$ 683
Cost of Sales
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ 373	$ 376	$ (461)
Canada, Dollars
Derivative [Line Items]
Notional Amount of Foreign Currency Derivative Purchase Contracts (Deprecated 2013-01-31)				$ 13

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2018		Mar. 31, 2017	Mar. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis		$ 12,037		$ 12,128
Unrealized Gain on AFS Securities		4,345		496
Unrealized Loss on AFS Securities		0		(72)
Investments, Fair Value Disclosure		16,382		12,552
Business Acquisition, Contingent Consideration, at Fair Value		8,068		4,451	$ 5,886
Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure	[1]	16,382		12,552
Cash and Cash Equivalents, Fair Value Disclosure	[2]	201,534		282,918
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]	0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]	0		0
Deferred Compensation Plan Assets	[1]	1,694		1,677
Long-term Debt, Fair Value	[4]	0		0
Business Acquisition, Contingent Consideration, at Fair Value		0	[5]	0
Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure		0	[1]	0
Cash and Cash Equivalents, Fair Value Disclosure	[2]	0		0
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]	187		160
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]	0		35
Deferred Compensation Plan Assets		0	[1]	0
Long-term Debt, Fair Value	[4]	1,305,181		1,496,966
Business Acquisition, Contingent Consideration, at Fair Value		0	[5]	0
Fair Value, Inputs, Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure		0	[1]	0
Cash and Cash Equivalents, Fair Value Disclosure		0		0
Foreign Currency Contract, Asset, Fair Value Disclosure		0	[3]	0
Foreign Currency Contracts, Liability, Fair Value Disclosure		0	[3]	0
Deferred Compensation Plan Assets		0	[1]	0
Long-term Debt, Fair Value	[4]	0		0
Business Acquisition, Contingent Consideration, at Fair Value	[5]	8,068		4,451
Capital Additions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		5,774		3,592
Reductions and Payout [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		(1,735)		(5,416)
Contingent consideration gain loss [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		(593)
Foreign Currency Gain (Loss)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		171		389
Cost of Sales
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gain (Loss) on Sale of Commodity Contracts		373		376	$ (461)
Mutual Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis		1,000		1,091
Unrealized Gain on AFS Securities	[6]	583		496
Unrealized Loss on AFS Securities		0	[6]	0
Investments, Fair Value Disclosure		1,583		1,587
Equity Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis		11,037		11,037
Unrealized Gain on AFS Securities	[6]	3,762		0
Unrealized Loss on AFS Securities		0	[6]	(72)
Investments, Fair Value Disclosure		14,799		10,965
Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure		16,382		12,552
Cash and Cash Equivalents, Fair Value Disclosure		201,534		282,918
Foreign Currency Contract, Asset, Fair Value Disclosure		187		160
Foreign Currency Contracts, Liability, Fair Value Disclosure		0		35
Deferred Compensation Plan Assets		1,694		1,677
Long-term Debt, Fair Value	[4]	1,316,001		1,478,361
Business Acquisition, Contingent Consideration, at Fair Value		$ 8,068		$ 4,451
[1]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment.
[2]	Money market fund holdings are valued at fair value using the net asset value per share practical expedient and are not included within the fair value hierarchy. These money market funds are being presented in the table above to permit a reconciliation of the fair value hierarchy to total cash and cash equivalents.
[3]	The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[4]	We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[5]	Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
[6]	(1) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Accumulated Other Comprehensi86

Accumulated Other Comprehensive Incom (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ 16,457	$ (238,525)	$ (72,594)
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	(6,742)	(2,355)	5,108
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	1,970	178	(673)
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ 11,685	$ (240,702)	$ (68,159)

Reclassifications out of AOCI87

Reclassifications out of AOCI (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		$ 1,970	$ 178		$ (673)
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax		(6,742)	(2,355)		5,108
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		16,457	(238,525)		(72,594)
Accumulated Other Comprehensive Income (Loss), Net of Tax		11,685	(240,702)		(68,159)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		(254,394)	170,677
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(2,007)	(1,866)
Total other comprehensive loss attributable to shareholders		252,387	(172,543)		(1,490)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		1,970	178	[1]	(673)	[1]
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	1,703	745
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[1]	(89)	(106)
Total other comprehensive loss attributable to shareholders		(1,792)	(851)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax		(6,742)	(2,355)	[2]	5,108	[2]
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[2]	(2,291)	(5,491)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	2,096	1,972
Total other comprehensive loss attributable to shareholders		4,387	7,463
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		16,457	(238,525)	[3]	$ (72,594)	[3]
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[3]	254,982	(165,931)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[3]	0	0
Total other comprehensive loss attributable to shareholders		$ (254,982)	$ 165,931
[1]	Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the ConsolidatedStatements of Income.
[2]	Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the ConsolidatedStatements of Incom
[3]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated other comprehensive income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Quarterly Results (Unaudited)88

Quarterly Results (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended							6 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Sep. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Effect of Fourth Quarter Events [Line Items]
Sales Revenue, Goods, Net	$ 351,010	$ 309,461	$ 286,557	$ 273,605	$ 332,093	$ 302,260	$ 271,750	$ 292,216	$ 1,220,633	$ 1,198,319	$ 1,128,985
Sales Revenue, Services, Net	364,963	352,439	347,602	334,359	349,096	344,514	366,628	354,199	1,399,363	1,414,437	1,109,779
Revenues	715,973	661,900	634,159	607,964	681,189	646,774	638,378	646,415	2,619,996	2,612,756	2,238,764
Cost of Goods Sold	187,710	162,611	152,611	143,245	173,333	152,879	142,698	155,110	646,177	624,020	617,368
Cost of Services	235,510	220,701	214,787	208,598	227,731	236,286	255,690	243,397	879,596	963,104	725,915
Cost of Revenue	423,220	383,312	367,398	351,843	401,064	389,165	398,388	398,507	1,525,773	1,587,124	1,343,283
Gross Profit	$ 292,753	$ 278,588	$ 266,761	$ 256,121	$ 280,125	$ 257,609	$ 239,990	$ 247,908	1,094,223	1,025,632	895,481
Gross Profit Percentage	40.90%	42.10%	42.10%	42.10%	41.10%	39.80%	37.60%	38.40%
Restructuring expenses	$ (53)	$ 78	$ 27	$ 51	$ (5)	$ 18	$ 154	$ 48	103	215	(501)
Net Income (Loss) Attributable to Parent	$ 73,598	$ 94,781	$ 64,459	$ 58,077	$ 26,143	$ (4,996)	$ 48,401	$ 40,416	$ 290,915	$ 109,965	$ 110,763
Earnings Per Share, Basic	$ 0.87	$ 1.12	$ 0.76	$ 0.68	$ 0.31	$ (0.06)	$ 0.56	$ 0.47	$ 3.42	$ 1.29	$ 1.57
Earnings Per Share, Diluted	$ 0.86	$ 1.11	$ 0.75	$ 0.68	$ 0.31	$ (0.06)	$ 0.56	$ 0.47	$ 3.39	$ 1.28	$ 1.56

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016		Mar. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Allowance for Doubtful Accounts Receivable, Current		$ 12,472	$ 10,357	[1]	$ 11,185	[1]	$ 9,415	[1]
Provision for Doubtful Accounts	[1]	2,183	1,248		3,362
Allowance for trade accounts receivable charges to other accounts	[1],[2]	1,925	11		(100)
Allowance for trade accounts receivable deductions	[1],[3]	(1,993)	(2,087)		(1,492)
Inventory Valuation Reserves		19,639	17,854		18,707		17,597
Inventory Write-down	[4]	(2,446)	(171)		(1,146)
Foreign currency translation and other adjustments	[2]	(661)	(682)		(36)
Deferred Tax Assets, Valuation Allowance		13,596	16,366		16,435		14,380
Valuation Allowances and Reserves, Additions for Adjustments		209	(214)		4,439
Valuation Allowances and Reserves, Deductions		6,514	(3,869)		(4,535)
Liability for Claims and Claims Adjustment Expense, Property Casualty Liability		20,949	22,718		20,222		18,078
Supplemental Information for Property, Casualty Insurance Underwriters, Paid Claims and Claims Adjustment Expense		5,713	5,000		4,141
Incurred Claims, Property, Casualty and Liability		(2,563)	(768)		(1,187)
Incurred Claims, Property, Casualty and Liability		(4,919)	(3,272)		(3,184)
Other Accrued Liabilities, Current					0		$ 16
Accrued Sys 1 Rebate and Class Action	[5]				0
Accrued System Rebate Other Charges					0
Loss Contingency Accrual, Carrying Value, Provision					(16)
Valuation Allowance of Deferred Tax Assets [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Additions for Charges to Cost and Expense		$ 3,535	$ 4,014		$ 2,151
[1]	Net allowance for doubtful accounts and allowance for sales and returns.
[2]	Change in foreign currency exchange rates and acquired reserves.
[3]	Uncollectible accounts written off, net of recoveries.
[4]	Provision for excess and obsolete inventory, net of inventory written off.
[5]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjkyMmFlZmU1MGU3OTRlNzZiOWViMjJjOGZhY2UyOThifFRleHRTZWxlY3Rpb246Nzc5REEyNDIzRjU2NTk3MEFEMDE0MEIzMEJCOTE2M0YM}